Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  a  
Establishing Novel Antiretroviral Imaging for Hair to 
Elucidate Non -Adherence (ENLIGHTEN)  
National Clinical Trial (NCT) Identified Number:  [STUDY_ID_REMOVED]  
Version Date:  13 May 2021  
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319      13 May 2021  
Establishing Novel Antiretroviral Imaging for Hair to 
Elucidate Non -Adherence (ENLIGHTEN)  
Protocol Number: 122319  
National Clinical Trial (NCT) Identified Number:  [STUDY_ID_REMOVED]  
Principal Investigator:  Angela Kashuba  
<IND/IDE > Sponsor: not applicable  
Sponsor means a n individual or pharmaceutical or medical device company, governmental agency, 
academic institution, private organization, or other organization  who takes responsibility for and 
initiates a clinical investigation.  
Funded by : NIAID (Grant Number R01 AI122319)  
Version Number:  v2.0 13 May 2021  
All versions should have a version number and a date. Use the international date format (day month 
year) and write out the month (e.g., 23 June 2015).  
 
 
Summary of Changes  from Previous Version:  
Affected 
Section(s)  Summary of Revisions Made  Rationale  
SOE, 
Introduction  
and 
Background  • Remov ed the term “ real-time ” throughout 
the document  
o Pertinent feasibility endpoints 
now use “delivery of the report to 
the designated research staff 
member within 2 hours of 
initiation of hair processing” 
rather than “…wit hin 2 hours of 
hair sample collection”  
•  Revisions made due to Covid -19 pandemic.  
 • Remove d mitra sampling for the remaining 
15 participants in cohort A  
o Now stated as “blood sample will 
be collected for 10 participants in 
Group A and a subset of 
participants in Group B.” After 
Mitra is analyzed for the first 10 
participants in Group B, we will 
reevaluate  to determine if  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  iii additional samples are needed to 
validate hair samples.  
 
2.A.1,  
6.A.1 , 
6.A.2  
8.0 
10.1.1  • V1 and V2 study activities will be 
conducted virtually (except hair collection 
and in -person patient provider clinic visits) 
to minimize in -person contact  
o Consent and screening will be 
conducted virtua lly using 
videoconferencing via zoom on 
computer, tablet or  phone  
o All questionnaires  (patient 
baseline, patient post -visit, 
patient endline, provider baseline, 
provider post -visit, and provider 
endline)  will be conducted  
virtually  through REDCap (emailed 
to participant or verbally 
administered via phone or 
videoconferencing)  
o Hair collection will be conducted  
by research staff at remote  
locations  to limit time in clinic  
o Implementation of the 
intervention will now be allowed 
in the setting of telehealth 
clinical visits between patient 
and provider in addition to in -
person clinical visits  
o MedViewer reports  will be sent to 
providers via secure email  
o All remaining V2s will be 
conducted virtually. Hair and 
bloo d samples will not be 
collected.  
•   
Section 8  • Consenting will take place up to 3 days 
before scheduled clinic appointment with 
provider  
o Hair sample will be collected  by 
research staff  at a remote  
location  in the 3 days between 
consent and the scheduled 
provider visit  
o MedViewer report will be 
discussed between patient and  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  iv provider (or patient and 
pharmacist, if needed) within 4 
weeks of hair sample collection  
•  
3.0, 9.1, 9.2, 
9.3, 9.4.2, 
9.4.7, 9.4.8  • Seven endpoints have been revised  
• Statistical analysis revised   
 • Interviewer -administered portions of the 
baseline questionnaire have been modified  
o Health Literacy measure (Newest 
Vital Sign) removed  
o ART adherence Visual Analog 
Scale modified to allow for 
remote self -administration  
•   
 • Maximum duration on study extended by 6 
months for providers (increased from 10 to 
16 months)  
• Provider sample size range reduced (from 
20-30 to 16 -30)  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319      13 May 2021  
Table of Contents  
Statement of Compliance  ................................ ................................ ................................ ................................ ..........  8 
1 Protocol Summary  ................................ ................................ ................................ ................................ ........  11 
Synopsis  11 
Schema  15 
1.A.1  Patient participant study schema  ................................ ................................ .................  15 
1.A.2  Provider participant study schema  ................................ ................................ ..............  15 
Schedule of Events (SOE)  ................................ ................................ ................................ ................................ ... 16 
2 Introduction  ................................ ................................ ................................ ................................ ....................  17 
Study Rationale  ................................ ................................ ................................ ................................ .....................  17 
A. Background ................................ ................................ ................................ ................................ .........  20 
Risk/Benefit Assessment  ................................ ................................ ................................ ................................ ..... 24 
2.A.1  Known Potential Risks  ................................ ................................ ................................ ... 24 
2.A.2  Known Potential Benefits  ................................ ................................ ..............................  27 
2.A.3  Assessment of Potential Risks and Benefits  ................................ ..............................  27 
3 Objectives and Endpoints  ................................ ................................ ................................ ...........................  28 
4 Study Design  ................................ ................................ ................................ ................................ .................  30 
Overall Design  ................................ ................................ ................................ ................................ .......................  30 
Scientific Rationale for Study Design  ................................ ................................ ................................ .................  30 
Justification for Dose  ................................ ................................ ................................ ................................ ............  30 
End of Study Definition  ................................ ................................ ................................ ................................ .........  31 
5 Study Population  ................................ ................................ ................................ ................................ ..........  31 
Inclusion Criteria  ................................ ................................ ................................ ................................ ...................  31 
A. Exclusion C riteria  ................................ ................................ ................................ ...............................  33 
B. Lifestyle Considerations  ................................ ................................ ................................ ....................  33 
C. Screen Failures  ................................ ................................ ................................ ................................ .. 33 
D. Strategies for Recruitment and Retention  ................................ ................................ ......................  34 
6 Study Intervention  ................................ ................................ ................................ ................................ ........  37 
Study Intervention(s) Administration  ................................ ................................ ................................ ..................  37 
6.A.1  Study Intervention Description  ................................ ................................ .....................  37 
6.A.2  Dosing and Administration  ................................ ................................ ............................  39 
Preparation/Handling/Storage/Accountability  ................................ ................................ ................................ ... 41 
6.A.3  Acquisition and accountability  ................................ ................................ ......................  41 
6.A.4  Formulation, Appearance, Packaging, and Labeling  ................................ ................  41 
6.A.5  Product Storage and Stability  ................................ ................................ .......................  41 
6.A.6  Preparation  ................................ ................................ ................................ ......................  41 
Measures to Minimize Bias: Randomization and Blinding  ................................ ................................ ..............  41 
Study Intervention Compliance  ................................ ................................ ................................ ...........................  42 
Concomitant Therapy  ................................ ................................ ................................ ................................ ...........  42 
6.A.7  Rescue Medicine  ................................ ................................ ................................ ............  42 
7 Study Inte rvention Discontinuation and Participant Discontinuation/ Withdrawal  ...............................  42 
A. Discontinuation of Study Intervention  ................................ ................................ .............................  42 
B. Participant Discontinuation/Withdrawal from the Study  ................................ ...............................  42 
C. Lost to Follow -Up ................................ ................................ ................................ ...............................  43 
8 Study Asse ssments and Procedures  ................................ ................................ ................................ ........  45 
A. Efficacy Assessments  ................................ ................................ ................................ .......................  45 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  6 B. Safety and Other Assessments  ................................ ................................ ................................ .......  48 
C. Adverse Events and Serious Adverse Events  ................................ ................................ ...............  51 
8.C.1  Definition of Adverse Events (AE)  ................................ ................................ ...............  51 
8.C.2  Definition of Serious Adverse Events (SAE)  ................................ ..............................  52 
8.C.3  Classification of an Adverse Event  ................................ ................................ ..............  52 
8.C.4  Time Period and Frequency for Event Assessment and Follow -Up .......................  53 
8.3.5  Adverse Event Reporting  ................................ ................................ ..............................  54 
8.3.6  Serious Adverse Event Reporting  ................................ ................................ ...............  54 
8.3.7  Reporting Events to Participants  ................................ ................................ .................  54 
8.3.8  Events of Special Interest  ................................ ................................ .............................  54 
8.3.9  Reporting of Pregnancy  ................................ ................................ ................................  55 
8.4 Unanticipated Problems  ................................ ................................ ................................ ....................  55 
8.4.1  Definition of Unanticipated Problems (UP)  ................................ ................................ . 55 
8.4.2  Unanticipated Problem Reporting  ................................ ................................ ................  55 
8.4.3  Reporting Unanticipated Problems to Participants  ................................ ...................  56 
9 Statistical Considerations  ................................ ................................ ................................ ............................  56 
9.1 Statistical Endpoints and Measures  ................................ ................................ ................................  56 
9.2 Sample Size Determination  ................................ ................................ ................................ ..............  60 
9.3 Populations for Analyses  ................................ ................................ ................................ ..................  62 
9.4 Statistical Analyses ................................ ................................ ................................ ............................  62 
9.4.1  General Approach  ................................ ................................ ................................ ..........  62 
9.4.2  Analysis of the Primary Efficacy EndpointS  ................................ ...............................  63 
9.4.3  Analysis of the Secondary Endpoints  ................................ ................................ .........  65 
9.4.4  Safety Analyses  ................................ ................................ ................................ ..............  70 
9.4.5  Baseline Descriptive Statistics  ................................ ................................ .....................  72 
9.4.6  Planned Interim Analyses  ................................ ................................ .............................  72 
9.4.7  Sub-Group Analyses  ................................ ................................ ................................ ..... 72 
9.4.8  Exploratory Analyses  ................................ ................................ ................................ ..... 73 
9.5 Qualitative Data Collection and Analyses  ................................ ................................ ......................  75 
10 Supporting Documentation and Operational Considerations ................................ ................................ . 76 
10.1  Regulatory, Ethical, and Study Oversight Consideratio ns ................................ ...........................  76 
10.1.1  Informed Consent Process  ................................ ................................ ...........................  76 
10.1.2  Study Discontinuation and Closure  ................................ ................................ .............  77 
10.1.3  Confidentiality and Privacy  ................................ ................................ ...........................  78 
10.1.4  Future Use of Stored Specimens and Data  ................................ ...............................  79 
10.1.5  Key Roles and Study Governance  ................................ ................................ ..............  79 
10.1.6  Safety Oversight  ................................ ................................ ................................ .............  79 
10.1.7  Clinical Monitoring  ................................ ................................ ................................ ..........  79 
10.1.8  Quality Assurance and Quality Control  ................................ ................................ .......  80 
10.1.9  Data Handling and Record Keeping  ................................ ................................ ............  82 
10.1.10  Protocol Deviations  ................................ ................................ ................................ ........  82 
10.1.11  Publication and Data Sharing Policy  ................................ ................................ ...........  82 
10.1.12  Conflict of Interest Policy  ................................ ................................ ..............................  83 
10.2  Additional Considerations  ................................ ................................ ................................ .................  83 
10.3  Abbreviations  ................................ ................................ ................................ ................................ ...... 84 
10.4  Protocol Amendment History  ................................ ................................ ................................ ...........  86 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  7 11 References  ................................ ................................ ................................ ................................ ....................  88 
Appendices  ................................ ................................ ................................ ................................ ................................  93 
Appendix A. Intervention Materials ................................ ................................ ................................ .....................  93 
A.1 Provider Training Materials ................................ ................................ ................................ .......................  93 
A.2 Patient Video Storyboard  ................................ ................................ ................................ ........................  102 
A.3 Provider Communication Aids  ................................ ................................ ................................ ................  112 
Appendix B. INFORMED CONSENT FORMS  ................................ ................................ ...............................  118 
B.1 Patient Study Visit 1 Informed Consent Form  ................................ ................................ .....................  118 
B.2 PATIENT STUDY Visit 2 Informed Consent  ................................ ................................ ........................  128 
B.3 Provider Informed Consent Form  ................................ ................................ ................................ ..........  136 
Appendix C. Data Collection Instruments ................................ ................................ ................................ ........  146 
C.1 Patient Baseline Questionnaire  ................................ ................................ ................................ .............  146 
C.2 Patient Post -Visit Questionnaire  ................................ ................................ ................................ ............  155 
C.3 Patient In -Depth Interview Guide  ................................ ................................ ................................ ..........  161 
C.4 Patient endline Questionnaire  ................................ ................................ ................................ ................  164 
C.5 Provider Post -Training (Baseline) Questionnaire  ................................ ................................ ...............  168 
C.6 Provider Post -Visit Questionnaire  ................................ ................................ ................................ ...............  171 
C.7 Provider In -Depth Interview Guide  ................................ ................................ ................................ ..............  173 
C.8 Provider Endline Questionnaire  ................................ ................................ ................................ ...................  178 
Appendix D. Benchmarking  ................................ ................................ ................................ ...............................  181 
D.1 Benchmarking of ir -maldesi msi longitudinal arv profiling in hair stra nds................................ ........  181 
Appendix E. IR -MALDESI Method Validation  ................................ ................................ ................................ . 186 
E.1 INTRODUCTION ................................ ................................ ................................ ................................ ..........  189 
E.2 MATERIALS AND METHODS  ................................ ................................ ................................ ...................  190 
E.2.1  Reference Standards  ................................ ................................ ................................ ... 190 
E.2.2  Reagents ................................ ................................ ................................ ......................  190 
E.2.3   Instrumentation and Supplies  ................................ ................................ ....................  190 
E.2.4  Preparation of Stock and Internal Standard Sol utions, and Calibration 
Standards  191 
E.3 Validation ................................ ................................ ................................ ................................ .......................  192 
E.3.1  Experimental Design  ................................ ................................ ................................ ... 192 
E.4 Results  ................................ ................................ ................................ ................................ ..............  193 
E.4.1  Verification o f Calibration Model  ................................ ................................ ................  193 
E.4.2  Lower Limit of Quantitation (LLOQ)  ................................ ................................ ...........  193 
E.4.3  Precision  ................................ ................................ ................................ ........................  194 
E.4.4  FTC and DTG Analysis of Five Incurred Samples  ................................ ..................  194 
E.5 Conclusion  ................................ ................................ ................................ ................................ ........  196 
E.6 REFERENCES  ................................ ................................ ................................ ................................ . 196 
Appendix F. IR -MALDESI Evaluation of Hair Color and Treatment  ................................ ............................  207 
F.1 IR -maldesi evaluation of hair color and treatment  ................................ ................................ ...............  207 
 
  
 
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  8 STATEMENT OF COMPLIANCE  
 
The trial will be carried out in accordance with International Conference on Harmonisation Good Clinical 
Practice ( ICH GCP) and the following :  
 
• United States (US) Code of Federal Regulations (CFR) applicable to clinical studies (45 CFR 
Part 46, 21 CFR Part 50, 21 CFR Part 56, 21 CFR Part 312, and/or 21 CFR Part 812)  
 
National Institutes of Health ( NIH)-funded investigators and clinical trial site  staff who are 
responsible for the conduct, management, or oversight of NIH -funded clinical trials  have 
completed Human Subjects Protection and ICH GCP Training.  
 
The protocol, informed consent form(s), recruitment materials, and all participant materials will 
be submitted to the Institutional Review Board ( IRB) for review and approval.  Approval of both 
the protocol and the consent form must be obtained before any participant is enrolled.  Any 
amendment to the protocol will require review and approval by the IRB before the changes are 
implemented to the study.  In addition, a ll changes to the consent form will be IRB -approved; a 
determination will be made regarding whether  a new consent needs to be obtained from 
participants  who provided consent , using a previously approved consent form . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  9 PROTOCOL TEAM ROSTER  
 
Protocol Chair/Principle Investigator  
Angela Kashuba, BScPhm, PharmD, DABCP , FCP  
Division of Pharmacotherapy and Experimental Therapeutics  
UNC Eshelman School of Pharmacy CB# 7569, 3318 Kerr Hall  
310 Pharmacy Lane  
Chapel Hill NC, 27599 -7569, USA  
Email: akashuba@unc.edu  
Phone: 919 -966-9998  
Fax: 919 -962-0644  
 
Project Manager  
Amanda Poliseno, BS  
Division of Infectious Diseases  
CB# 7361, 1st Floor Genetic Medicine Building  
120 Mason Farm Road, Suite 1 100A  
Chapel Hill, NC 27599 -7215, USA  
Email: amanda_poliseno@unc.edu  
Phone: 919 -962-5344  
Fax: 919 -966-1020  
 
Study  Medical Officer  
Cynthia L. Gay, MPH, MD  
Division of Infectious Diseases  
CB# 7215, 2112 Bioinformatics Building  
130 Mason Farm Road, 2nd Floor  
Chapel Hill, NC 27599 -7215, USA  
Email: Cynthia_gay@med.unc.edu  
Phone: 919 -843-2726  
Fax: 919-966-8928  
 
Co-Investigators  
Elias Rosen, PhD  
Eshelman School of Pharmacy  
CB# 7261, 1st Floor Genetic Medicine Building  
120 Mason Farm Road, Suite 1096  
Chapel Hill, NC 27599 -7215  
Email: eli@unc.edu  
Phone:  919 -962-5151  
Fax: 919-962-0644  
 
Carol Golin, MD  
Division of General Medicine and Epidemiology, Department of Medicine  
UNC School of Medicine  
Department of Health Behavior, UNC Gillings  School of Global Public Health   
CB # 7440, 310 Rosenau Hall  
135 Dauer Drive  
Chapel Hill, NC 27599 -7440 , USA  
Email: carol_golin@unc.edu  
Phone: 919-966-0334 
Fax: 919-966-2921  
  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  10 DAIDs Clinical Representative  
Tia Morton, RN, MS  
5601 Fishers Lane 9E48  
Rockville, MD 20852  
Office Phone:  240 -627-3073  
Office Cell phone:  301 -222-7795  
E-mail:  frazierti@niaid.nih.gov  
 
 
 
  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  11 1  PROTOCOL SUMMARY  
SYNOPSIS  
 
Title:   
Establishing Novel Antiretrovira L Imaging for Hair to Elucidate 
Nonadherence   
Study Des cription : The proposed study is a single -arm cross -sectional study  to pilot  test the 
implementation of infra -red (IR) matrix -assisted laser desorption 
electrospray ionization (MALDESI) for mass spectrometry imaging (MSI) of 
hair among patients receiving HIV c are in the University of North Carolina 
(UNC)  Infectious D isease s (ID) C linic. The study will  investigate  feasibility, 
acceptability , and appropriateness  of utilizing the IR-MALDESI  MSI assay  
(named MedViewer)  as an investigational  clinical adherence -monitoring  
tool.  The aim of the  MedViewer  test is to a) longitudinally quantify , in easy 
to understand patient and provider reports,  antiretroviral (ARV) 
concentrations in patient hair; and b) enhance adherence couns eling 
conversations between people living with HIV  and their medical providers  
through review and discussion of the MedViewer report during a clinic 
visit. The study will i mplement the MedViewer test with 50 eligible  
patients  who are living with HIV  across two viral load strata , administer 
brief  visit-specific  questionnaires  to all patient and provider participants , 
and conduct  qual itative in-depth interviews  (IDIs)  and quantitative endline 
questionnaire s with a subsample  of patient  participants  (n=30)  and all 
provider  participants. The two strata  will be based on the participants ’ 
viral load within the past two years. Group A (n=25) will consist of 
participants with a viral load below the limit of quantification for the 
previous two years with documentation of at least one test in the last six 
months. Group B (n=25) will consist of participants who have had at least 
one HIV RNA test a bove the  limit of quantification within the previous two 
years.  
 
This study comprises Aim 3B of R01A I122319.  
  
Objectives:  Primary Objective:  
Investigate the feasibility of delivering the MedViewer intervention as 
planned, the acceptability to patients of participation in the MedViewer 
intervention, and the appropriateness of MedViewer use for adherence 
counseling.  
 
Secondary Objective:  
Investi gate additional dimensions of feasibility, acceptability, and 
appropriateness of using hair (MedViewer) to provide feedback to people 
living with HIV  regarding longitudinal patterns of medication adherence.  
  
Endpoints:  Primary Endpoints:  
1. Feasibility: Pr oportion of participants receiving the MedViewer 
report during their provider visit, as planned . 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  12 2. Acceptability: Proportion of contacted patients who are eligible 
for a screening visit (not including inclusion criterion 9) who 
agree to participate in the MedViewer Intervention pilot study.  
3. Appropriateness: Perceived usefulness of the MedViewer 
intervention for adherence counseling (assessed through in -
depth interviews).  
 
Secondary Endpoints:  
       Feasibility:  
1. Reasons for patient’s non -receipt of the MedViewer report 
during a visit with provider or pharmacist within 4 weeks of hair 
collection (if applicable).  
2. Reasons for non -discussion of the MedViewer report with 
provider or pharmacist (if applicable).  
3. Duration of time (in minutes) from initiation of hair processing to 
MedV iewer report delivery to designated research staff member . 
 
     Acceptability:  
1. Provider -reported likelihood of recommending MedViewer to 
future patients.  
2. Patient -reported likelihood of agreeing to future MedViewer use.  
3. Patient comprehension of the MedView er report.  
 
     Appropriateness:  
1. Perceived usefulness of MedViewer to promote ART adherence.  
2. Perceived impact of MedViewer use on patient -provider 
communication and relationship.  
  
Study Population:  Patient participants:  
We will enroll 50 patients , aged 18 or older with at least 1.0  cm natural 
caput hair , from the UNC ID Clinic . All participants will be people living 
with HIV, prescribed  an ARV regimen eligible for the MedViewer test, and 
willing to participate .  Pa tients  will be enrolled into one of two strata : 
Group A will be patients with  all HIV RNA  results  below the limit of viral 
quantification  over  the previous 2 years  with documentation of at least 
one test in the previous six months. Group B will be patients who have had 
at least one HIV RNA result above the limit of viral quantification  within 
the previ ous two years.  
 
We will screen and enroll  patients of all gender identities, racial identities, 
ethnicities, and ages (above 18 years), s o the demographic distribution of 
screened participan ts reflects that of  patients at the UNC ID Clinic  who are 
living with HIV. We will enroll participants into two viral load strata  as 
defined above for  Group A (N= 25) and Group B (N= 25).  
 
We will also enroll  a subsample of up to 30 participants enrolled  in the 
larger study to participate in  a follow -up study visit , which will includ e an 
in-depth  interview (IDI)  and an endline questionnaire . 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  13  
Provider participants:  
We will seek to enroll all (~ 15-30) medical providers who see HIV-positive 
patients at least one half -day per week in the UNC ID Clinic , who  have 
stated willingness and availability to  comply with all study procedures for 
the duration of the study.  
  
Phase : N/A 
 
Description of 
Sites/Facilities Enrolling 
Participants:  The study will include only one  main research  site, UNC Medical Center, a 
large academic hospital -based p rimary and tertiary care center in Chapel 
Hill, North Carolina.  The study procedures will be conducte d in the 
hospital’s Clinical  & Translational  Research Center (CTRC) and the satellite 
UNC Infectious Diseases (ID) Clinic,  which serves  approximately  1900  HIV-
positive  patients  living with HIV  from a wide catchment area.  
  
Description of Study 
Intervention:  The study intervention consist s of four main components:  
 
1) Standardized training session for medical providers: Training session  
(approximately 30 -60 minutes)  at the start of the study  (and offered at 
alternate later times) to introduce providers to MedViewer, how the 
report will be obtained and shared with patients, how to interpret 
MedViewer report, and possible strategies to discuss results with 
patients using IRB -approved communication aids .  
 
2) Informational video for pati ents:  Approximately e ight-minute video to 
introduce patients to the MedViewer test, the hair collection process, 
and how test results can provide useful information to both patients 
and providers.  Patients will have the opportunity to watch the video 
more than once if requested . 
 
3) Hair sample, MedViewer test, and accompanying MedViewer report 
(patient and provider versions).  Patient participants will provide a hair 
sample, which will be used for a  MedViewer test to generate two 
distinct visual reports of the results (one version for patients and one 
version for provi ders), which will be delivered to the provider to discuss 
with the patient during  a clinic visit (telehealth or in -person) with the 
provider  or pharm acist within 4  weeks of hair sample collection . 
 
4) Communication aids for providers:  Aids intended to facilitate 
providers’ discussions of MedViewer report with their patients, 
including a one -page reference sheet with possible strategies to counsel 
patients on adherence using MedViewer report and a one -page FAQ to 
clarify potential concerns.  
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  14 The intervention will be conducted with both patient and provider 
participants to learn about feasibility, appropriateness, and acceptability 
of using MedViewer  from both the patient and provider perspective.  
 
For patients, intervention activities include  watching the brief MedViewer 
video, providing a hair sample to be sent to the laboratory for the 
MedViewer test, and receiving and reviewing the MedViewer repo rt with 
their provider  or a pharmacist . Patients in Group B and a subset of  patients 
in Group A will also provide a blood sample to measure antiretroviral 
concentrations in comparison to the hair.   
 
For providers, intervention activities  include  participating in t he prov ider 
MedViewer training session  and integrating each patient’s investigational 
MedViewer report into a clinic  visit that occurs within 4 weeks of hair 
sample collection for investigational  purposes . Each time the provider has 
an a ppointment scheduled with a patient participating in the stu dy, 
MedViewer results  will be delivered to the provider  before the patient’ s 
appointment . During the appointment,  the provider will review and 
discuss the MedViewer report with the patient as part  of their routine 
adherence counseling discussion. The provider may refer to the 
communication aids, per personal preference, to help guide the 
MedViewer discussion. If the provider does not receive the report before 
the patient appointment, he or she will decide with the patient whether to 
postpone the  provider’s  MedViewer discussion with the patient until the 
result is ready or request that the UNC Infectious Diseases Clinic HIV 
Pharmacist discuss the results with the patient.  
 
To produce the MedViewe r report, a  trained researcher will collec t a 
sample of hair from the participant ’s head  and transport the sample to the 
laboratory  per standard operating procedures . The analyst  will run the 
MedViewer  test to generate two distinct visual results reports ( one version 
for patients and one version for providers)  and send the visual MedViewer 
reports  back to the research team member  via a secure (encrypted) email. 
The research team member will match the patient’s unique ID number 
back to the patient’s name, print the MedViewer report s, and deliver 
electronic or hard -copy report s to the provider before the appointment 
with the participating patient .  
  
Study Duration:  The estimated time of the study , from the start of enrollment  to 
completion of data collection , is expected  to be  approximately 16 months . 
This includes 1 month of initial provider participant enrollment, 
approximately 7.5 months of patient participant enrollment and data 
collection , and 1.5 months of final follow -up patient participant and 
provider participant data collection ). The study  duration has been 
extended by 6 months due to delays related to  COVID -19. 
  
Participant Duration:  Patient Participants : Expected duration of pa tient  participation in the 
study is one day  (approximately 4 hours) , with intervention activities and 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  15 quantitative data collection conducted during  a single study visit  that can 
take place over multiple days as needed .  
 
IDI subsample of pati ent participants : A subsample of up to 30 patient 
participants will be enrolled  for 2 -13 additional weeks depending on how 
soon they complete their  second study visit, including an  IDI and endline 
questionnaire (scheduled for 28 days  (-14 days /+60 days ) following the 
MedViewer clinic al visit with the provider or pharmacist) . The  IDI and 
endline questionnaire s are expected to occur on a sin gle day but  may 
occur on separate days.  
  
Provider Participants:  Expected duration of medical provider participation 
in the study is approximately 10 months, corresponding to  1 month of  the 
initial  provider recruitment  period  (pre-patient -involvement ), 
approximately 7.5 months conducting patient clinic visits  to deliver 
MedViewer reports , and 6 weeks  (1.5 months) after the close of  patient  
enrollment to  complete the endline questionnaire  and IDI . The IDI with  
each  medical provider will be conducted  at any point  after  the provider 
has delivered MedViewer report s to at least two patients  or following the 
close of patient enrollment, whichever comes first . 
SCHEMA  
1.A.1  PATIENT PARTICIPANT STUDY SCHEMA  
 
Figure 1: Patient participant study schema. Sequence of ENLIGHTEN study activities for patient participants.  
*NOTE: MedViewer Report Review can be conducted up to 28 days from hair sample collection if not completed at 
Day 1 Clinic Visit with Providers  
 
1.A.2  PROVIDER PARTICIPANT STUDY SCHEMA  

Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  16  
Figure 2 : Provider participant study schema. Sequence of ENLIGHTEN study activities for provider participants.   
 
SCHEDULE OF EVENTS (SOE ) 
 
There are two Schedules of Events (SOEs) shown below: one for patients and one for providers.  
 
Patients:  This table represents the SOE that will occur for each  patient participant. Day 1 represents  the 
day of enrollment for each patient participant.  
 
Procedures  
Pre-screening  
Day -6 months to Day 1  
Screening and 
Enrollment  
(-3 Days to Day 1)  
Study Visit 1/Day 1  
Study Visit 2  
Day 28  ( -14/ +60 days)  
Pre-screening  X    
Screening Visit    X   
Informed consent and MedViewer video   X   
Collect Study samples  (Hair and Mitra*)  X   
Demographics   X   
Baseline patient questionnaire   X   
Clinic Visit with Provider    X  
MedViewer Report Discussion**    X  
Post -visit patient questionnaire    X  
In depth i nterviews and endline  questionnaire (phone , computer -based  
or in -person) to subsample of ~30 patients     X 
Adverse event review    X X 
  
*- Mitra will only be collected for participants in Group B  and a subset in Group A . 
**- MedViewer Report Review can be conducted up to 28 days from hair sample collection if not 
completed at Day 1 Clinic Visit with Providers  

Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  17 Providers:  This table shows the SOE for provider participants . The exact duration of time for provider 
study visits with patients will vary based on the date of each provider’s enrollment.  Days -30 to 0 
represent the initial provider recruitment period. Day 1 represents the first day of provider enrollment. 
Day 228 represents the final day of provider enrollment (corresponding with the last day of the 7.5-
month period of patient enrollment and patient Study Visit 1). Day 270 (Day 228 + 42 days for endline 
provider data collection following the close of provider enroll ment) represents study close and the end 
of provider involvement.  Time  frames  represent providers’  active participation  in the  study, not 
including study delays related to COVID -19.  
 
Procedures  
 Initial Recruitment 
period  
Days -30  to 0 
Screening/Enrollment/
Training,  Baseline  Data 
Collection , Day 1  - 228  
Visits with patients  
Days 2 – 228  
In-depth interview  
Days 2 – 270  
Endline questionnaire  
Days 2 – 270 
Provider recruitment  X     
Provider consent, screening, demographics   X    
Provider training   X    
Post -training questionnaire   X    
Patient Visits –Provider receipt of MedViewer 
reports and MedViewer discussion with patients 
(see patient SOE above )   X   
Post-visit provider questionnaire (1 per enrolled 
patient visit)    X   
In-depth  interview ( after  seeing at least two  patient s 
or before study close, whichever comes first)     X  
Endline questionnaire        X 
Adverse event review   X X X X 
 
 
2  INTRODUCTION  
 
STUDY R ATIONALE   
 
This study is part of a larger research program  (R01AI122319) that is generating  data on a novel non-
invasive and longitudinal  approach to rapidly quantify antiretroviral (ARV)  concentrations and provide 
evidence of drug ingestion . The goal  is to provid e the clinician/researcher and patient/study participant 
feedback on ARV adherence. The novel approach utilizes infra -red (IR) matrix -assisted laser desorption 
electrospray ionization (MALDESI) technology for mass spectrometry imaging (MSI) to visualize and 
quantify ARV concentrations in h air. For the ease of patient/provider c ommunication, w e have labeled 
this IR-MALDESI MSI approach as “MedViewer ” and will refer to it as such throughout this protocol.  
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  18 Adherence to ARV therapy is critical for achie ving HIV RNA suppression in people living with HIV  and for 
preventing HIV acquisition in uninfected individuals using pre -exposure prophylaxis (PrEP).  Yet a high 
level of adherence can be  challenging for  people living with HIV  on life -long ARVs  and for HIV -negative 
individuals using daily PrEP who are not at daily risk for HIV acquisition. In multiple recent double -blind, 
placebo -controlled PrEP studies, p oor adherence was primarily responsible for a lack of drug efficacy  [1–
4]. These studies found that counting product returns and using patient self -report significantly over 
predicted adherence as measured by ARV concentra tions in blood plasma or cells  [1]. Since the 
consequences of poor or intermittent adherence are significant, valid measures of adherence, 
particularly adherence patterns over time, are critical for optimizing the effectiveness of bo th HIV 
treatment and prevention  in clinic and research settings. Blood plasma or intracellular concentration 
monitoring has been considered the “gold standard” for determining whether  an ARV has been ingested 
and is a comm on marker for therapeutic drug monitoring or clinic al trial adherence monitoring. 
However, this approach has its own set of limitations, including being invasive, requiring advanced 
processing or storage (e.g. intracellular measures), being a short -term me asure of drug taking behavior 
(depending on the half -life of the analyte), and requiring long turn -around times or substantial sample 
processing prior to analysis.  
 
We propos e the use of MedViewer to quantify and visualize ARV concentrations in hair. We hypothesi ze 
that MedViewer  can rapidly quantify ARV concentrations , provide non-invasive  and longitudinal  
evidence of drug ingestion, and allow for clinician/researcher and patient/study participant fee dback on 
adherence performance. Preliminary results fr om our investigation of MSI in hair suggest it has potential 
value in measuring longitudinal drug exposure [5].  Preliminary results from our R01 suggest  that 
MedViewer has potential value in distinguishing between patients who don’t initiate  ARV medication , 
those who miss dose s, and those who don’t persist  [54]. However, little is known about whether or how 
such an intervention tool would be acce pted by patients or providers or how best to implement it in the 
context of a clinic setting. The aim of this pilot study is to investigate the acceptability, appropriateness, 
and feasibility of using MedViewer  in the setting of clinical monitoring. The goal of this work is to 
develop a simple, noninvasive, longitudinal depiction of ARV adherence th at will provide high clarity 
feedback for both clinicians and patients.  Given that this is a feasibility pilot, no change in clinical care is 
anticipated  from the intervention.  While providers will use the investigational reports during their 
conversation s with patients a bout ARV adherence, p rovider participants will still only utilize currently 
accepted measures of ARV adherence, including measuring HIV viral load , utilizing the results of HIV 
genotyping in the setting of viremia , and utilizing therapeuti c drug monitoring of antiretrovirals  in 
making clinical decisions .   
 
Results from our formative work  in Aim 3a  suggest  that a fully validated MedViewer would be an 
acceptable, appropriate , and f easible method for providing patients  living with HIV  with feedback 
regarding longitudinal patterns of medication adherence [6,7] . Piloting the implementation of 
MedViewer is critical for determining the extent to which the formative results hold true and  identifying  
potential modifications to the MedViewer procedures for future optimal implementation at scale.  
 
We will use 2 viral load strata for recruitment and main analyses and 3 viral load groups for some 
exploratory analyses.  We selected and defined these strata based on several factors: (1) clinical 
importance of understanding adherence and the potential effects of MedViewer on adherence among 
patients with different VL levels; (2) empirical data of the distribution of VL levels among patients in 
the UNC ID Clini c; (3) practical considerations of the need to enroll participants efficiently; (4) 
considerations of the statistical precision and power.   
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  19 1. Clinical importance of understanding adherence and the potential effects of MedViewer on 
adherence among patients wi th different VL levels:  Input from the medical officer and clinic 
director of the study were based on clinical judgement and literature review. Based on their input, it 
was deemed that a 2-year viral load history w ill provide sufficient data to identify an d distinguish 
patients with at least 1 detectable VL from patients with a history of ALL undetectable viral loads.  
Considered of particular importance, suboptimal adherence is most likely to occur (and hence be 
most important to explore) among patients wit h a history of at least 1 detectable viral load.  Thus, 
it will be particularly useful to understand the longitudinal adherence patterns (as reflected by the 
concentration of medication in hair) among patients with history of having at least one detectable  
viral load.  
 
Whereas serum viral load is checked  every three to six months and is challenging to relate to specific 
adherence patterns, ARV concentration measurements in hair provide more granular information 
about day -to-day adherence in the weeks or months prior to hair sample collection. Therefore, 
recruiting patients with a history of ALL undetectable VL levels in the past two years at this pilot 
stage of research, will help clinicians and researchers understand the extent to which undetectable 
VLs measured only periodically reflect consistently good  adherence. It will also help researchers and 
clinicians understand the extent to which variability in concentrations of ARV s in the body/hair over 
time does not lead to virologic failure.  
 
Thus, it was deemed important to explore MedViewer among both (i)  patients with histories of ALL 
undetectable viral loads, and (ii) patients with a history of at least 1 detectable viral load.  These 
same strata will be used for our main analyses . 
 
Regarding recruitment and analysis of the strata of participants who had  at least 1 detectable viral 
load, it was deemed clinically important to investigate, in an exploratory manner, longitudinal ARV 
concentration s of patients who are usually undetectable but experience occasional low -level “blips” 
in their viral load (e.g. a t levels up to 1,000 or 10,000 copies/mL) compared to those with higher 
levels of detectable VL. The clinical etiology and full implications of such blips are not well 
understood, but it is increasingly evident that any time with detectable viral load conf ers higher risk 
of morbidity (including vascular inflammation, neurologic and cognitive impact, risk of malignancy, 
and immunologic compromise). Exploring the relationship between longitudinal patterns of ARV 
concentrations  in hair among people having vira l blips and comparing these patterns with those of 
undetectable and higher level detectable VL will shed light on the clinical importance of blips. 
Therefore, it will be important to recruit sufficient numbers of individuals who have such blips as 
describe d below in points 2 -4.  
 
2. Empirical data of the distribution of VL levels among patient s in the UNC ID Clinic . While it will be 
important to recruit enough patients with blips, patients with VL between undetectable to 1,000 
copies/mL (or even undetectable to 10,000 copies/mL) represent a relatively small proportion of the 
UNC ID Clinic  population (15%), and the bes t viral load to use as a cut -off for determining a blip 
remains undefined . In descriptive analyses among over 2,000 patients living with HIV in the UNC ID 
Clinic  with at least 1 VL measure in the last 2 years, 15% had at least 1 undetectable VL and 1 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  20 detec table VL while on ARVs. These individuals were evenly  distributed among those whose highest 
detectable VL was <1,000 copies/mL versus those >1,000 copies/mL.  Hence, we determined that 
recruitment stratification requiring balanced numbers would not be nece ssary to obtain sufficient 
numbers of patients within each of the two detectable VL groups (those below , vs. at or above , 
1,000 copies/mL) in order to conduct exploratory analyses because they were evenly distributed in 
the clinic naturally.  
 
3. Practical co nsiderations of the need to enroll participants efficiently.  Further, recruiting all eligible 
patients with at least 1 detectable viral load would enable recruitment to proceed faster (and more 
flexibly) than if stratified by the level of detectable VLs.  
 
4. Considerations of the statistical precision and power.  The m ain analyses will use these two strata 
(described in 9.2). However, exploratory analyses will be conducted using the 3 viral load groups: (i) 
all undetectable at the level of quantification of th e laboratory, (ii) those with at least 1 detectable 
but < 1,000 copies/mL and (iii) those with at least 1 detectable VL > 1,000. Given that the proportion 
of patients in the two upper strata are approximately equal, but combined are only 15% of the total 
available participants, oversampling of the detectable stratum (compared with its natural 
distribution) during recruitment at a 1:1 ratio ( 25 in detectable stratum and 25 in the undetectable 
stratum) will allow sufficient number of participants in each of t he 3 analytic groups to enable 
exploratory comparisons as per the statistical power calculations.  
 
A. BACKGROUND   
 
Over the past 10 years, hair analysis has gained importance in forensic sciences [8], drug testing  [9,10] , 
toxicology investigations [11], and for evaluating drug adherence [12].  Hair is unique in that it has the 
potential to provide information about drug intake over a longer period of time compared to other 
biological fluids, including plasma [2], blo od cells [13], and urine [14]. Advances in analytical technology 
have transitioned hair analysis from gas chromato graphy -mass spectrometry (GC -MS) methods to more 
efficient and sensitive liquid chromatography -triple quadr upole (LC -MS/M S) methods. However, several  
limitations exist  to current hair analysis techniques that constrain the utility of this technology to rapidly 
quantify drug exposure over time and be used as a measure of adherence to inform and influence drug 
taking behavior:   
 
1.  LC-MS/MS QUANTIFICATION REQUIRES LARGE AMO UNTS OF HAIR.  Despite the advances in 
sensitive LC -MS/MS instrumentation, some ARVs require collecting a thatch of up to 100 strands 
of hair (20).  Since no one multiplex LC -MS/MS method exists to measure all ARVs in a single 
sample, multiple thatches are  required for complete ARV evaluation.  This can be a significant 
deterrent for individuals with short hair, for those who require hair collected between braids, or 
who object to the collection of large amounts for cultural reasons [15].  Conversely, mass 
spectro metr y imaging (MSI) utilizes  single hair strands for analysis. MSI is the only imaging 
technique that can determine the identity and distribution of drugs and their metabolites in 
biological matrices with one test without complicated labelling approaches.  We have previously 
demonstr ated that our IR-MALDESI MSI technique is suitable for ARV detection in biological 
samples [16–18], and  show here that it can quantify ARVs in hair.  
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  21 2. LC-MS/MS HAIR QUANTIFICATION REQUIRES TIME -CONSUMING PROCESSING . Although 
sensitive and specific, LC -MS/MS data requires at least 7 steps to process hair for analysis, 
including segmentation, decontamination,  cutting or grinding, extracting, and purifying before 
analysis can occur [19].  In addition, these tests require processing of “blank” matrices for 
standard curve and quality control samples.  IR -MALDESI MSI requires minimal sample 
processing, allowing the sample to be analyzed within two hours .   
 
3. NO DATA EXIST ON USING R EAL-TIME HAIR MONITORING IN PEOPLE LIVING WITH HIV . Because 
of the time -consuming nature of sample processing, real -time monitoring of adherence in hair 
has not yet been performed.  Rather, this technique has been limited to retrospective analysis of 
clinical trial or clinical cohort data.  Utilizing an IR -MALDESI approach can shorten the time to 
data generation to two hours. We will investigate the feasibility of conducting adherence 
monitoring in a clinic setting utilizing this novel technology.   
 
4. LC-MS/MS PROVIDES LIMITED DATA ON ADHERENCE OVER TIME . Current homogenate methods 
only provide drug exposure averaged a cross hair strands and lengths and do not provide 
adherenc e information on a time scale. For example, for those with long hair, recent changes in 
adherence can confound  past adherence patterns. Normalization of hair length between 
subjects is not routinely performed, as logistical difficulties (e.g. amount of hair curl, large 
number of strands needed for analysis) precl ude uniformly segmenting hair. MSI combines the 
specificity of current LC -MS/MS  methods with localization information similar to whole body 
autoradiography. By combining rate of hair growth (~1cm/month) with the amount of drug 
exposure along the length of the hair strand, drug exposure over time can be accurately 
determined. Furtherm ore, it is possible that a more granular dosing history can be constructed 
by mathematical modeling of the concentration data along the strand over time by 
incorporating partial differential equations.  
 
5. LIMITED DATA EXIST ON ACCEPTABILITY OF HAIR COLLECTION FOR DRUG MONITORING . Most 
hair sampling to date has been conducted in the context of clinical investigations with 
retrospective analyses. Recently, a clinical study evaluating the use of ARV hair concentrations 
from Ugandan children  living with HIV found collection challenging, and the investigators 
suggested that community education and buy -in was integral to impleme nting this intervention 
[20]. In a study that examined perspectives, beliefs, and concerns of ARV users providing hair 
specimens for ARV concentration, participants found this request to be unusual, and identified 
several  cultural beliefs that could impede sample collection. However, the majority of 
participants were willing to give hair if provided with enough information beforehand [21]. In 
Aim 3a, we conducted formative work by engaging with patients and providers to understand 
the anticipated acceptability of a  hypothetical tool to monitor ARV adherence in the clinica l 
setting, but we lack data on acceptability from actual implem entation of a longitudinal 
adherence monitoring tool.   
 
6. MEDICAL PROVIDERS COULD BENEFIT FROM SUPPORT TO HELP THEM OVERCOME SUBSTANTIAL 
CHALLENGES THEY FACE ADDRESSING ARV ADHERENCE WITH THEIR PATIENTS. Research, 
including our statewide survey of NC HIV providers, has found that physicians face challenges 
when c ounseling their patients about ART adherence [22–30], and that health care professionals 
would benefit from additional suppo rt to effectively address adherence [30–33]. Our research, 
and that of  others, has demonstrated that counseling with feedback can enhance medication 
adherence [34–40]. For example, in PACT, we tested the use of motivational interviewing with 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  22 visual feedback of MEMS adherence data in the UNC ID Clinic ; the intervention group had 2.75 
times higher odds of achieving >95% adherence than controls (95% CI:1.023 -7.398) [41]. 
Through additional studies, we have documented methods for supporting HIV providers in 
effectively adopting new practices and tools t o improve patient outcomes, and  strategies to 
encourage patient -provider partnerships in medical decision -making [41–49]. Hair MSI 
adherence data will allow us to take this work a step further, using state -of-the-art technology 
to give providers a new tool for conducting data -driven, rea l time adherence counseling.  
  
An IR -MALDESI MSI method has been validated for the quantitation of emtricitabine (FTC) and 
dolutegravir (DTG) in hair strands ( Appendix E.1. As part of t his validation, we have determined lower 
limits of quantitation for each of these two ARVs (FTC: 0.27 ng/mg; DTG: 0.04 ng/mg) based on 
calibration of IR -MALDESI MSI response using a series of prepared hair standards are within the range of 
incurred samples  we have evaluated as part of Study Aim 1. These medicines are available in many 
combination pills, such as Truvada®, Biktarvy®, and Tivicay®, and several others. Method accuracy and 
precision have been evaluated from incurred samples for each of the two t argeted ARVs, meeting 
acceptance criteria, and are also summarized in the method validation report . We have developed a 
quantitative workflow for rapid, sensitive analysis of hair strands that is performed in two steps. First, a 
calibration of IR -MALDESI MSI response to ARVs is conducted by uniformly spraying ARV standards in 
increasing concentration onto  blank hair strands using a templated acrylic mask, resulting in a linear 
response to ARVs over relevant concentration ranges. Second, evaluation of all ARV response in hair 
strands is measured simultaneously with an internal standard (IS) and melanin biom arker.  
We have investigated differences in IR -MALDESI ARV response based on hair color and cosmetic 
alteration  (Appendix F.1).  Through simultaneous assessment of ARVs and a melanin biomarker, we 
observed a positive correlation between IR -MALDESI ARV and melanin response in hair strands for 
dolutegravir, and a slightly negative correlation between emtricitabine and melanin. Normalizing the 
average IR -MALDESI response to daily dosing for FTC and DTG did not improve the relative standard 
deviation of observa tions. These results indicate no advantage to scaling IR -MALDESI signal abundance 
based on melanin content in hair. Mechanical manipulation of hair strands collected from Aim 1 were 
performed according to specified package instructions from commonly used p roducts for bleaching, 
dyeing, and relaxer treatments. Matched treated and untreated hair strands were evaluated under the 
same experimental conditions to assess any changes in IR -MALDESI MSI response to ARVs resulting from 
the treatment process. Only dyei ng resulted in decreased response  for dolutegravir  in hair, but all 
treatment regimens reduced emtricitabine below the limit of detection . Evaluation of emtricitabine in 
hair strands collected as part of [STUDY_ID_REMOVED]  from patients reporting a variety of rec ent hair 
treatments indicated that treatments within a period of 4 weeks from sampling did reduce the IR -
MALDESI signal abundance, but that treatments further in the past would not influence measurements 
focused on the past month of adherence.   Therefore, volunteers will be excluded if they have had  
treatment to their hair within the past 4 weeks  per self -report .  For this protocol, chemical hair 
treatments will be defined as partial or complete bleach, dye or relaxer with in the 28 days prior to the 
enrollment visit.  Other hair treatments are not exclusionary.  Volunteers enrolled in the sub -study will 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  23 also be excluded if they have self-reported chemical  hair treatments within the 28 days prior to that 
visit.  
Benchmarking of I R-MALDESI MSI longitudinal ARV profiling (Appendix D.1) has been conducted through 
3-phase (single dose, daily dose, dose proportionality) directly observed therapy studies with FTC+TFV  
and DTG  ([STUDY_ID_REMOVED]) . IR-MALDESI MSI longitudinal profiles from sampl es collected at the end of the 
third phase detected changes in the intensity of response to ARVs along hair strands corresponding to 
the prescribed phases of the directly observed therapy studies. Steady -state profile response to daily 
dosing across study participants was measured to establish optimal hair response and adherence 
thresholds analysis  based on receiver operat ing characteristic curves of the IR -MALDESI MSI ARV 
profiles .  
 
Additionally, we have conducted a formative qualitative study (Aim 3a of R01AI122319) to inform 
intervention development for this pilot study around feasibility, acceptability, and appropriateness of 
MedViewer implementation in a busy clinic environment. We collected qualitative  data fr om 30 patients 
and 29 providers of the UNC ID Clinic  and obtained input from two Community Advisory Boards to refine  
the procedures that will be used to deliver MedViewer test results  to patients in this pilot study.  First, 
we developed three prototype graphical displays of hypothetical adherence data and interviewed 30 
patients  living with HIV  and 29 clinicians to explore their reactions to each graphical display . Patients 
and clinicians expressed enthusiasm about using the  graphs to facilitate und erstanding of patient 
adherence. Several themes also emerged regarding enhancing usability of the graphs: Patients and 
clinicians questioned why graphs would show drug c oncentrations above the therapeutic range. For 
patients with lower health literacy, the graphs did not provide enough  understanding of the link 
between medication -taking and drug concentrations in hair - these patients also preferred pictographs 
over bar o r line graphs. Clinicians preferred daily drug concentration data in bar graphs accompanied by 
information about the measure’s variability . These findings indicated a need for  separate visual results 
displays for patients and providers, with provider displ ays offering more complex information . [6] 
 
We also sought patient and provider opinions about apply ing real-time feedback in to patient -provide r 
conversations about adherence. Both patients and providers suggested that identifying patterns of non -
adherence with real -time feedback could facilitate problem -solving , provide motivation to improve 
adherence, and reinforce the importance of optimal adh erence to ART by comparing adherence and 
viral load results. Some providers worried that discussing real -time monitoring results could harm the 
patient -provider relationship by implying mistrust of patient -reported adherence . A few providers were 
also conc erned that adherence monitoring could discourage patients’ retention in care  if they feel they 
are being “policed .” Similarly, several patients felt that receiving suboptimal results could make 
participants feel defeated and reduce their adherence motivation . To address these concerns, we found 
that communication guidance to providers about discussing real -time MedViewer Report  with patients 
should focus on both optimizing adherence and mitigating negative perceptions of adherence 
monitoring to pres erve trust and engagement in care.  While our formative work indicates that patients 
and providers anticipated finding MedViewer acceptable and appropriate, no data exist regarding actual 
acceptability, appropriateness, or feasibility of MedViewer implement ation in a busy clinic, a gap that 
we will address with this study.  [7] 
  
Our proposed study  is highly significant in that it not only addresses the limitations of current biologic 
appr oaches to quantifying adherence  but also provides solutions to many of the current analytical 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  24 limitations of hair analysis. Our novel comprehensive engagement of s takeholders for determining 
optimal approaches to providing hair adherence data will allow a complete understanding of strengths 
and limitations of implementing this a pproach in a clinical setting. Achieving the goals set forth in this 
application will sig nificantly enhance our understandin g of drug pharmacology in hair and place hair 
data generated by MedViewer  in context for clinical studies and clinical practice. Although these data 
may not, by themselves, solve all issues related to measuring adherence,  our current success in mass 
spectrometry evaluation of ARVs in complicated matrices, track -record of measuring  ARVs by IR -
MALDESI MSI, and  expertise in social and behavioral research highly justifies further pharmacologic 
investigations into the use of ha ir imaging to quantify adherence. The approach we discuss here has 
widespread implications in clinical and research settings.  
 
 
RISK/BENEFIT ASSESSMENT     
2.A.1  KNOWN POTENTIAL RISKS  
 
Risks from participation in this study and from exposure to  the intervention are minimal . 
 
Risks to patient p articipants  
 
• Video.  Although the MedViewer intervention video is designed to introduce patients to 
MedViewer in an approachable manner, it is possible that patients will experience disco mfort or 
anxiety watching a video about providing a hair sample for  conducting the  MedVie wer test and 
about antiretroviral medication circulating in their body depositing in their hair.  To minimize this 
risk, in addition to having designed the video with extensive input from patients, we will also 
inform patient participants prior to watching the video that it is currently for investigational use 
only and that they may stop it at any time if they feel uncomfortable.  
 
• Baseline and post -visit  questionnaires : Immediate known potential risks to participating in the 
questionnaires include the potential for patients to feel uncomfortable or experience anxiety 
when being asked questions about their medication adherence and about their interaction with 
their provider.  To minimize this risk, questions are designed to be asked in a neutral, non -
judg mental manner and patients will be provided assurance that their information will remain 
private, will not be known to their provider nor affect their medical care. They will also be 
informed that they may stop o r skip any questions that they do not wish t o an swer.  
  
• Hair collection : There is no foreseeable risk with hair collection. No hair related adverse events 
have been reported on prior hair collection protocols , and we will collect hair samples on this 
protocol using the same operating procedures.  
 
• Blood collection : Blood will be collected via phlebotomy or fingerstick.  Risks associated with 
blood draws include bleeding, discomfort, feelings of dizziness or faintness, and/or bruising, 
swelling and/or infection.  A finger stick is a bit uncomfortable and may cause some soreness and 
bruising. Very rarely, the  site can become infected.   The research team will attempt to minimize 
these risks by having all samples collected by trained professionals  using aseptic technique .  
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  25 • MedViewer test and r eport: It is possible that discussing MedViewer report  may alter patient -
provider communication  during the clinic visit, such that the patient and/or provider feels 
uncomfortable. Patient  participant s may feel anxious or embarrassed reviewing their 
MedViewer Report  with the provider or pharmacist or uncomfortable if the Med -Viewer results 
contradict  self-reported adherence. Additionally, misinterpretation of MedViewer report  may 
lead to misunderstanding of or confusion about adherence patterns and pot entially 
misinformed conversations about patient medication -taking. To minimize these risks the study 
team will take every measure to answer patient questions about the report and to normalize 
nonadherence nonjudgmentally during the MedViewer video . The st udy team wil l also  train 
providers to clearly understand and explain MedViewer results  and inform both patient and 
provider participants that MedViewer reports are  currently for investigational use only  and that 
no clinical decisions should be made based on MedViewer reports.   The study team will also ask 
patients, in post -visit questionnaires and  (for the subsample)  IDIs, to report the extent to which 
they perceive that the report and their beliefs abou t their medication -taking align.  
 
• Confidentiality:  Participation in clinical research includes the risks of loss of confidentiality and 
discomfort with the personal nature of questions. Although the study site makes every effort to 
protect participant pri vacy and confidentiality, it is possible that participants’ involvement in the 
study could become known to others  and that social harms may result (i.e., because participants 
could become known as HIV -infected ). For example, participants could be treated un fairly or 
discriminated against  or could encounter lack of acceptance  by thei r families and/or 
communities. Several systems are in place to maintain participant confidentiality. All hard copies 
of study records , including all documents with perso nally identifiable information,  will be kept in 
a locked drawer in a locked office to which only the study  investigators will have access. 
Sample s, study data, and study report forms will not contain patient names ; rather they will be 
labeled with a  unique  study identification (ID) number  with a combination of letters and 
numbers . The file that links participant identification numbers to their names and other 
identifiable information will be password -protected and kept by one study investigator on a 
secure internal computer network, separate from the study data . All electronic data for this 
study will be stored on a dedicated University server which contains extensive protections and 
securities. The server is housed and administered at the server farm at the  Manning data center 
located at 211 Manning Drive Chapel Hill, NC 27599 -3420. Though every effort  will be made to 
keep research records private, there may be times when federal or state law requires the 
disclosure of such records, including personal inform ation. This is very unlikely, but if disclosure 
is ever required; UNC -Chapel Hill will take steps allowable by law to protect the privacy of 
personal information. Additionally, all patient  recruitment and screening phone calls will be 
conducted in a privat e room with the door closed  to prevent inadvertent disclosure of 
participant information . All recruitment  emails will use a standard IRB -approved script including 
only general information that the patient may be eligible for a research study at the UNC 
Medical Center  and request ing that they contact the study staff by phone , if interested , to learn 
more.  
 
• Long -range risks: There are no known long -range risks of the study.  
 
• Unknown risks:  There may be risks unknown to the study researchers, so all pa tient s are 
encouraged to report all problems.  
 
  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  26 Additional risks to a subsample of patients pa rticipating in in -depth interview s (IDI)  
 
• Semi-structured IDIs: Risks to participation in the interviews includes the potential for patient 
participants to feel uncomfortable or experie nce anxiety when being asked in -depth questions 
about their medication adherence and about their experiences during adherence counseling 
with Me dViewer.  To minimize these risks the study team will conduct the interviews in a neutral 
and non -judgmental manner and patients will be reminded that they can stop at any time o r 
skip any questions that make them feel uncomfortable.  In a case in which a pa tient does 
experience anxiety that is particularly uncomfortable, they will be offered the opportunity for a 
referral to a mental health counselor in the clinic.  
 
• Confidentiality : In addition to the steps mentioned above to maintain participant 
confidentialit y, all interviews  and brief questionnaires  will take place in a private room with a 
closed door  or on a secure IRB approved video or phone call  in a private room with a closed 
door to prevent inadvertent disclosure of participant information . All interview data, including 
audiotapes, will be stored either in a locked drawer in a locked office to which only the study 
investigators will have access or electronically in a password -protected folder on the dedicated 
university server.  
 
• Long range r isks: There are no  known long -range risks of the study.   
 
• Unknown risks:  There may be risks unknown to the study researchers, so all patients are 
encouraged to report all problems.  
 
Risks to provider/pharmacist p articipants  
 
• Questionnaires : Immediate known risks to participating in the questionnaires include the 
potential for providers to feel uncomfortable or experience anxiety when being asked questions 
about their patients’ medication adherence and about their adherence counseling practice s. To 
minimize these risks the study team will conduct the interviews in a neutral and non -judgmental 
manner and providers  will be reminded that they can stop at any time o r skip any questions that 
make them feel uncomfortable.  
 
• MedViewer test and r eport: It is possible that discussing MedViewer report  may alter patient -
provider communication during the clinic visit,  such that the patient and/or provider feels 
uncomfortable.  To minimize this risk, will inform provider participants that the MedViewer 
Report is currently for investigational use only. Providers may s pend  extra time with patients to 
discuss  MedViewer report , which  may prolong the appointment and delay the providers ’ 
schedule for the day.  As a primary goal of this study is to assess whether the use of the report 
will prolong patient visits or be a feasible, useful and acceptable tool, we may not be able to 
fully pre vent this risk. To minimize it, however, we will obtain feedback after each patient visit 
about both patient and provider experiences with the tool.  
 
• Semi -structured IDIs : Risks to participation in the interviews includes the potential for providers 
to feel uncomfortable or experience anxiety when being asked about their patients’ medication 
adherence and about their adherence counseling practices.  To minimize these risks the study 
team will conduct the interviews in a neutral and non -judgme ntal manner and providers will be 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  27 reminded that they can stop at any time o r skip any questions that make them feel 
uncomfortable.  
 
• Confidentiality:  Participation in research includes the risks of loss of confidentiality and 
discomfort with personal natu re of questions. Although the study site makes every effort to 
protect participant privacy and confidentiality, provider participants’ involvement in the study 
could become known to others, and it is possible, although not likely, that social harms may 
result. The same steps listed above to maintain patient confidentiality will be used to ma intain 
provider confidentiality, and all in -depth interviews will take place in a private room  or through 
a secure IRB approved video or phone call . 
 
• Long -range risks: There are no known  long -range risks of the study.  
 
• Unknown risks:  There may be risks unknown to the study researchers, so all participants are 
encouraged to report all problems.  
 
2.A.2  KNOWN POTENTIAL BENEFITS   
 
Participants may not receive a direct benefit from being in this study, as this research  is designed to 
generate information to benefit others in the future. While t here are no yet known benefits of the 
intervention, one possible immediate benefit is that the viewing investigational  longitudinal  adherence  
information  in the investigational MedViewer report  may facilitate  provider -patient communication and 
help  patients develop strategies for improving their adherence. Additionally , patients  may become more 
knowledgeable  about ARV medicat ion and their medication -taking patterns . Through the MedViewer 
intervention video, patients will learn how medication  is distributed in their body  and how the 
MedViewer test works . It is possible that increased information and knowledge will help patients 
become more adherent to their medication leading to longer -term health benefits.  
 
Additionally, medical providers may find MedViewer useful in facilitating adherence counseling with  
their patients, prompting patients to offer the provider  more information that the provider can use to 
more appropriately tailor their counseling to patients’ circumstances. Knowledge  to be gained from this 
study has the potential to inform further develo pment of the MedViewer test, a novel  method  to 
improve medication adherence of people living with HIV  and other chronically medicated patients.  Such 
a method  has the potential to , in turn , improve patients’ health outcomes by  facilitating their  
medication adherence patterns and helping them reach optimal levels of the indicated medication.  
 
2.A.3  ASSESSMENT OF POTENTIAL RISKS AND BENEFITS  
 
The proposed research presents very min imal risks to the participants and has the potential to benefit  
the participants by assisting  in the development  of a new tool to help patients improve their 
medication -taking behaviors . The information to be gained from this study cannot be obtained without 
exposure of par ticipants to the intervention.  
  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  28 3 OBJECTIVES AND ENDPOINTS  
 
OBJECTIVES  ENDPOINTS  JUSTIFICATION FOR ENDPOINTS  
Primary    
Investigate the feasibility 
of delivering the 
MedViewer intervention 
as planned, the 
acceptability to patients 
of participation in the 
MedViewer 
intervention, and the 
appropriateness of 
MedViewer use for 
adherence counseling  1. Feasibility : proportion of participants receiving 
the MedViewer report during their provider visit, 
as planned (i.e. the result s are  delivered to 
designated research staff member  within 2 hours 
of initiation of hair processing  and the results are 
discussed with provider/pharmacist within 4 weeks 
of hair collection ).  
 
2. Acceptability : proportion of contacted patients 
who are eligible for a screening visit (not including 
inclusion criterion 9) who agree to participate in 
the MedViewer intervention pilot study.   
 
3. Appropriateness : perceived usefulness of the 
MedViewer intervention for adherence coun seling.  
 Evaluation of these 
implementation domains will 
indicate the potential for future 
application of MedViewer in 
routine care and will help to 
identify needed modifications to 
the MedViewer intervention to 
improve delivery. Proctor et al.’s 
(2011) fr amework for outcomes 
in implementation research 
indicates the importance of 
assessing feasibility, acceptability, 
and appropriateness  [50]. 
Secondary    
Investigate additional 
dimensions of feasibility, 
acceptability, and 
appropriateness of using 
hair IR -MALDESI MSI 
(MedViewer ) to provide 
patients  living with HIV  
with feedback regarding 
longitudinal patterns of 
medication adherence  
 
 
 
 
 
 
 
 
 Feasibility : 
1. Reasons for patient’s non -receipt of the 
MedViewer report during a visit with provider or 
pharmacist within 4 weeks of hair collection  (if 
applicable).  
2. Reasons for non -discussion of the MedViewer 
report with provider or pharmacist (if applicable).  
3. Duration of time (in minutes) from initiation of 
hair processing  to MedViewer report delivery to 
designated research  staff member . 
 
Acceptability : 
1. Provider -reported likelihood of recommending 
MedViewer to future patients.  
2. Patient -reported likelihood of agreeing to future 
MedViewer use.  
3. Patient comprehension of the MedViewer 
report.  
 
Appropriateness : 
1. Perceived usefulness of MedViewer to promote 
ART adherence.  
2. Perceived impact of MedViewer use on patient -
provider com munication and relationship.  
 Evaluation of these 
implementation domains will 
indicate the potential for future 
application of MedViewer in 
routine care and will help to 
identify needed modifications to 
the MedViewer procedure to 
improve delivery. Proctor et al.’s 
(2011) framework for outcomes 
in implementation research 
indicates the importance of 
assessing feasibility, acceptability, 
and appropriateness  [50]. 
Exploratory    
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  29 OBJECTIVES  ENDPOINTS  JUSTIFICATION FOR ENDPOINTS  
1. Assess exploratory 
aspects of MedViewer 
feasibility  and 
acceptability, and 
patient and provider 
views of and experiences 
with the MedViewer 
test. 
 
Explore the impact of 
adherence cou nseling 
using MedViewer on  
ART adherence and 
hypothesized 
mechanisms of change 
(adherence information, 
motivation, behavioral 
skills). 
 
2.  Feasibility :  
1. Patient -reported maximum out of pocket cost 
willing to pay for MedViewer.  
2. Cost of MedViewer delivery per person.  
3. Compatibility of MedViewer with current clinic 
practices.  
 
Acceptability :  
1.Patient -reported reasons for declining 
participation in the MedViewer intervention pilot 
study.  
2. Reasons would/would not agree to (patient -
reported ) or recommend (provider -reported ) 
future MedViewer use.  
3. Acceptability of specific components of 
MedViewer procedure (a -d): 
a. Suffic iency of provider training & materials . 
b. Sufficiency of patient education (video) . 
c. Provider s atisfaction with results delivery 
(discussion format and content) . 
d. Patient satisfaction with results delivery 
(person, discussion format, and content)  
Adherence -Related :  
1. ART adherence measured by self -reported 
assessment of 3 -day, 7-day,  and 30 -day adherence.   
2. Adherence information (qualitative assessment 
of information/ understanding gained of patient 
adherence resulting from use of MedViewer)  
3. Adherence motivation (quantitative and 
qualitative assessment of adherence motivation 
resulting from use of MedViewer)  
4. Adherence behavioral skills (quantitative and 
qualitativ e assessment of adherence behavioral 
skills and self -efficacy resulting from use of 
MedViewer)  
 Preliminary assessment of 
MedViewer’s impact on the 
intended behavioral outcome 
(ART adherence) and 
hypothesized mechanisms of 
influence (based on Information, 
Motivation, and Behavioral Skills 
model) will be used inform the 
design of a future randomized 
trial to evaluate the effect of 
MedViewer on these endpoints  
[51]. 
Further explore the 
accuracy of the 
MedViewer test as an 
adherence measure  1. ARV  concentrations in blood collected for first 
patient study visit  and follow -up patient study visit , 
when  applicable.  
2. Patient viral load assessed with a  clinical care  
visit linked to a patient -provider MedViewer visit 
and abstracted from the medical record by study 
staff . 
3. log10 antiretroviral drug concentrations i n hair   
collected for first patient study visit  and follow -up 
patient study visit , when  applicable . These endpoints will allow for 
comparison of reported 
concentrations of medi cation in 
hair with recent ART adherence, 
as measured via Mitra  and 
current viral load. These 
comparisons will provide further 
evidence to assess MedViewer 
accuracy (in addition to that 
gathered in Aims 1,2) among a 
larger group of patients.  
 
  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  30 4 STUDY DESIGN  
 
OVERALL  DESIGN  
 
This is a pilot study to assess the feasibility, acceptability and appropriateness of delivery of the  
investigational  MedViewer intervention  in an academic Infectious D iseases  clinic with adult patients 
living with HIV who have been prescribed ARV medication by a  UNC provider in the last three months. 
We hypothesize that patients and medical  providers will find IR -MALDESI MSI (MedViewer) to be an 
acceptable, appropriate , and fe asible method for providing patients  living with HIV  with feedback 
regarding longitudinal p atterns of medication adherence. As this does not entail a medication, trial 
phase is not applicable.  
 
The proposed study is a single -site, single -arm cross -sectional pilot study  that will implement the 
MedViewer intervention to 50 eligible  patients  living  with HIV  and administer brief, post -visit patient 
questionnaires (Appendix C.2 ) and provider  questionnaire s (Appendix C.6). A subset of up to 30 patient 
participants and all  provider participants will also participate in semi -structured in -depth interviews 
(Appendix C.3 and Appendix C.7 , respectively ) (IDIs)  and endline  questionnaires  (Appendix C.4, 
Appendices C.8 -9).  
 
SCIENTIFIC R ATIONALE FOR STUDY DESIGN  
 
To address the proposed study objective  to pilot test the MedViewer intervention for feasibility, 
acceptability, and appropriateness, a single arm study is appropriate. This study will provide data to 
inform a subsequent  larger randomize d controlled trial to assess  efficacy of the intervention to improve 
patient outcomes, including medication adherence and viral load. Data will be collected from both 
patient and provider participants as well as clinic tracking records. The combination of quantitative and 
qualitative  data collection  from various sources  will provide information about various as pects of 
feasibility , acceptability , and appropriateness  of the MedViewer intervention from the patient, provider, 
and clinic perspective.  
 
JUSTIFICATION FOR DO SE 
 
There are no study medication products in this pilot study . Patient participants will be on  clinically 
acceptable ARV regime ns as prescribed by their regular HIV  care providers. No alterations  in patients’ 
medication list s will be undertaken  as part of  this study.    
 
Patient exposure to the study  intervention will be measured as time , in minutes.  Time spent by patients 
to undergo  the intervention will include  1) approximately eight minute s of exposure to the MedViewer 
video  (with the opportunity to watch the video multiple times, as needed) ; 2) approximately 2-5 
minutes to collect  the hair  sample ; and 3) the duration of time spent rev iewing the MedViewer report 
with the provider/pharmacist during the provider or pharmacist visit (estimated at 2-10 minutes).  The 
video  observation , hair sample collection , and review and discussion of the MedViewer report may each 
occur on different days  (with up to 3 days between the video and hair sample collection and up to 4 
weeks between hair sample collection and MedViewer report review and discussion ). The study  
intervention has been designed to introduce the minimum amount of time necessa ry to run t he 
MedViewer test and report the  results  back to the patient while maintaining  accuracy  and 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  31 confidentiality . Use of daily adherence monitoring feedback during adherence counseling has shown 
promise as an effective strategy to promote medication adherence  [35,39] . As this is a cross -sectional 
pilot study, there will  be one single exposure to the MedViewer intervention.  
 
Provider  exposure to the  study  intervention will also be measured as time in minutes, including 
approximately 30-60 minutes for the MedViewer provider training as well  as the  duration of  time spent 
reviewing the MedViewer report with the patient during the provider or pharmacist visit (estimated 2 -
10 minutes) . Unlike patient participants, providers will be exposed to the interv ention over  multiple 
time points. Providers will be exposed to the intervention each time they have an appointment with a 
patient who  is participating in the stud y throughout the 7.5 months of patient enrollment . Providers will 
have varying levels of exposure depending on the number of enrolled patients they see as part of the 
study.  
 
END OF STUDY DEFINITION    
 
A patient  participant is  considered to have completed the study if he /she/ze/they  has completed all 
aspects of the study , including the last scheduled procedure (i.e. the post -visit patient questionnaire , 
and/or the blood sample , when applicable , whichever comes last ) shown in th e Schedule of Events (SOE) 
in Section 1.3.  Further , participants in the  IDI subsample  (approximately 30 patients) are considered to 
have completed the study when they have completed the aforementioned study procedures, as well as 
the IDI  and endline  questionnaire, within 28 days (-14/+ 60 days) of the MedViewer visit with the 
provider or pharmacist , as shown in the SOE in Section 1.3 . A provider participant is considered to have 
completed the study after the last patient participant has completed the  study  and the provider  has 
completed both the IDI and the endline provider questionnaire .  
 
Based on our prior experience with other similar studies and the rate of potentially eligible patients seen 
in the clinic per week, we anticipate recruiting patients for 33 weeks  (7.5 months) . After  IRB approval, 
we will  recruit providers for a period of approximately  4 weeks (1  month ) before beginning patient 
recruitment . We will also include up to six weeks  (1.5 months)  of follow -up data collection for provider 
participants after the last day of  patient participant enrollment . Thus, we  anticipate that the study  
activities  will last up to 44 weeks  (10 months) . The end of th e study is defined as completion of  the last 
visit or proc edure shown in the SOE in the study  globally  for the last study participant . 
 
5 STUDY POPULATION  
 
INCLUSION CRITERIA  
 
Patient participants:  To be eligible to participate in this study as a patient participant, an individual must 
meet all the following criteria:  
 
1. Documentation of HIV -1 infection by means of any one of the following:  
a. Documentation of HIV diagnosis in the medical record by a licensed health care 
provider;  
b. OR HIV -1 RNA detection by a licensed HIV -1 RNA test demonstrating >1000 RNA 
copies/mL;  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  32 c. OR any li censed HIV screening antibody and/or HIV antibody/antigen combination test 
confirmed by a second licensed HIV test such as a HIV -1 Western blot confirmation or 
HIV rapid Multispot antibody differentiation test. 
NOTE: A “licensed” test refers to a US FDA -approved test, which is required for all IND 
studies. Non -US sites are encouraged to use FDA -approved methods; if not available, then 
each non -US site must use a test that has been certified or licensed by an oversight body 
within that country and validated internally.  WHO (World Health Organization) and CDC 
(Centers for Disease Control and Prevention) guidelines mandate that confirmation of the 
initial test result must use a test that is different from the one used for the initial 
asses sment.  
2. At least 18 years of age  on the day of consent . 
3. Documentation of HIV viral loads over 2 -year period prior to screening.  
4. Has been a patient at the UNC ID Clinic  for at least 90 consecutive days prior to the date of 
enrollment in the study (i.e. attended first appointment with  the UNC ID Clinic  at least 90 days 
prior to the date of enrollment in the study).  
5. Has attended at least one HIV appointment with  the UNC ID Clinic  within the 365 days p rior to 
the date of enrollment in the study.  
6. Has been prescribed one of the ARV medications eligible in this study (Dolutegravir, 
Emtricitabine ) by a UNC provider for at least 90 days prior to the date of enrollment in the 
study.  
7. Has an HIV appointment sch eduled with  the UNC ID Clinic  during the enrollment period of the 
study with a medical provider enrolled in the stud y.  
8. Documentation that the individual has provided consent to participate in the study  and ha s 
been informed of all pertinent aspects of the  study.  
9. Has stated willingness and availability to comply with all study procedures for the duration of 
the study.  
10. Literate in English.  
11. Has at least 1.0 cm of natural caput  hair.  
12. As enrollment will occur in a stratified manner based on 2 viral load strata, (n = 25 for patients 
with viral loads  below the limit of quantification , n = 25 for those with viral  loads  above the limit 
of detection ), once a stratum quota is reached, patients whose viral loads  fall within that 
stratum will not be eligible to participate in the study.  
 
Provider participants:  To be eligible to participate in this study as a provider participant, an individual 
must meet all the following criteria:  
 
1. Medical provider ( including , but not limited to: attending physician, ID fello w, nurse 
practitioner, physician  assistant, or a designated HIV Care  pharmacist) for UNC ID Clinic  patients  
living with HIV . 
2. Provides medical care for patients at the UNC ID Clinic  at least one half -day per week (i.e. 4 
hours per week).  
3. Evidence of a personally signed and dated informed consent form indicating that the participant  
has been informed of all pertinent aspects of th e study.  
4. Has stated willingness and availability to comply with all study procedures for the duration of 
the study.  
  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  33 A. EXCLUSION CRITERIA  
 
We will target patients of diverse ages, gender identities, racial identities, and ethnicities to test 
MedViewer with different hair types and capture a range of patient perspectives (reflective of the 
diversity of  patients seen in the clinic  who are people living with HIV ) on acceptability, appropriateness, 
and feasibility of MedViewer test procedures.  
 
Patient participants:  Pregnant patients will not be excluded from the study as participation does not 
pose any increased risk during pregnancy to the mother or fetus.   
 
An individual who meets any of the following criteria will be excluded from participation as a patient 
participant in this study:  
 
1. Previous participation in the study IGHID 11530 - Formative Sub -Study for Novel Mass 
Spectrometry Imaging Methods to Quantify Antiretroviral Adherence.  
2. Deemed, by medical provider in UNC ID Clinic , too ill, or other relevant reason, to  participate in 
the study.  
3. Prior history of clinically significant alteration of the gastrointestinal system or drug absorption  
capability , including but not limited to : gastrectomy, total colectomy  
4. Any chemical hair treat ment with dye, bleach, or relaxers within the 4 weeks  prior to sampling . 
 
Provider participants:   An individual who meets any of the following criteria will be excluded from 
participation as a provider participant in this study:  
 
1. Not willing or able to participate in any of the provider training sessions for this study or any 
form of make -up training  session with research team.  
 
B. LIFESTYLE CONSIDERATIONS  
 
<Not Applicable>  
 
C. SCREEN FAILURES  
 
Screen failures are defined as participants who are pre-screened via the IRB -approved questionnaire 
and are found to not currently be eligible for any reason. A minimal set of screen failure information is 
required to ensure transparent reporting of screen failure participants, to meet the Consolidated 
Standards of Reporting Trials (CONSORT) publishing requirements and to respond to queries from 
regulatory authorities. Minimal information includes demograph ic characteristics , screen failure details, 
eligibility criteria, and any serious adve rse event (SAE).  
 
Rescreening : Participants may be rescreened at any point during open recruitment if their eligibility 
requirements align with the protocol.  Rescreened participants should be assigned the same participant 
number they were assigned for th e initial screening  (if they were assigned one) . 
 
  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  34 D. STRATEGIES FOR RECRUITMENT AND RETENTION  
 
Recruitment and r etention strategies for patient p articipants:   
 
We plan to enroll  50 patient participants who  are patients at  a single U.S.  site, the UNC ID Clinic , a 
hospital -based outpatient clinic in Chapel Hill, North Carolina. Data collection will occur in the UNC ID 
Clinic , the  Clinical & Translational Research Center (CTRC) , and possibly  other areas of the UNC -Chapel 
Hill campus . We wi ll enroll  participants into 2 viral load strata, with a target of 25 participants in  Group A  
–the lower  viral load stratum  (those with  viral load  below the limit of viral quantification over the 
previous 2 years with documentation of at least one test in the previous six months ) – and 25 
participants in Group B  –the upper viral load stratum  (those who have had at least one HIV RNA result  
above the limit of viral quantification within the previous two years ). We anticipate enrolling  an average 
of 6.67 patients per month  (1.52 per week) , over the course of 7.5 months ( 33 weeks ), to reach our 
target of  50 total participants . We will screen and enroll  patients of all gender id entities, racial identities,  
ethnici ties, and ages (above 18 years), such that the  demographic distribution of screened participants 
reflect s that of patients  at the UNC ID Clinic  who are people living with HIV .  
 
Of all the people living with HIV who attend the UNC ID Clinic , 95% have consented to having their 
patient information available in a secure clinic database where it can be viewed to identify potential 
eligibility for open research studies and to being notified of studies for which they are potentially eligible 
(as p er IRB form 99 -MED -408). The ID Clinic  has a full -time research screener to assess patient eligibility 
for open research projects. We will use the IRB-approved screening and recruitment process that has 
been used in the ID Clinic  for over ten years, whereb y the clinic screener pre -screens patients in the 
clinic database and alerts research staff to potentially eligible patients. Specific recruit ment methods 
used (phone, email,  in person) for any individual patient participant will depend upon the methods fo r 
which that patient has previously provided permission  (on IRB form 99 -MED -408).  
 
We will use the following recruitment strategies  and steps :   
 
• Posting IRB -approved culturally appropriate flyers in designated areas of the clinic for the 
duration of study enrollment with information about the name and overarching purpose of the 
study.  
 
• Contacting  prospective, pre -screened  patients , who have given permission  to be contacted  by 
phone , before their next scheduled HIV appointment , using an IRB approved script  to notify 
them about the study  and verify their eligibility  using a brief standardized IRB -approved 
script/screening form . Phone calls will be conducted in a private room to prevent  inadvertent 
disclosure of participant information.  
 
• Contacting potentially eligible patients , who have given permission  to be contacted by secure 
email , before their next scheduled HIV appointment , using an IRB -approved template  to notify 
them about the study, provide them with a contact phone number, and ask them , if interested,  
to contact the study staff by phone to undergo a brief IRB -approved initial screening process. 
Emails will be sent from an encrypted email server.  Follo w-up screening phone calls will be 
conducted in a private room to prevent inadvertent disclosure of participant information.  
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  35 • For patients who cannot be contacted by phone  and/or  email after multiple (a maximum of 
three) attempts  and who have an in person clinical visit schedule with their provider , research 
staff  will approach them  in the clinic waiting room  (if the  patient has  given permission to do so)  
on the day of their visit to notify them that they may be eligible for a stu dy. Those who are 
interested will be asked to move to a private room in the UNC ID Clinic  or research clinic  to 
undergo further screening and, if eligible and interested, informed consent. (Appendix B.1)  The 
priva te room will have a closed door  to prevent inadvertent disclosure of subject information.  
 
• If one or more of the basic inclusion crit eria are not met, the individual  will be  informed that 
they are not eligible.  
 
Research staff will obtain informed consent from each potential participant before starting any study 
procedures according to the standards set forth in the ICH Good Clinical Practice guidelines and per unit 
SOPs.   
 
The UNC ID Clinic saw  1900  patients  living with HIV  in 2018 (approximately 150 patient visits/month). 
Based on the number of patients seen in the ID Clinic , the high percentage of participants prescribed 
eligible ARV medications for this study, the ID Clinic ’s commitment to public health research, and past 
experience with recruitment , we do not expect difficulty enrolling an adequate number of patient 
participants.  Since the onset of the COVID 19 epidemic, the UNC ID Clinic has shifted to conducting the 
option of  telehealth clinical visits with providers . In person visits are also sti ll currently permitted. Based 
on reports from the UNC ID Clinic Medical Director, with the shift to including the option for telehealth 
visits, the volume of patient visits scheduled and attended has increased, therefore enhancing our 
capacity to identify eligible patients based on the number of patients who are scheduled for clinical 
visits.  
 
Recruitment and retention procedures for in-depth interview (IDI) subsample of up to 30 patient  
participants:   
 
We will also enroll  a subsample of up to 30 patient participants ( from those enrolled in the larger study) 
to participate in a follow -up study visit, including an  IDI and brief endline  questionnaire . We will invite 
every enrolled patient to participate.   
 
To recruit participants into the IDI subsample , we will use  the following strategies:  
• During the initial study visit  for the main study , research staff will inform all participants about 
the follow -up visit  activities and invite them to participate. However, to ensure that the 
subsample is re presentative of the full study sample, accounting for time of enrollment in the 
study ( i.e. to obtain approximately equal numbers of patients at various points during the 
enrollment period for  the larger study), we will monitor the rate of subsample enrollment  every 
month and adjust our recruitment methods , as needed , to increase the likelihood of obtaining a 
representative sample of participants throughout the duration of the study.  
 
• During the study visit, a ll commu nication regarding the IDI subsample activities  and informed 
consent will take place in a private room with a closed door  or via secure IRB -approved video 
conferencing or phone call conducted in a private room with a closed door  to prevent 
inadvertent dis closure of participant  information (Appendix B.2).  
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  36 Research staff will obtain informed consent from each prospective subs ample  participant before starting 
any study procedures according to the standards set for the in the ICH Good Clinical Practice guidelines 
and per unit SOPs.  
 
Recruitment and Retention Procedures for Provider P articipants:   
 
We will also aim to recruit and enroll all (~ 15 but up to 30 ) medical  providers who provide care to 
patients in the ID Clinic ( for example, attending physicians, fellows, nurse practitioners, physician  
assistants, nurses, and pharmacists).  
 
Providers will be recruited through  the following strategies/steps:  
 
• Posting a n IRB -approved informational  flyer in  designated areas of the UNC ID Clinic , including 
the physician work room  and in providers’ mailboxes at the ID Clinic. 
 
• Contacting providers through secure email  (using an existing list of current providers in the UNC 
ID Clinic  provided to research staff by Co -Investigator and Clinic Medical Director, Claire Farel, 
MD) to notify them about the study  and invite them to provi de their availability to undergo 
screening with research staff and provide written  informed consent, if interested  and eligible . 
The emails will also include information about the provider training session required for all 
enrolled providers prior to seeing patients for their MedViewer study visits. Invitation emails will 
use an IRB-approved  template. Invitation emails will be sent from an encrypted email server.   
 
• Interested providers will be sent the IRB -approved informed consent form prior to meeting with 
study staff for informed consent so that they can review it ahead of time . (Appendix B.3)   
 
• Presenting IRB-approved verbal and PowerPoint announcements about the study  during weekly 
Infections Disease conferences  and other relevant events  typically attended by ID Clinic  
providers. The announcements will includ e information about  the provider training session s 
 
• Holding multiple  provider training sessions  on different dates. Attendance of a training is 
required for enrolled providers to see patients for MedViewer study visits. For providers who 
cannot participate in any of the group training sessions, study staff will provide the opportunity 
to complete a one -on-one training with a research staff member.  
 
As practitioners at a state medical facility, the clinic providers are a highly dedicated group of clinicians 
with a clinic culture that embodies and reflects their strong commitment to public health and to clinical 
research to improve health outcomes in North Carolina. Based on this commitment to public health and 
the research team’s past experience with recruitment , we do not anticipate difficulty enrolling ID Clinic  
providers to participate in this study.   
 
Participating providers will be compensated for completing study activities  over the entire study period, 
including study activities  related to each of their individual patients who participate s in the study  over 
the 7.5 month patient recruitment period . This amount reflects the assumption that each participating 
provider’s activities will involve multiple patient visits. Since provide rs will participate in the study  for up 
to 10 months, they will be compensated  for completing the IDI and endline questionnaire to encourage 
retention.   
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  37 6 STUDY INTERVENTION  
 
STUDY INTERVENTION(S) ADMINISTRATION  
6.A.1  STUDY INTERVENTION DESCRIPTION  
 
The study intervention includes four  components : 
 
1. Standardized training  session  for medical providers : This 30-60 minute  training  session , 
designed to orient  providers to the MedViewer test and prepare them to participate  in th is 
study, will be  held at the start of the study before enrolling patient participants  and at various 
points  throughout the study . The training will  introduce the providers to the MedViewer patient 
video (see component 2), the MedViewer  test and report (see component 3) , and provider 
communication aids (see component 4). The training  will also prepare provider s to incorporate 
the delivery of the investigational MedViewer test results  into discussions with patients  during 
routine HIV care appointments by providing an opportunity to practice  interpreting and 
discussing MedViewer results with patients  using an example MedViewer  report. The training 
session will be required for all enrolled providers  parti cipat ing in the  study  before providers can 
be scheduled to see enrolled patients for visits to review their MedViewer report. Before the 
training session , in the provider’s pr ivate office , another private space  on campus , or via IRB -
approved videoconferencing or phone call, via an IRB -approved e -consent process, study staff  
will obtain written informed consent from providers  who are both eligible and interested  in 
enrolling in the study.  Training sessions may be in -person or virtual. Multiple training dates will 
be offered to providers. For providers who are interested in participating in the study but unable 
to attend a scheduled group training session, study staff  will offer one-on-one t raining  
(Appendix A. 1). Supplemental training sessions  with the same training materials  will be offered, 
as needed .  
 
2. Informational video for patients:  This approximately eight -minute  video will introduce  patients 
to the  MedViewer test, the hair collection process , and how test results can be useful for 
conversations between patients and providers about adherence . More specifically, the video 
will explain : 1) how ARVs are processed  in the body and end up i n hair;  2) what the hair sample 
collection  process  will be like ; 3) how the test results are produced in the lab ; 4) how the hair 
sample  will be disposed of; 5) how the provider may  review the results with the patient; and 6) 
how the test results can inform  conversation s about the patient’s adherence . The video will also 
address potential patient concerns about the test (as identified i n a formative study conducted 
prior to intervention development ). Potential concerns include , but are not limited to , whether 
it is painful to provide a hair sample and  how  patient  privacy will be protected. This video will be 
part of the informed consent process for patient participants to facilitate their understanding of 
the MedViewer  aspect of the study . Eligible and  interested patients will watch the video  during 
the informed consent process either  in a private room located in the UNC CTRC  or ID Clinic or via 
an IRB -approved videoconferencing call .  Patients will have the opportunity to watch the video 
multiple times, as needed. (Appendix A.2) 
 
3. Hair sample, MedViewer test, and accompanying  MedViewer report (patient and provider 
versions) . After providing informed consent, patient participants will provide a hair sample for 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  38 MedViewer testing. Hair sample collection will take place in the ID Clinic  or CT RC or in a private 
remote location  to minimize clinic exposure , where a  trained clinical research staff member will 
pluck five strands of hair from the back of the patient’s head. The research team member  will 
then place the hair on a foil pa ckage  and affix the distal end of the hair with a label.  The folded 
hair foil will be  placed into a resealable  biohazard  bag in a closed container and then 
transport ed promptly to the lab for MedViewer testing  in accordance with EHS policy . At the 
lab, the  imaging scientist  will place the sample in the MedViewer  machine to run the test and 
generate two distinct visual reports  of the results  (one version for patients and one version for 
providers). The scientist  will send the report  via secure email to the research  team , who will 
print the report and deliver  a hard -copy or electronic version  to the appropriate provider 
participant in the ID Clinic . (Appendix A.3) 
 
The patient version of the investigational report will show a monthly calendar display of color -
coded results indicating whether daily ARV drug concentrations in the patient’s body were at 
optimal or sub -optimal concentrations each day  (Appendix D.1). Each report will have a  key of 
relevant information about the test . The investigational provider report will have  bar graph of 
daily  drug concentrations  as well as information reflecting the variability  of the lab test. The 
investigational patient report will be formatted as a calendar with dichotomous color 
assignment to each day on the report indicating an optimal or sub -optimal medication 
concentration.  All reports will be clearly labeled that this information is for investigational 
research use only.  (Appendix A.3) 
 
During the patient’s regularly scheduled appointment  at the ID Clinic , the goal is for the provider 
and patient to view the investigational  reports together and  use them to have a conversation 
about the patient’s ART medication adherence . If the MedViewer report is not available during 
the patient’s regularly scheduled ID Clinic appointment , the provider and patient participants 
will discuss them during a separately scheduled MedViewer appointment within four weeks of 
hair sample collection. The provider will not follow a standardized sc ript to discuss the results 
with the patient ; rather, the provider will conduct the appointment based on their  clinical 
judgement and discretion, drawing on information from the provider training session (see 
Component 1) and communication aids (see Component 4), medical expertise, and  the 
individual  needs and  circumstances of the  patient participant.  If the provider chooses to follow 
suggested communication strategies listed in the  reference sheet (see Component 4), he or she  
may discuss MedViewer reports with patients by : explaining  the summary statistics printed with 
the results or point ing out any patterns of insufficient drug concentrations and adherence 
successes ; asking patients about event -level and/or chronic and psych osocial causes of missed 
doses ; asking patients about successful adherence  strategies ; work ing with patients to identify 
personalized strategies that could help patients overcome causes of missed doses in the future 
or to replicate successes ; offer ing enco uragement  for good adherence ; and work ing with 
patients to set goals for improving future adherence.  
 
The investigational  MedViewer reports will NOT be entered into the patient ’s Electronic Health 
Record (in EPIC) or become a formal part o f the clinical patient record  or be used for clinical 
decision making . After the provider and patient have reviewed the MedViewer report s, both 
versions of the report  will be destroyed in accordance with standard medical documents with a 
certified copy of each stored in the research record . The research team will document receipt of 
the MedViewer report  by the provider  on the study forms . 
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  39 If the provi der does not receive the MedViewer  reports on time for the scheduled appointment, 
the research team  will notify the provider, who will decide to either 1)  delay seeing the patient 
for the scheduled appointment until the report arrives; or  2) meet with the patient at the 
scheduled appointment time and schedule a separate appointment to review the MedViewer 
report with the patient within 4 weeks of hair sample collection ; or 3) request that the clinic  HIV 
care  pharmacist discuss the MedViewer report  with the patient  within 4 weeks of hair sample 
collection . This decision will also be based on whether  the patient is  willing or able to attend a 
separate appointment to  receive the results  and whether they are comfortable receiving the 
results from the pharmacist . Any of the aforementioned appointments or discussions may occur 
in-person or virtually, as appropriate for the patient and provider and/or pharmacist. The 
research team  will work with the  patient,  initial provider , and clinic pharmacist using procedures 
as specified in a study  SOP.  
 
4. Communication aids for providers : Communication aids for providers, intended to facilitate 
providers’ discussions of  the investigational  MedViewer report s with their patients, will include  
a one-page reference sheet  with  information and tips to interpret the Med Viewer results 
reports, understand the accuracy and certainty of different aspects of the test, and discuss the 
results with patients. The document will include possible strategies to counsel patients on 
adherence using the investigational MedViewer report  and a one -page FAQ to clarify potential 
concerns. The  counseling  reference sheet  will indicate  the potential  utility of the investigational 
MedViewer test as an  objective, real -time measure of longitudinal adherence that provides 
concrete adherence feedbac k for patients  and list s suggested steps , cover ed during the provider 
training, to counsel patients on adherence using MedViewer report . These include :  
 
• reviewing the MedViewer report  with  patients  
• understanding potential implications of patterns  of missed or successful doses  
• strategizing to overcome challenges and replicate successes  
• motivating patients to  improve or maintain adherence  
 
The communication aid and  reference sheet will be delivered to providers along with  
MedVi ewer reports . The IRB-approved FAQ sheet will include logistical information about the 
MedViewer test , information about test sensitivity and specificity to detect missed doses,  as 
well as  questions and concerns raised by providers during the formative study prior to 
intervention development.  Research staff will update the FAQ sheet, as necessary , to include 
additional questions and concerns that arise throughout study implementation. The F AQ sheet 
will be placed in the provider workroom  and exam rooms  within the ID Clinic . (Appendix A.3) 
6.A.2  DOSING AND ADMINISTRATION  
 
Patient participants:  For patients, the MedViewer intervention is a single intervention, with a single 
intervention exposure (over one, and in rare cases multiple , in-person or virtual clinic visits ). Each 
exposure to the intervention will include  1) watch ing an informational video about the MedViewer test 
2) providing  a hair sample that will be sent to a laborat ory for MedV iewer testing , and 3) receiving the 
MedV iewer visual results report  from the provider  or pharmacist  during the regularly scheduled clinic 
visit or a separate MedViewer appointment within 4 weeks of hair collection . The MedViewer 
intervention will be administered  similarly for each patient particip ant, with slight variations in timing 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  40 and level of exposure to individual components , based on t he patient -provider interaction s as well as 
clinic flow  on the day of the study visit.   
 
Exposure to the MedViewer tool will be measured as time in minutes. Each  participant will first view the 
same informational video  (approximately 8 minutes long) on a tablet in private room or over a secure 
IRB-approved video conferencing  call during the consent process . Within three  days following informed 
consent , the patient will have a hair sample  collected , which  should take  appro ximately  2-5 minutes . 
The research team collects the hair in the exact same way with each patient according to standard SOPs.  
For patients in Group B and a subset in Group A , a matched blood sample will be collected for research 
purposes only. The patient’s blood will be wicked onto a  Mitra microsampling device  that is based on 
Volumetric Absorptive Microsampling (VAMS) technology .  The Mitra device has advantages over DBS 
cards and filter paper  in the areas of collection, processing, and extraction. The Mitra device provides 
the key benefits of working with dried blood, but with a volumetricall y accurate, stable dried blood 
sample that reduces the incidence of reworks.   
 
While we will aim to schedule hair sample collection within 4 days prior to the schedule d clinical HIV 
appointment with the provider, we will allow the clinical visit to take pl ace up to 4 weeks following hair 
sample collection . At the next clinical visit that occurs after and within 4 weeks of hair sample collection, 
the patient participant will meet with their  provider and the provider will incorporate  review and 
discussion of MedViewer report  into usual care . Since the provider will not use a standardized script to 
discus s the results with the patient, the degree of exposure to the MedViewer  report  will vary among 
participants . Because this is a feasib ility study, mode of exposure to the results  report  (e.g. over 
videoconferencing versus in -person  and provider -delivery versus pharmacist ) may vary across patient 
participants, as appropriate, based  on clinic flow , availability of the MedViewer report , and  whether the 
visit with the provider was scheduled in person or by videoconferencing . For example,  if, for any reason,  
a provider does not receive the MedViewer report  for a patient participant prior to the patient’s 
scheduled clinic al visit, the visit may be postponed until the report is delivered to the provider  or a 
separate follow -up- appointment  may be scheduled with the same provider or the designated clinic 
pharm acist  for review and discussion  of the MedViewer report.  If the patient does not receive the 
report from  their provider  or pharmacist and does not complete a post -visit questionnaire , they will be  
eligible to return to participate in another baseline visi t in the future .  
 
Provider participants:  All enrolled providers will have a similar time of study exposure, with the 
opportunity to be enrolled from study initiation, or their individua l date of enrollment, through  the 
estimated 16 -month duration of the study, including 10 months of active participation in the study, 
comprised of 7.5 months of patient enrollment.   Providers will have a standard, single exposure to the  
in-person or virtual provider training with the option to partici pate in supplemental training sessions, as 
needed.  Providers will also have a single initial exposure to the  communication guides, which they can 
use during visits with patients, as desired. However, providers will have varying levels of exposure to 
receiv ing patients’ MedVi ewer results and reviewing results with patients, depending on their patient 
population and number of  their  patients  participating in the study. I n the case of clinic pharmacists,  
exposure will depend on  the number of patients referred to them for the MedViewer report  discussion. 
Quality of exposure to patients’ MedViewer report  will also depend on clinic flow and whether providers 
receive the results on time for  patients’ scheduled HIV appointment s.  
 
 
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  41 PREPARATION/HANDLING/STORAGE/ACCOUNTABILITY  
 
6.A.3  ACQUISITION AND ACCOUNTABILITY  
 
To create and distribute the MedViewer report of results, hair sample processing by IR -MALDESI -IMS 
methods will be performed in the lab located in the Genetic Medicine Building in  the Eshelman School of 
Pharmacy. All samples will be processed according to SOPs.   This laboratory has validated analytical 
methods for all currently marketed antiretrovirals  by LC -MS/MS techniques, and is CLIA - (#34D1022136) 
and CAP - (LAP#7521077; AU -ID#1589458) accredited .  However, the MedViewer technology is 
considered an experimental approach  indicated for investigational use only .  The validation reports for 
emtricitabine and dolutegravir can be found in Appendix E.     
6.A.4  FORMULATION, APPEARANCE, PACKAGING, AND LABELING  
 
There are no study drug product s on this study, nor will we be utilizing the services of Investigational 
Drug Services . 
 
As the intervention  centers around delivery and discussion of the MedViewer  report of results , we 
describe its appearance, packaging , and labeling. The study intervention has been designed and will be 
manufactured by the study team.  Each patient participant’s MedViewer repo rt will be individualized to 
reflect the measured concentration of ARV in their hair over  time .  (Appendix A.3) 
 
6.A.5  PRODUCT STORAGE AND STABILITY  
 
There are no study products that are part of the intervention for which we would need to assess stability 
or provide storage.  
 
6.A.6  PREPARATION  
 
There are no study products on this protocol that need preparation in the pharmacy.   
 
MEASURES TO MINIMIZE BIAS: RANDOMIZATION AND BLINDING  
 
As this is a single arm pilot feasibility study  in which all participants will receive the same intervention , 
there will be  no randomization o f intervention assignment .  Similarly, as all patient participants will 
receive the intervention and data are only being collected on patients participatin g in t he study, blinding 
of data collectors or other researchers to participants’ intervention assignment  will not be feasible , 
necessary,  or practical. In addition, as the design of the intervention requires providers to deliver the 
MedViewer report to particip ating patients, it is not feasible for the providers to be blinded to patients ’ 
intervention assignment/study participation.   
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  42 To obtain a representative subsample of patients to participate in the IDIs,  we will  initially  invite  all 
patients to participate  in the follow -up study. We will monitor the rate of subsample enrollment every 
month , adjust ing our recruitment methods, as needed , to increase the likelihood of obtaining a 
representative subsample of participants throughout the duration of the study.  
 
STUDY INTERVENTION COMPLIANCE  
 
This study will be conducted in full compliance with the protocol  and all study procedures will be tracked 
for compliance as outlined in the CQMP . The protocol will not be amended without prior written 
approval by the  protocol chair and the NIAID Medical Officer. All protocol amendments must be 
submitted to and approved by the relevant IRB prior t o implementing the amendment.   
 
Provider Training Attendance. At the provider training, attendance  will be taken , and the research team 
will note all participating providers  and whether all slides and intended activities were covered. During 
any supplemental trainings that take place, attendance and training content will be documented in 
study records.  
 
 
CONCOMITANT THERAPY  
 
There are no concomitant therapy exclusions in this protocol.   
 
6.A.7  RESCUE MEDICINE  
 
Not Applicable.  
 
 
7 STUDY INTERV ENTION DISCONTINUATION AND PARTICIPANT DISCONTINUATION/ 
WITHDRAWAL  
 
A. DISCONTINUATION OF STUDY INTERVENTION  
 
If one participant experiences a Serious Adverse Event (SAE)  deemed related to the study , enrollment 
will be held while the protocol undergoes review.   
 
 
B. PARTICIPANT DISCONTINUATION/WITHDRAWAL FROM THE STUDY  
 
Enrolled participants are free to withdraw from participation in the study at any time and for any reason 
upon request. Participants may also choose to withdraw from the intervention for any reason but still 
complete other study activities.  
 
An investigat or may withdraw a patient participant  from the study for the following reasons:  
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  43 • If any clinical adverse event (AE), laboratory abnormality, or other medical condition or situation 
– related or unrelated to the study – develops after enrollment such that c ontinued 
participation in the study would not be in the best interest of the participant . 
 
• If a patient presents a safety risk to the research staff .  
 
• If their participation in the study is disruptive to the study or the clinic .  
 
• If the participant meets  an exclusion criterion  (either newly developed or not previously 
recognized) that precludes further study participation . 
 
• At the  discretion of the provider that pursuing on study is not in the best interest of the patient.  
 
An investigator may withdraw a provider participant  from the study for the following reasons:  
 
• If their participation is disruptive to the study or the clinic . 
• If participation is no longer of interest to the provider participant  
 
The reason for any participant’s discontinuation or withdrawal from the study will be recorded in the 
research record . While the study is intended to be completed in one day and thus discontinuation or 
withdrawal are unlikely, as data are collected at seve ral time points during the study visit, it is possible 
that some participants  will not be fully retained. Participants  who sign the informed consent form but  do 
not r eceive the study intervention will be replaced. Participants  who sign the informed consent  form 
and receive the  full study intervention , and subsequently withdraw , or are withdrawn or discontinued 
from  the study will not be replaced.  For example, participants  who do the intervention but leave or are 
withdrawn (e.g. due to being too sick) before  completing the post -visit questionnai re would not be 
replaced. And  participants  who do some  but not all of the intervention (e.g. get hair plucked but don’t 
wait for result), will be replaced.   
 
C. LOST TO FOLLOW -UP 
 
Because most study procedures for patients are designed to take place over several time points within 
several weeks of enrollment, (based on a combination of participant availability, provider schedule, 
MedViewer test timeline ), there are several points at which patient participants may be lost to follow -
up.  
 
Patient participants:  Patient participants will be considered lost to follow -up if, after enrollment , they 
do not present for any scheduled component of the intervention  within the allowable timeframe  and 
are not reachable to reschedule  (including hair sample collection or their visit with their 
provider/pharmacist at which MedViewer results are to be discussed) or on the day s of their study visit  
activities , they leave the study site  or become unreachable  at any point before completing  the 
intervention or study activities and they do not explicitly inform research staff that they would like to 
withdraw from the study .  
 
Patient part icipants who are part of the IDI  subsample will be co nsidered lost to follow -up if they do not 
attend their scheduled follow -up interview, are unreachable for their interview, or do not complete  
their interview  and endline questionnaire  and they both: 1) do not explicitly inform research staff they 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  44 would like to withdraw from the study; and 2) they are unreachable by phone , email, or at the study site 
within 60 days of their missed IDI ).  
 
The following actions will be taken if a patient  participant fails to present for a scheduled study visit or 
interview:  
 
• The research team will attempt to contact the participant, reschedule the missed visit within 60 
days  of the initially scheduled date, and ascertain if the participant wishes to and/or should 
continue in the study.  
 
• The research team will allow some study activities to be completed by phone , secure video 
conferencing, email, or secure online completion of study questionnaires, if needed to facilitate 
completion of all study activities.  Until we have verified that the person we are speaking to is 
the i ntended patient participant, we will not provide any information that we are calling from a 
UNC clinic. To ensure that the person we are speaking to on the phone is the intended patient, 
in addition to obtaining at enrollment, detailed information about wh ether and where it is okay 
to leave messages, we will use a standardized  script that asks the individual to confirm their 
identity.  
• Before a participant is deemed lost to follow -up following failure to attend a scheduled activity , 
a research team member will make every effort to regain contact with the participant 
(maximum of 3 attempts ) within 14 days of the missed Visit 1  activity  or 60 days for Visit  2 
activity .  These contact at tempts will be documented in the  chart.  
 
• Should the participant continue to be unreachable, they  will be considered lost to follow -up. 
 
Provider participants:  Provider participants will be considered lost to follow -up if, after enrollment, they 
do not complete any intervention or study activities and they both 1) do not explicitly inform research 
staff that they would like to withdraw from the study ; and 2) are  unreachable by phone, email, or in -
person before study close.  
 
The following actions will be taken if a provider participant fails to complete intervention or study 
activities (i.e. post -visit questionnaires , endline questionnaire , IDI) before study close:  
 
• For missed study activities, the research team will attempt to contact the provider, request th at 
the provider complete the activity, and ascertain if the provider participant wishes to and/or 
should continue in the study.  
 
• Before a participant is deemed lost to follow -up, a research team member will make every effort 
to regain contact with the provider (with up to 3 phone calls or emails prior to study close).  
These contact attempts will be documented in a Study Participation Case Report Form.  
 
• Should the participant continue to be unreachable before study close, he or she will be 
considered lost to follow -up. 
 
  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  45 8 STUDY ASSESSMENTS AND PROCEDURES  
A. EFFICACY ASSESSMENTS  
 
Administration of questionnaires or other instruments : 
All patient questionnaires will be administered through computer -assisted self-interviewing (CA SI), 
unless otherwise noted. In some cases, questionnaire  items  may be administered verbally by a trained 
research team member via  computer -assisted personal interviewing (CAPI) , if needed . There will also be 
a paper copy of the questionnaires available as backup, if needed . All provider questionnaires will be 
administered through CA SI when possible or a paper copy of the q uestionnaire, unless otherwise noted. 
All in -depth interviews will be conducted by trained research team members using semi -structured 
interview guides and will be digitally recorded with participant consent.  
 
PATIENT ASSESSMENTS  
Patient chart and medicati on review: For screening purposes, UNC ID Clinic  screeners  or a trained 
research team member  will review medical records of patients who have consented to having their 
patient information available in a secure clinic database, where it can be viewed to identify potential 
eligibility for open research studies (as per IRB form 99 -MED -408).  
 
Patien t screening questions:  Using the list of potentially eligible study participants, the research team 
will attempt to contact prospective participants  by phone , or – if needed secure (encrypted) email -- to 
conduct  or arrange for  a pre-screening phone call b efore the scheduled clinic visit (as outlined in Section 
5.3). This will be done with a standardized IRB -approved questionnaire.  If contact with the patient 
cannot be established before a scheduled  in-person  clinic  visit, the research team  will approach the 
patient in the clinic for pre-screening. During the phone call or in -person screening, the research team  
will assess patient eligibility using a standard IRB-approved screening form with questions pertaining to 
patient age, amount of time as a  patient at the UNC ID Clinic , HIV appointments in the last year, current 
and past prescribed ARV medications and length of caput  hair (which needs to be at least 1  cm in 
length).  
 
Provider screening and demographics questions:  Following informed consent,  the research team  will 
assess provider  eligibility using a standard screening form with questions pertaining to  number of clinic 
hours per week  and type of provider . Providers will also be asked to report demographic characteristics  
including gender, age,  race/ethnicity , and  length of time working as a provider at UNC .  
 
Reasons for patient participation decline : If an eligible prospective participant declines participation in 
the study, and does not provide informed consent, the research team  will ask them to indicate the 
primary reason(s) for this refusal from a list of common reasons for declining participation; an open -
ended option will also be available  and the patient may refuse to answer . This will be documented in the 
database . 
 
Patient  withdrawal/discontinuation reasons:  If an enrolled participant withdraws from the intervention 
or from the study at any point  after providing informed consent , the research team member  will ask 
them to indicate the primary reason(s) for withdrawing. Simil arly, if an investigator discontinues or 
withdraws a participant from the intervention or study, the investigator will record the reason for 
participant discontinuation or withdrawal in the chart . 
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  46 Hair Sample and MedViewer laboratory test:  During the firs t study visit, the research team will collect 5 
plucked strands of hair from the patient to be delivered  to the laboratory for MedViewer testing  per 
local SOPs.  The patient will receive the MedViewer report  from the provider during the clinic visit.  
 
Pharmacokinetic Blood Sample:  During the first study visit, either before or after hair sample collection, 
the research team member or another  trained clinician will collect a blood sample via fingerstick or 
phlebotomy  for a subset of  patient participants in Group  A and  patient participants in Group B.  The 
blood sample will be used for  measuring concentrations of antiretrovirals for comparison with the 
MedViewer results. Our lab has validated antiretroviral tests for drug monitoring.  Patient participants 
who came in advance of their visit to have blood drawn for this clinical visit or those who will not have 
blood drawn on the day of the provider visit will have their blood collected  during the first day of their 
study visit for study purpose s. This is necessary because drug concentrations collected  on days after 
receiv ing the MedViewer report may  be affected  by receipt of the MedViewer re port . ARV 
concentrations in th is blood sample  will be compare d with the MedViewer report  findings to indicate 
the extent to which it reflects adherence behavior before the clinic visit . These samples were obtained 
in the directly observed therapy study in Aim 2 of the grant for benchmarking purposes, along with hair.  
Blood sample  storage, processing and analysis will be conducted in the CTRC and UNC School of 
Pharmacy Clinical Pharmacology and Analytical Chemistry (CPAC) Lab  located on the 1st floor of Genetic 
Medicine Building on UNC campus . 
 
Patient baseline questionnaire:  After informed consent and screening  and prior to receiving and 
discussing the MedViewer report , the pat ient will be administered a baseline questionnaire by a trained 
research team member using the CA SI system . Questionnaires may  also be administered verbally  by a 
trained research team member  (via CAPI) , if needed. Questionnaire items will pertain to: self-rated 
health, patient sociodemographic information  (time to travel from home to ID Clinic ; age; sex 
assignment at birth and gender identity ; sexual orientation ; race/ethnicity ; current marital status ; 
education lev el; income in past year ; current employment status ; health insurance status and type ; 
method of paying for ART), comprehension and sufficiency of video content, self -reported ART 
adherence over  the past 3 days , past 7 days, and  past 30 days , and adherence motivation and self -
efficacy.  (Appendix C.1)  
 
Patient post -visit questionnaire: As soon as possible following the clinic appointment during which 
MedViewer report  receipt is intended to occur, patients will be asked to complete a 13-item  
questionnaire  comprising questions regarding their experience receiving and discussing the MedViewer 
report  with their provider. Questionnaire items will pertain to: affirmation of MedViewer report receipt, 
person report delivered/discussed by, future like lihood of using MedViewer and recommending to 
others,  perceived  comprehension of MedViewer report,  satisfaction with the adherence counseling 
discussion, acceptability of wait time, acceptability of hair sample collection, satisfaction with the 
MedViewer r eport, maximum acceptable future  out-of-pocket  cost of MedViewer test, perceived 
usefulness of MedViewer to promote ART  adherence, perceived impact of MedViewer use on patient -
provider communication and relationship , and adherence motivation and self -effic acy. (Appendix C.2) 
 
Patient in -depth interview  (IDI) :  A subsample of up to 30 patients will complete semi -structured IDIs 
(either in -person or via IRB -approved videoconferencing) during the second study visit, approximately 
four weeks  (28 days  (-14/+ 60 days)  following the MedViewer visit with the provider or clinic pharmacist. 
If the visit to discuss MedViewer is scheduled but does not occur, the second study visit will take place 
28 days ( -14/+60 days) following the date on which the MedViewer visi t was scheduled to occur.  Trained 
research assistants will conduct the interviews using semi -structured interview guides. Interview topics 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  47 will include: perceived usefulness of MedViewer for adherence counseling, reasons would/would not 
agree  to/recommend future MedViewer use, satisfaction with patient education video, comprehension 
of MedViewer report  (cognitive interview) , satisfaction with adherence counseling discussion using 
MedViewer report, attitude toward wait time and hair sample collection, antici pated effect of regular 
MedViewer use on patient -provider communication and relationships , and perceived effect of 
MedViewer on comprehension of own adherence behavior, adherence motivation, and adherence 
behavioral skills . (Appendix C.3) 
 
Patient endline questionnaire: The subs ample of patients completing IDI s will also complete a  brief  
structured endline questionnaire. Questionnaire items will pertain to: self-reported percentage  of 
missed doses over past 3 days , past 7 days, and  past 30 days , perceived usefulness of MedViewer to 
promote ART adherence , maximum out -of-pocket cost willing to pay for MedViewer , adherence self -
efficacy, and adherence motivation . (Appendix C.4) 
 
PROVIDER ASSESSMENTS  
Provider participation refusal: If an eligible prospective provider participant declines participation and 
does not provide informed consent, the research team  will ask them to indicate the primary reason(s) 
for this refusal from a list of common reasons f or declining participation with an open -ended option. The 
research assistant will record this information in the screening and enrollment database.  
 
Provider withdrawal/discontinuation reasons:  If an enrolled provider withdraws participation at any 
point, the research assistant will ask them to indicate the primary reason(s) for withdrawing their 
participation. Similarly, if an investigator discontinues or withdraws a provider participant from the 
study, the investigator will record the reason for participa nt discontinuation or withdrawal from the 
study on the Study Participation Case Report Form.  
 
Provider post -training baseline questionnaire: All clinicians participating in the provider training will 
complete a self -administered post -training evaluation questionnaire, which will include an assessment 
of satisfaction with the training quality, content, perceived knowledge  gained  of the MedViewer  test 
and study procedures, and self -efficacy to deliver MedViewer report  to patients. (Appendix C.5) 
 
Provider post -visit questionnaire:  After each patient study visit, providers will complete a brief  
questionnaire pertaining to the content of the MedView er counseling session (one questionnaire per 
patient). Providers will be asked to complete the questionnaire  pertinent to a particular patient by the 
end of day of the patient participant visit, ideally  immediately after the relevant patient appointment , 
whenever possible . Providers who do not complete  the questionnaire  on the day of the relevant patient 
appointment  will be contacted by the study team the next day and asked to complete it as soon as 
possible (within seven  days after the visit). On the questionnaire, providers will indicate if  the 
MedViewer report  was discussed with the patient. If results were not discussed, they will indicate 
reasons f or non -discussion. If results were discussed, the provider will indicate the estimated time spent 
discussing the MedViewer results  patient, their perceptions of patient comprehension of the results,  
perceived usefulness of the report in promoting and motiv ating patient adherence, and perceived 
usefulness of the MedViewer Report in improving their understanding of patient adherence and in 
promoting quality of the adherence discussion with the patient . (Appendix C.6) 
 
Provider in -depth interview:  All providers will participate in an IDI within 180 days of seeing a t least 2  
patient participant s or before study close, whichever comes first. Trained research team members  will 
conduct the interviews using semi -structured interview guides. Interview to pics will include: usefulness 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  48 of MedViewer for adherence counseling,  perceived usefulness of MedViewer in encouraging patients to 
sustain or improve adherence , reasons would/would not  recommend future MedViewer use, 
satisfaction with the MedViewer report a nd adherence counseling using the report, perceived ease of 
delivering and discussing MedViewer resu lts during typical appointment, p erceived level of disruption to 
clinic flow by MedViewer procedures , and the anticipated effect of regular MedViewer use on patient -
provider communication and relationships . (Appendix C.7) 
 
Provider endline questionnaire:  Providers will complete an endline ques tionnaire within 6 weeks  of 
closure of the  patient participant enrollment period  or before closing the ir participation in the study , 
whichever comes first . Questionnaire items will pertain to: likelihood of recommending MedViewer to 
other patients, satisfaction with adherence counseling discussions using MedViewer report , perceptions 
of the most appropriate clinician for future MedViewer counseling, perceived usefulness of MedViewer 
in encouraging patients to sustain or improve adherence, and influence of MedViewer use on patient -
provider communication and relationships.  (Appendix C.9) 
 
ADMINISTRA TIVE DATA COLLECTION  
Detail ed Patient Contact Information Form: For each enrolled participant we will collect detailed 
contact information in the event that we have to reach them regarding study procedures.  
 
Participation database:  The research team will maintain a database of participants approached or 
contacted for participation, screened for eligibility, enrolled, and withdrawn from the study. These data 
will be used to assess participation acceptance rates and to assess differen ces between participants and 
non-participants.  
 
Sample Tracking and Processing:   All samples will be collected, processed and transported in 
accordance with local standard operating procedures.  All necessary sample data will be collected, 
recorded and tra cked on study forms  with detailed chain of custody and documentation of compliance 
with all processing procedures  that will include but is not limited to time  of sample collection and time 
of MedViewer report delivery to provider or pharmacist . 
 
B. SAFETY AND OTHER ASSESSMENTS  
 
Safety Monitoring  
Close cooperation between the Protocol Chair(s), study site Investigators, NIAID Medical/Program 
Officer, and other relevant parties will be necessary in order to monitor patient safety and to respond to 
occurrences of toxicity in a timely manner. The team will have regular calls and/or meetings during the 
period of study implementation, and additional ad hoc calls will be convened if required.  
 
The study site investigators are responsible for continuous c lose monitoring of all AEs that occur among 
study patients after enrollment, and for alerting the team if unexpected concerns arise.   
 
A multi -tiered safety review process will be followed for the duration of this study.  The study site 
investigators are the first layer of this tiered system and are responsible for the initial evaluation and 
reporting of safety information at the participant level, and for alerting the Protocol Safety Review Team 
(PSRT) if unexpected concerns arise.   The PSRT will consist  of the following study site investigators: 
Angela Kashuba, PharmD (Principle Investigator), C ynthia  Gay, MD (Study Physician),  Carol Golin, MD 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  49 (Co-Investigator), Claire Farel , MD  (Co-Investigator), Amanda Poliseno  (Project Manager ) and Al exandra  
Munson , MPH  (Behavioral Studies Research Coordinator) along with the Biostatistician.  
 
During the trial, the PSRT will review safety reports (all AEs included, independent of determination of 
relatedness to study products /intervention) and conduct calls to review  the data as appropriate.  If 
necessary, experts external to the protocol team, representing expertise in the fields of microbicides, 
biostatistics, medical ethics  or other specialty  may be invited to join the PSRT safety review.  
 
Procedures in place as a part of safety monitoring include the assessment and documentation at each 
study contact after consent with a patient participant of any adverse events (as defined and described 
below in 8.3). In addition, all study procedures will be carried out by qualif ied personnel as described in 
their respective sections in the protocol.  Finally, to reduce variability in the quality of study procedures, 
all hair and blood samples will be processed in one central labor atory, all participants will view the same 
video t o receive information about  MedViewer and the study questionnaires will be administered using 
a standardized CA SI system , incorporating the CA PI system  and verbal administration of questionnaires 
by trained research team members, if needed . 
 
Screening , Eligibility and Enrollment of Patient Participants  
Several  steps are in place to ensure safety during screening and enrollment procedures :  
 
• Study Visibility.  To enhance patient awareness of and hence comfort with the study, we will 
place IRB -approved informational flyers in the clinic.  
 
• Pre-consented use of database . Of all the  patients in the UNC ID Clinic  who are living with HIV , 
approximately 95% have conse nted to having their patient information available in a secure 
clinic database, where it can be viewed to identify potential eligibility for open research studies, 
and to being notified of studies for which they are potentially eligible (as per IRB form 99 -MED -
408). Patients in the database have indicated all the methods of contact to which they have  and 
have not  agreed for contact by researchers for potential participation.   
 
• Pre-screening . In addition, the ID Clinic  has a full -time research screener to assess patient 
eligibility for open research projects. We will use the IRB -approved screening process that has 
been used in the ID Clinic  for over ten years, whereby the clinic screener  or a trained research 
team membe r will pre -screen patients scheduled for an appointment in the upcoming week in 
the clinic database. To pre -screen patients, using the clinic database, the screener or trained 
research team member will assess for eligibility criteria outlined in sections 5 .1 and 5.2  under an 
IRB-approved limited waiver of HIPAA . At regular intervals , the clinic screener will share the l ist 
of scheduled patients who meet eligibility in pre -screening to the  research team . 
 
• Recruitment . Using the list of potentially eligible study participants the research team  will 
contact potentially eligible patients who have given permission by phone before their next 
scheduled HIV appointment using an IRB -approved  phone screening questionnaire  to not ify 
them about the study  and assess their interest. Phone calls will be conducted in a private room 
to prevent inadvertent disclosure of participant information.  Patients may also contact study 
staff in response to IRB -approved study recruitment flyers.  
 
• Screening . For participants who express interest on the phone , the researchers  will continue 
with the phone contact to verify their eligibility using a brief standardized IRB -approved 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  50 script/screening form  (with questions pertaining to patient age, amount  of time as a patient at 
the UNC ID Clinic , HIV appointments in the last year, current and past prescribed ARV 
medications and length of caput hair) , and if confirmed to be eligible  for a screening visit , 
schedule them for the first study visit .  
 
• Alternate Recruitment  and Screening . If contact with the patient cannot be established by 
phone despite multiple attempts (as outline d in section 5.5) before the patient visit, the RA may 
use several alternate approach es to recruit, screen and schedule the patient.  First for patients 
who have given permission, the RA may contact them by email using an IRB -approved script to 
invite them to call for further screening  by phone. For patients who call for further screening , 
the RA would follow phone -screening  procedures outlined above.  Second , for patients who 
cannot be contacted by phone  or email after multiple attempts,  and who are scheduled for  an 
in-person clinical visit with their provider, the  research staff will approach them in the  ID Clinic  
waiting room (if the patient has given permission to do so) on the day of their visit to notify 
them that they may be eligible for a study. Those who are interested will be asked to move to a 
private room in the ID Clinic  or CTRC to undergo further screeni ng and, if eligible and interested, 
informed consent. The private room will have a closed door to prevent inadvertent disclosure of 
subject information.  
 
• Exclusion. If one or more of the basic inclusion criteria are not met,  or an exclusion criterion  is 
met,  the subject will be  informed that they are not eligible.  
 
• Consent.  Research staff will obtain written informed consent from each potential participant 
before starting any study procedures according to the standards set forth in the ICH Good 
Clinical Practice guidelines and per unit SOPs.  
 
Screening and Enrollment of Patient IDI Subs ample. We will also enroll  a subsample of patients to 
participate in follow -up IDIs and endline questionnaires . We will use the following process to recruit and 
enroll a target of up to 30 patients for this  portion of the study:  
 
• Screening and Recruitment. During the initial study visit for the main study, research staff will 
inform eligible participants about the IDI subsample activities  and invite them to participate. 
Every enrolled participant in the main pilot study will be invited to participate in the  IDI. We will 
monitor t he rate of subsample enrollment every month and adjust our recruitment methods, as 
needed . This approach will be used to ensure that the subsample is re presentative of the larger 
study  sample, including regarding time of enrollment in  the study (so that we obtain equal 
numbers of patients enrolling early and late in the larger study).   
 
• Consent.  Research staff will obtain a second written informed consent from each potential 
participant before starting study procedures for the IDI according to the standards set forth in 
the ICH Good Clinical Practice guidelines and per unit SOPs.  
 
• Monitoring of Enroll ment Rate. We will monitor the rate of subsample enrollment  every  month 
and adjust our recruitment methods as needed to increase the likelihood of obtaining a 
representative sample of participants throughout the duration of the study.  Specifically, if after  
two months of enrollment, more than  15 participants have enrolled, we will invite every other 
participant to enroll . 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  51  
• All commu nication regarding the IDI subsample activities  and informed consent will take place 
in-person or by IRB -approved phone or videoconferencing call in  a private room with a closed 
door to prevent inadvertent di sclosure of participant  information . 
 
Screening  and Recruitment  Procedures for Provider Participants:  We will also aim to recruit and enroll 
all (~ 15 and up to 30 ) medical providers who provide medical care to patients in the ID Clinic  (attending 
physicians,  fellows, nurse practitioners, physician  assistants, nurses, and pharmacists).  
 
• Information Provision. We will use an IRB -approved verbal and written  announcements about 
the study and training during weekly Infectiou s Disease conferences typically attended by ID 
Clinic  providers.  
 
• Recruitment. A recruitment email that uses an IRB -approved script will be sent to providers by 
the research team to invite them to attend a training session about the MedViewer test. 
Providers will be asked to RSVP to the email to sign up for or decline attendance of the training. 
Attendance of a training is required for their study participation, however, participation in the  
training does not require their participation in the study. Invitation emails will be sent from an 
encrypted email server.  
 
• Consent.  Research staff will obtain written informed consent from each potential provider 
participant before starting any study procedures according to the standards set forth in the ICH 
Good Clinical Practice guidelines and per unit SOPs.   
 
Alternate training. For providers who cannot participate in the original training, we will provide the 
opportunity to attend an alternat e training session or to complete a one -on-one training with a research 
staff member.  Supplemental training  will be offered , as needed . 
Assessment of study intervention adherence: See Section 6.4  
 
Assessment of Adverse events : Adverse events, including serious adverse events will be documented 
throughout the duration of the study. See Section 8.3.  
 
 
 
C. ADVERSE EVENTS AND S ERIOUS ADVERSE EVENTS  
 
8.C.1  DEFINITION OF ADVERSE EVENTS (AE)  
 
Adverse event means any untoward medical occurrence associated with the use of an intervention in 
humans, whether or not considered intervention -related (21 CFR 312.32 (a)).]   As such, an AE can be an 
unfavorable or unintended sign (including an abnormal laboratory finding, for example), symptom or 
disease temporally associated with the use of an investigational product, whether or not considered 
related to the product.  Study participants will be instructed to contact the study site staff to report any 
AEs they may experience at any time during the study pe riod.    
 
In the case of a life -threatening event, they will be instructed to seek immediate emergency care. Where 
feasible and medically appropriate, participants will be encouraged to seek evaluation where the study 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  52 clinician is based, and to request that  the clinician be contacted upon their arrival. Sites will obtain 
written permission from the participant to obtain and use records from non -study medical providers to 
complete any missing data element on a CRF related to an adverse event.  All participant s reporting an 
untoward medical occurrence will be followed clinically, until the occurrence resolves (returns to 
baseline) or stabilizes.  
 
The site clinicians will determine AE resolution or stabilization in their best clinical judgment  but may 
seek PSRT  medical consultation regarding follow -up or additional evaluations of an AE.  Study site staff 
will document in source documents all AEs reported by or observed in enrolled study participants 
regardless of severity and presumed relationship to study produ ct. Study staff also will record all AEs on 
study logs . 
 
8.C.2  DEFINITION OF SERIOUS ADVERSE EVENTS (SAE)  
 
An adverse event ( AE) or suspected adverse reaction is considered "serious" if, in the view of either the 
investigator or sponsor, it results in any of th e following outcomes: death, a life -threatening adverse 
event, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant 
incapacity or substantial disruption of the ability to conduct normal life functions, or a con genital 
anomaly/birth defect. Important medical events that may not result in death, be life -threatening, or 
require hospitalization may be considered serious when, based upon appropriate medical judgment, 
they may jeopardize the participant  and may requir e medical or surgical intervention to prevent one of 
the outcomes listed in this definition. Examples of such medical events include allergic bronchospasm 
requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that d o 
not result in inpatient hospitalization, or the development of drug dependency or drug abuse.  
 
No ARVs or HIV -related conditions will be considered for expedited reported as protocol -related adverse 
events.  
 
Study staff will report all AEs that meet serious adverse event (SAE) reporting requirements according to 
the DAIDS -defined “standard” reporting requirements.  Information on all AEs will be included in reports 
to any applicable government and regulatory authorities.  Study staff will report infor mation on all AEs 
and SAEs to the IRB  and the DAIDs Medical Officer  in accordance with all applicable regulations and 
requirements.   
 
 
8.C.3  CLASSIFICATION OF AN ADVERSE E VENT  
8.3.3.1  SEVERITY OF EVENT  
All AEs will be categorized by severity, by the study physician, using the following guidelines to describe 
severity.  
 
• Grade 1 Mild – Events require minimal or no treatment and do not interfere with the 
participant’s daily activities.   
 
• Grade 2 Moderate – Events result in a low level of inconvenience or concern with the 
therapeutic measures. Moderate events may cause some interference with functioning.  
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  53 • Grade 3 Severe – Events interrupt a participant’s usual daily activity and may require systemic 
drug therapy or other treatment.  Severe events are usually potentially life -threatening or 
incapacitating.  [Of note, the term  “severe” does not necessarily equate to “serious”. ] 
 
• Grade 4 Life-threatening  – A life -threatening event is one where the patient is in immediate 
danger of death  unless intervention is done.  It does not mean that the patient may die at some 
time in the future from the event or may have died if the event had been more serious or 
specific.  
 
8.3.3.2  RELATIONSHIP TO STUDY INTERVENTION  
 
All adverse events ( AEs) will have their relationship to study intervention assessed by the clinician who 
examines and evaluates the participant based on temporal relationship and his/her clinical judgment. 
The degree of certainty about causality will be graded using the categories be low. In a clinical trial, the 
study product must always be suspect. Determination of relationship to study intervention will be based 
on what is known about the natural history of the underlying disease, a subject(s ) concurrent  illness(es), 
concomitant the rapy, study -related procedures, accidents, temporality and other external factors.   
 
Instead of SAE reporting category, the SUSAR (Suspected, Unexpected Serious Adverse Events) reporting 
category will be utilized.  
 
The terms used to assess the relationshi p of an event to the study intervention are:  
 Related —There is a reasonable possibility that the AE may be related to the study intervention  
 Not Related —There is not a reasonable possibility that the AE is related to the study  
 intervention  
 
 
We will also document the outcome of the AE, categorizing the outcome as unknown, ongoing, 
death, resolved, or resolved with sequelae.  
 
8.C.3.3  EXPECTEDNESS  
 
Expected adverse reactions are AEs that are known to occur for the study intervention  being studied and 
should be collected in a standard, systematic format using a grading scale based on functional 
assessment or magnitude of reaction. There are no known AEs that are expected to occur as a result of 
patie nt exposure to the MedViewer interve ntion. H owever, the study physician  will be responsible for 
determining whether an adverse event ( AE) is expected or unexpected.  An AE will be considered 
unexpected if the nature, severity, or frequency of the event is not consistent with the risk informa tion 
previously described for the study intervention . 
8.C.4  TIME PERIOD AND FREQUENCY FOR EVENT ASSESSMENT AND FOLLOW -UP 
 
The occurrence of an adverse event ( AE) or serious adverse event ( SAE) may come to the attention of 
study personnel during study visits and interviews of a study participant presenting for medical care, or 
upon review by a study monitor.  
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  54 All AEs including local and systemic reactions not meeting the criteria for SAEs will be captured on the 
appropriate  case report form  (CRF). Information to be collected includes event description, time of 
onset, clinician’s assessment of severity, relationship to study product (assessed only by those with the 
training and authority to make a diagnosis), and time of resolution/stabilization of t he event. All AEs 
occurring while on study must be documented appropriately regardless of relationship. All AEs will be 
followed to adequate resolution.  
 
Any medical condition that is present at the time that the participant is screened will be considered as 
baseline and not reported as an AE. However, if the study participant’s condition deteriorates at any 
time during the study, it will be recorded as an AE.  
 
Changes in the severity of an AE will be documented to allow an assessment of the duration of th e event 
at each level of severity to be performed. AEs characterized as intermittent require documentation of 
onset and duration of each episode.  
 
The research team  will record all reportable events with start dates occurring any time after informed 
consen t is obtained until 7 days after the last day of study participation.  At each study contact occurring 
after consent , the researchers will inquire about the occurrence of unsolicited  AE/SAEs since the last 
visit using a standardized questionnaire .  Events will be followed for outcome information until 
resolution  or stabilization. In addition, the study staff  will inquire in a solicited  manner about whether 
the participant has experienced: 1) any negative changes in their relationship with their provider; 2)  any 
unplanned disclosure of their HIV status.  
 
8.3.5  ADVERSE EVENT REPORTING  
 
Information regarding all A Es regardless of seriousness or severity will be recorded in the participant’s  
source files.  Grade 1 clinical symptoms (non -laboratory, e.g., headache, nausea) that lead to a 
temporary or permanent hold of study intervention, and all Grade 2 and higher AEs, will be collected on 
standard case report forms (CRFs) for entry into the study database and future reporting to appropriate 
agencies at sta ted intervals consistent with all local policies.  
 
8.3.6  SERIOUS ADVERSE EVENT REPORTING  
 
Expedited Adverse Event Reporting  
No ARVs or HIV -related conditions will be reported as expedited reporting as protocol -related adverse events.  
8.3.7  REPORTING E VENT S TO PARTICIPANTS     
 
Any new safety information learned during the course of study conduct that might affect participant 
willingness to participate will be shared.  
 
8.3.8  EVENTS OF SPECIAL INTEREST  
 
Not applicable.  
  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  55 8.3.9  REPORTING OF PREGNANCY  
 
Not Applicable.  
 
 
8.4 UNANTICIPATED PROBLEMS  
 
8.4.1  DEFINITION OF U NANTICIPATED PROBLEMS (UP)  
 
The Office for Human Research Protections ( OHRP ) considers unanticipated problems involving risks to 
participants or others to include, in general, any incident, experience, or outcome that meets all of the 
following criteria:  
 
• Unexpected in terms of nature, severity, or frequency given (a) the research  procedures that are 
described in the protocol -related documents, such as the Institutional Review Board ( IRB)-
approved research protocol and informed consent document; and (b) the characteristics of the 
participant population being studied;  
 
• Related or possibly related to participation in the research (“possibly related” means there is a 
reasonable possibility that the incident, experience, or outcome may have been caused by the 
procedures involved in the research); and  
 
• Suggests that the rese arch places participants or others at a greater risk of harm (including 
physical, psychological, economic, or social harm) than was previously known or recognized.  
 
8.4.2   UNANTICIPATED PROBLEM REPORTING  
 
The investigator  will report unanticipated problems ( UPs) to the reviewing Institutional Review Board 
(IRB) and t o the Protocol Safety Review Team (PSRT), which includes the study PI. The UP report will 
include the following information:  
 
• Protocol identifying information: protocol title and number, PI’s name, and the IRB project 
number;  
 
• A detailed description of the event, incident, experience, or outcome;  
 
• An explanation of the basis for determining that the event, incident, experience, o r outcome 
represents an UP;  
 
• A description of any changes to the protocol or other corrective actions that have been taken or 
are proposed in response to the UP. 
 
To satisfy the requirement for prompt reporting, UPs will be reported using the following ti meline:   
 
• UPs that are serious adverse events ( SAEs) will be reported to the IRB and to the PSRT and study 
sponsor in accordance with the DAIDS -defined “standard” reporting requirements, which is  as 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  56 soon as possible, but in no event later than  within 7days  of the investigator becoming aware of 
the event.  
 
• Any other UP will be reported to the IRB and to the PSRT /study sponsor in accordance with the 
DAIDS -defined “standard” reporting requirements, which is as soon as possible, but in no event 
later than within 7 days   of the investigator becoming aware of the problem.  
 
• All UPs should be reported to appropriate institutional of ficials (as required by an institution’s 
written reporting procedures), the supporting agency head (or designee), and the Office for 
Human Research Protections ( OHRP ) in accordance with the DAIDS -defined “standard” 
reporting requirements, which is within 7 days of the IRB’s receipt of the report of th e problem 
from the investigator.]  
 
8.4.3  REPORTING UNANTICIPATED PROBLEMS TO PARTICIPANTS  
 
Any new safety information or problems that occur during the conduct of the study that might affect a 
participant’s willingness to participate will be shared.  
 
 
9 STATISTICAL CONSIDERATIONS  
9.1 STATISTICAL ENDPOINTS AND MEASURES  
 
Our study objectives are to:  
 
1. Primary Objective: Investigate the feasibility of delivering the MedViewer intervention as 
planned, the acceptability to patients of participation in the MedViewer intervention, and the 
appropriateness of MedViewer use for adherence counseling.  
 
2. Secondary Objective: Investigate additional dimensions of feasibility, acceptability, and 
appropriate ness of using hair (MedViewer) to provide patients  living  with  HIV feedback 
regarding longitudinal patterns of medication adherence.  
 
3. Exploratory Objective 1: Assess exploratory aspects of MedViewer feasibility  and acceptability, 
and patient and provider v iews of and experiences with the MedViewer test. 
 
4. Exploratory Objective 2: Explore the impact of adherence counseling using MedViewer on ART 
adherence and hypothesized mechanisms of change (adherence information, motivation, 
behavioral skills).  
 
5. Exploratory Objective 2: Further explore the accuracy of the MedViewer test. 
 
As this is a feasibility study, the objective is to accurately assess and describe outcomes among the study 
sample. Our analytic approach  for quantitative endpoints , therefore, f ocuses on calculating precise 
estimates of the outcomes rather than testing hypotheses. Our analytic approach for qualitative 
endpoints focuses on describing participant perceptions, attitudes , and recommendations in depth.  
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  57 • Primary Endpoint(s):  
 
1. Feasibi lity: proportion of participants receiving the MedViewer report during their provider 
visit, as planned  (i.e. the result is delivered to the  designated research staff  member  within 
2 hours of initiation of hair processing  and the results are discussed with 
provider/pharmacist within 4 weeks of hair collection ).  
 
We anticipate 80% or more of participant visits will meet criteria for th is primary 
endpoint.   
 
Time period:  This is a cross -sectional study; here and elsewhere, except where specified 
otherwise, the time period is a single study  visit.  Activities in Study Visit 1 may occur 
over multiple days.  
 
2. Acceptability : proportion of contacted patients who are eligible for a screening visit  (not 
including inclusion  criteri on 9) who agree to participate in the MedViewer  intervention  pilot 
study.  
 
We anticipate 80% or more of contacted, screening eligible, patients (not including 
inclusion criterion 9) will agree to participate in the MedViewer intervention  pilot study .  
 
3. Appropriateness:  perceived usefulness of the MedViewer  intervention  for adherence 
counseling; assessment will occur via in -depth interviews.  
 
Hypothesis testing and precision estimates are not applicable. A description of planned 
qualitative analyses of in-depth interviews ( IDIs) is provided below in section 9.5.  
 
• Secondary Endpoint(s):  
 
Feasibility:  
1. Reasons for patient’s non -receipt of the MedViewer report during  a visit with 
provider or pharmacist within 4 weeks of hair collection  (if applicable). Descriptive 
analysis.  
 
2. Reasons for non -discussion of the MedViewer report with provider or pharmacist (if 
applicable). Descriptive analysis.  
 
3. Duration of time (in minut es) from initiation of hair processing to MedViewer report 
delivery to the designated research staff member . We anticipate the duration will 
be 120 minutes or less in approximately 80% or more of the study participants.  
 
Acceptability : 
1. Provider -reported l ikelihood of recommending MedViewer to future patients. We 
anticipate 80% or more of providers will score 3 or greater on the  5-point  likelihood 
of future MedViewer use item.  
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  58 2. Patient -reported likelihood of agreeing to future MedViewer use. We anticipate 
80% or more of participants will score 4 or greater on the likelihood of future 
MedViewer use item.  
 
3. Patient comprehension of MedViewer report. We anticipate 80% or more of 
patients will score 3 or greater (out of 4) on the comprehension measure . We 
further anticipate that most  patients completing cognitive interviews will display 
good comprehension of the report content.  
 
Appropriateness : 
1. Perceived usefulness of Med Viewer to promote ART adherence .  Rating of patients’ 
and providers’ perceived usefulness of MedViewer to promote ART adherence 
measured by multi -5-item scales.  
i. Patients:  We anticipate a mean score of 4.0 or higher  
ii. Providers: We anticipate a mean score of 4.0 or higher  
 
We further anticipate that a majority of patients and providers completing in -
depth interviewers will express that they feel MedViewer is useful to promote 
ART adherence.  
 
2. Perceived impact of MedViewer use on patient -provider communication and 
relationship : Rating of comparative overall satisfact ion with patient -provider 
interaction during the MedViewer visit as compared to a typical visit rated on a 5-
point comparative satisfaction scale . 
 
Patients:  We anticipate a mean score of 4.0 or higher.  
 
Providers:  We anticipate a mean score of 4.0 or higher.  
 
We further anticipate that a majority of patients and providers competing in -
depth interviews will express that they feel MedViewer is useful to promote ART 
adherence.  
 
• Exploratory Endpoints : 
 
Exploratory Feasibility Endpoints : 
1. Patient -reported maximum out -of-pocket cost willing to pay for MedViewer . We will 
estimate the proportion of participants who would be willing to pay a range of 
potential out-of-pocket costs of MedViewer  (range: $0 to $25 0). Descriptive 
analysis.  
 
2. Cost of MedViewer delivery per person. Descriptive analysis and cost estimation.  
 
3. Compatibility of MedViewer with current clinic practices.  Qualitative assessment of 
provider perceptions.  
 
Exploratory Acceptability Endpoints : 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  59  
1. Patient -reported reasons for declining participation in the MedViewer intervention  
pilot study. C ategorical variable. Descriptive analysis.  
 
2. Reported reasons would/would not agree to (patient -reported) or recommend 
(provider -reported) future MedViewer use. Qualitative analysis.  
 
3. Acceptability of specific components of MedViewer procedure (a -d): 
a. Sufficiency of provider training & materials : Assessed by provider -reported 
self-efficacy, knowledge and perceived quality rated on a  5-point scale). We 
anticipate 80% or more of providers will have a mean score of 4 or greater.  
Additional qualitative asse ssment and description.  
 
b. Sufficiency of patient education (video ): Assessed by four knowledge 
questions – we anticipate that 90% of patients will correctly answer each 
question; 2 self -efficacy questions rated on a 5 -point response scale - we 
anticipate 80 % or more of patients will have a mean score of 4 or greater.  
Additional qualitative assessment and description.  
 
c. Provider satisfaction with results delivery (person, discussion format , and 
content ), with specific items to be  assessed by provider on 5 -poin t scale. We 
expect 80% or more of providers will score 4 or greater  on each item . 
Additional qualitative assessment and description.  
 
d. Patient satisfaction with results delivery (person, discussion format and 
content), wait time, hair sample collection and MedViewer report, with 
specific items to be  assessed by patients on a 5 -point scale. We expect 80% 
or more of patients will have a mea n score of 4 or greater.  Additional 
qualitative assessment and description.  
 
Exploratory Adherence -Related Endpoints : 
 
1. ART adherence (self -reported assessment of 3 -day, 7-day,  and 30 -day adher ence ) 
for IDI subsample. Assessed during patient study visit 1 and follow -up patient study 
visit for IDI subsample.  
 
2. Adherence information (qualitative assessment of information/understanding 
gained of patient adherence resulting from use of MedViewer).   Assess ed during 
follow -up patient study visit for IDI subsample.   
 
3. Adherence motivation (quantitative and qualitative assessment of adherence 
motivation resulting from use of MedViewer).  Assessed during follow -up patient 
study visit for IDI subsample.  
 
4. Adherenc e behavioral skills (quantitative and qualitative assessment of adherence 
behavioral skills and self -efficacy resulting from use of MedViewer).  Assessed during 
follow -up patient study visit for IDI subsample.  
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  60  
Exploratory Endpoints for Assessment of Accuracy of Hair as an Adherence Measure : 
 
1. ARV concentrations  in blood collected for first patient study visit  and a follow -up 
patient study visit , when  applicable . 
 
2. Patient viral load assessed with a clinical care visit linked to a patient -provider 
MedViewer visit (within the last 6 months) and abstracted from the medical record 
by study staff . 
 
3. Log 10 antiretroviral  drug concentrations in hair  collected for first  patient  study visit  
and follow -up patient study  visit, when applicable . 
 
We will estimate log 10 ARV hair concentrations in 3 viral load (VL) groups  
(undetectable, detectable but < 1,000, and > 1,000 copies/mL) and plan to 
conduct hypothesis testing. Alternative Hypothesis: There will be a difference in 
log 10 ARV hair concentrations among the 3 viral load strata such that log 10 ARV 
hair concentrations will be highest in those with VL below the limit of 
quantification for the lab  and lowest in those with VL > 1,000.  
 
9.2 SAMPLE SIZE DETERMINATION  
 
Primary sample size consideration : We will estimate the probability (p) that participants have their hair 
sample -based MedViewer report delivered as planned (for primary feasibility) within each VL strata with 
a corresponding 95% Wilson -Score binomial confidence interval (CI). The same appro ach will be used for 
acceptability, appropriateness, and additional binary endpoints.  
A sample size of 50 would enable sufficient precision for a pilot study to estimate main and secondary 
outcomes as well as sufficient power for exploratory data analyses . Specifically, the table below shows 
the anticipated CI half -widths under the statistically conservative assumption that p=0.50 (50%, the 
point of highest variance) and p=0.80 (80%, as anticipated) assuming n= 25 individuals with undetectable 
VL and n= 25 with detectable VL. When the sample is split evenly between the low VL and high VL strata 
(n=25 per stratum), each stratum has a high probability of achieving a CI half -width of 0.1 9 (19%) or 
narrower if p=0.50 and 0.1 8 (18%) or narrower if p=0.80.  
Table: Precision Calculations  for full sample (N = 50)  
Total  
Sample 
Size Low VL  
(undetectable)  
n= High VL  
(detectable)  
n= Assumed 
true 
probability  Precision:  
95% CI Half -
Width  P (achieving this 
precision)  
50 25 25 p=0.5  Low VL 0.1 9 
High VL 0.1 9 95% 
95% 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  61    p=0.8  Low VL 0.1 8 
High VL 0.1 8  95% 
95% 
CI = confidence interval (two -sided); VL = viral load; P(·) = probability  
For primary outcomes with homogeneous results by VL strata, we will use a weighted analysis to 
estimate the overall proportion for feasibility, acceptability and appropriateness at the UNC clinic, with 
weights corresponding to the VL distribution in the UNC CFAR HIV Clinical Cohort (UCHCC).  
For exploratory analysis, we will  further divide the 2 VL groups to all for  consider ation of  3 VL groups 
(below level of viral quantification (which is <40 at UNC), detectable to <1000, and 1000+ copies/mL). 
Based on analyses of preliminary clinical cohort viral load data, we anticipate t he participants with 
detectable VL to be approximately evenly split between the 25 to <1000 and 1000+ copies/mL VL 
groups , respectively . Association between VL group and each primary outcome for acceptability and 
appropriateness will be explored using a 3x 2 χ2 test for trend (i.e., Cochran –Armitage test for trend)  
although as an exploratory analysis, the study is not powered to identify statistically significant 
differences .  
 
Association between VL group and each primary outcome for acceptability and additional exploratory 
analyses evaluating VL as continuous with left -censored observations <40 copies/mL can compare the VL 
distributions between participants who find the hair evaluation appropriate vs. those who do not 
(anticipated outcome group sizes of n= 25 and 10 assuming 80% of participants report the hair 
evaluation is appropriate).  
 
For additional exploratory analysis, we will also conduct descriptive analyses of the primary outcomes 
with homogeneous results by VL strata for the 40 patient participants who participated in the study 
following modifications made in response to the COVID 19 pandemic to  explore estimation of the overall 
proportion of this subsample for feasibility, acceptability and appropriateness, using weighted analysis 
with weights corresponding to the VL distribution in the UCHCC.  The table below shows the anticipated 
CI half -width s under the statistically conservative assumption that p=0.50 (50%, the point of highest 
variance) and p=0.80 (80%, as anticipated) assuming n= 20 individuals with undetectable VL and n= 20 
with detectable VL. When the sample is split evenly between the low VL and high VL strata (n= 20 per 
stratum), each stratum has a high probability of achieving a CI half -width of 0. 21 (21%) or narrower if 
p=0.50 and 0. 20 (20%) or narrower if p=0.80.  
Table: Precision Calculations  for subsample of participants enrolled after  COVID 19 modifications       
(N = 40)  
Total  
Sample 
Size Low VL  
(undetectable)  
n= High VL  
(detectable)  
n= Assumed 
true 
probability  Precision:  
95% CI Half -
Width  P (achieving this 
precision)  
40 20 20 p=0.5  Low VL 0.21  
High VL 0.21  >95% 
>95% 
   p=0.8  Low VL 0.20  
High VL 0.20   >95% 
>95% 
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  62  
 
9.3 POPULATIONS FOR ANALYSES  
 
We plan to enroll a total o f 50 patient participants, which will be split into 25 patients in Group A and 25 
patients in Group B. We plan to enroll ~ 15 and up to 30 provider participants.  
 
Screen ing eligible patient cohort:  This cohort will include all potential patient participants who were 
found to be eligible to participate in a screening visit (not including inclusion criterion 9), regardless of 
whether they enrolled in the study or not.  
 
Enrolled patient cohort:  The enrolled patient cohort will include all patient participants who screene d 
eligible and signed an informed consent form.  
 
Per-protocol delivery patient cohort:  This cohort will include all patient participants enrolled in the 
intervention who had their hair sample collected and had a MedViewer report delivered to  designated 
research  staff member . 
 
Viral load patient subgroups:  Patients are enrolled based on their being in one of two viral load strata 
defined as those patients with two consecutive years of undetectable  (below the level of viral 
quantification)  viral loads and th ose patients with at least one detectable  (at or above the level of viral 
quantification)  viral load within the previous two consecutive years.  
 
In-depth interview patient subcohort:  (Statistical analyses are not applicable to in -depth interviews .) 
 
Post -COVID  modification enrolled patient subcohort: This will include members of the enrolled patient 
cohort who enrolled in the study after the COVID modification to study procedures. Analysis conducted 
on this cohort will be done solely for exploratory d escriptive purposes.  
 
Enrolled provider cohort:  This will include all providers who screened eligible for and signed an 
informed consent form to participate in the study.   
 
For this study, analysis of the primary feasibility outcome (p roportion of partic ipants receiving 
MedViewer report during their provider visit as planned)  will be conducted on the enrolled patient 
cohort.  
 
Analysis of the primary acceptability outcome ( proportion of  contacted patients eligible for a screening 
visit who agree to partic ipate will be conducted on the screening eligible patient participant cohort .  
 
 
9.4 STATISTICAL ANALYSES  
 
9.4.1  GENERAL APPROACH  
 
As this is a pilot feasibility study, our analytic approach focuses on calculating precise estimates of the 
outcomes, rather than on making comparisons or testing hypotheses. Descriptive statistics of categorical 
variables will be presented as counts and p ercentages, and descriptive statistics of continuous variables 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  63 will be presented as means with standard deviations or median, 25th to 75th percentiles and ranges. We 
will plot and visually inspect the distribution of continuous variables. Generally, we do not anticipate 
variable transformations other than those pre -specified in the endpoints / measures section ( e.g., log 10 
viral load).  
 
With respect to estimation, a maximum likelihood estimate (MLE) will be presented together with a 95% 
confidence interval (CI) for the proportion, or arithmetic mean of a continuous variable. Estimated 
proportions will be presented with a corresponding Wilson -Score 95% CI and estimated means will be 
presented with a corresponding t -distribution 95% CI. If an estimated proport ion is unexpectedly near 
the 0 or 1 boundary (e.g., <0.1 or >0.9), an exact Clopper -Pearson 95% CI will be used as a sensitivity 
analysis.    
 
Main protocol analyses will be conducted withi n the 2 enrollment  viral load strata separately, as the 
strata samp le sizes were selected for stratum -specific estimation and precision. We anticipate that 
patients in Group B will be over -sampled for study participation compared to the general clinic 
population. At the time of final analysis, data from the UNC CFAR HIV Clinical Cohort (UCHCC) will be 
used to define we ights for each viral load stratum,  such that a combined, weighted analysis can be used 
to generalize back to the clinic population. Details of a combined analyses will be pre -specified in a 
separate anal ysis plan, with consideration to additional patient characteristics such as gender, 
race/ethnicity, and age.   Some exploratory analyses will be conducted using the 3 VL groups as 
described in Section 9.2.  
 
9.4.2  ANALYSIS OF THE PRIMARY EFFICACY ENDPOINTS  
 
Primary Feasibility Endpoint : This primary endpoint (proportion of patient participants receiving the 
MedViewer report during their clinic visit as planned), is the proportion of participants who both: (i) had 
their MedViewer report delivered to the design ated research staff member within 2 hours of initiation 
of hair processing  and (ii) discussed the results with a provider (i.e. their medical provider or the HIV 
Care Pharmacist)  within 4 weeks of hair collection .  
 
• Measurement/observation:  To assess the p rimary feasibility endpoint, the numerator will be 
calculated using two separate data sources. First, to assess whether the designated research 
staff member received the patient’s MedViewer report within 2 hours of initiation of hair 
processing a study tra cking log will be maintained by the study team on which the following 
times will be recorded: hair collection, hair transport, hair processing, and delivery of the report 
to the designated research staff member. The  study team will also note which clinicia n reviewed 
the report with the patient, and in their self -report post -visit questionnaires patients will be 
asked to indicate whether the MedViewer report was discussed following clinic visits with their 
medical provider and/or the HIV Care Pharmacist. As a backup data source, providers will also 
be asked in their post -visit questionnaire if they discussed the report with the patient.  
 
• Scale:  This will be a single dichotomous (yes/no) measure. Patients will be counted in the 
numerator of the primary outcome  if:  
o (i) the study team member indicated on the tracking log that, yes, study  staff received 
the patient’ results within 2 -hours of initiation of hair processing in the lab . This will be 
determined by subtracting Time 1 (when hair processing was initiated ) from Time 2 
(when results were delivered to the designated research staff member, and  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  64 o (ii) the patient self -reported on the post -visit questionnaire that, yes, they discu ssed 
results with the provider. As a backup data source, providers will also be asked in their 
post -visit questionnaire if they discussed the report with the patient.  
 
• Statistical analysis:  The proportion of enrolled participants who achieved the primary f easibility 
endpoint will be estimated. An estimated proportion and corresponding 95% Wilson -Score CI 
will be used to analyze this endpoint and all similar dichotomous (i.e., binary) endpoints.  
 
• Statistical procedures:  
o Covariates and factors:  Not applicable.  
o Rationale for covariates:  Not applicable.  
o Details to check assumptions:  If an estimated proportion is unexpectedly near the 0 or 
1 boundary (e.g., above 0.9), an exact Clopper -Pearson 95% CI can be used as a 
sensitivity analysis.  
 
• Planned presentation of results:  Results will be presented as a count/denominator and 
percentage.  
 
• Populations for Analysis:  Enrolled patient cohort.  
 
• Missing data : All enrolled patients will contribute to the analysis denominator; those failing to 
achieve the fea sibility success definition (for any reason) will be counted as a failure for the 
feasibility outcome.  If the patient has missing data on the pertinent item of the patient post -visit 
questionnaire, we will substitute the missing value with the provider’s r esponse to the parallel 
item in the provider post -visit questionnaire.  
 
Primary Acceptability Endpoint:  This primary endpoint is assessed based on the proportion of 
contacted patients who are eligible, who agree to participate I the MedViewer intervention pilot study.  
 
• Measurement/observation:  Data for this measure that will be obtained from the study 
participation log.  
 
• Scale:  This will be a single dichotomous (yes/no) measure  for each individual part icipant . To 
create this measure, the denominator will include all potential patient participants who were 
contacted and found to be eligible for the study  as documented on their pre -screening 
questionnaire . The numerator will be those who agreed to partici pate in the study as 
documented by their informed consent form. The primary endpoint is descriptive.  
 
• Statistical analysis:  The proportion of potential patient participants eligible for a screening visit 
(not including inclusion criterion 9) who achieved t he primary acceptability endpoint (accepted 
enrollment) will be estimated. An estimated proportion and corresponding 95% Wilson -Score CI 
will be used to analyze this endpoint.  
 
• Statistical procedures:  
o Covariates and factors:  Not applicable.  
o Rationale for covariates:  Not applicable.  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  65 o Details to check assumptions:  Exact Clopper -Pearson 95% CI can be used as a sensitivity 
analysis.  
 
• Planned presentation of results:  Results will be presented as a count/denominator and 
percentage.  
 
• Populations for Analysis:  Screened Eligible patient cohort.  
 
• Missing data:  Not applicable; all patients found eligible for a screening visit (not including 
inclusion criterion 9)  will be counted in the analysis.  
 
Primary Appropriateness Endpoint: This primary endpoint (pe rceived usefulness of MedViewer for 
adherence counse ling) will be assessed via IDIs  and thus statistical considerations do not apply for this 
endpoint. Qualitative data collection and analytic methods used for IDIs is described below in section 
9.5.  
 
9.4.3  ANALYSIS OF THE SECONDARY ENDPOINTS  
 
Secondary Feasibility Endpoint:  Reasons for patient’s non -receipt of the MedViewer report during  a 
visit with provider or pharmacist within 4 weeks of hair collection (if applicable) . 
 
• *Note: analysis is not dependent on findings of primary endpoint although it does use a data 
point that is part of the primary endpoint.  
 
• Measurement/observation:  Reas ons for patient’s non -receipt of MedViewer report during a 
visit with provider or pharmacist within 4 weeks of hair collection (if applicable)  will only be 
assessed for the subsample of patient participants for whom non -receipt of the MedViewer 
report is r eported (either by a provider in the provider post -visit questionnaire, or by a research 
team member in a study activities tracking form). Reasons for non -receipt will be assessed using 
a one -item multiple -choice question with a “check all that apply” appr oach in provider post -visit 
questionnaires and an open -ended response on study tracking forms completed by the research 
team. The multiple responses of common reasons for non -receipt of results will also include an 
open -ended (other) option.  
 
• Scale:  Each response option will be a dichotomous (yes/no) item.  
 
• Statistical proc edures:  Statistical analyses will report, for each response option:  
o The proportion of patients in the subsample (patient participants for whom non -receipt 
of the MedViewer report is reported) for whom each response option is endorsed.  
o Covariates and factor s, rationale for covariates : Not applicable.  
o Details to check assumptions: Not applicable.  
 
• Planned presentation of results:  Results will be presented as a count/denominator and 
percentage.  
 
• Populations for Analysis:  MedViewer non -receipt patient cohort.  
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  66 • Missing data:  A complete -case analysis will be used; participants with missing reasons will be 
listed as “Reason Missing” and not counted in the denominator for percentages.  
 
Secondary Feasibility Endpoint:  Reasons for patient’s non -discussion of the MedV iewer report with 
provider  or pharmacist (if applicable) . 
 
• *Note: analysis is not dependent on findings of primary endpoint although it does use a data 
point that is part of the primary endpoint.  
 
• Measurement/observation:  Reasons for patient’s non-discussion of the MedViewer report 
during visit (if applicable) will only be assessed for the subsample of patient participants for 
whom non -discussion of the MedViewer report is reported (either by the patient in the post -
visit patient questionnaire o r by a provider in the post -visit provider questionnaire). Reasons for 
non-discussion will be assessed using a one -item multiple -choice question with a “check all that 
apply” approach in the provider post -visit questionnaires. The multiple responses of com mon 
reasons for non -discussion of results will also include an open -ended (other) option.  
 
• Scale:  Each response option will be a dichotomous (yes/no) item.  
 
• Statistical procedures:  Statistical analyses will report, for each response option:  
o The proportion of patients in the subsample (patient participants for whom non -receipt 
of the MedViewer report is reported) for whom each response option is endorsed by 
the patient or provider.  
o Covariates and factors, rationale for covariates : Not applicable.  
o Details to check assumptions: Not applicable.  
 
• Planned presentation of results:  Results will be presented as a count/denominator and 
percentage.  
 
• Populations for Analysis:  MedViewer non -discuss patient cohort.  
 
• Missing data:  A complete -case analysis will be used; participants with missing reasons will be 
listed as “Reason Missing” and not counted in the denominator for percentages.  
 
Secondary Feasibility Endpoint:  Duration of time  (in minutes)  from initiation of hair processing  to 
MedViewer report delivery  to designated research staff member . This variable is defined as the amount 
of time elapsed (in minutes) from the time of initiation of hair processing in the lab  to time of results 
delivery to designated research st aff member .  This variable will be determined by subtracting Time 1 
(when hair processing is initiated ) from Time 2 (when results were delivered to the designated research 
staff member.)  
 
• *Note: This analysis is not dependent on findings of primary endpoin t 
 
• Measurement/observation:  This variable will be measured using the study visit hair sample 
tracking log. The log will be maintained by the study team  who will report  the time at which 
each study activity occurs.  
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  67 • Scale:  Duration of time will be determined based upon subtracting the time of initiation of hair 
processing from the time of report deliver y. 
 
• Statistical procedures:  We will conduct descriptive statistics for a continuous outcome of time 
(in minutes) indicating  the mean, standard deviation, range and distribution of the time  elapsed .  
o Covariates and factors: Not applicable.  
o Rationale for covariates: Not applicable.  
o Details to check assumptions: The distribution of time elapsed will be plotted.  
 
• Planned presentation of results:  Results will be presented in a table as a mean and SD. Results 
may also be presented as a box plot or histogram.  
 
• Populations for Analysis:  Per-Protocol delivery patient cohort.  
 
• Missing data:  A complete -case analysis will be used;  those with missing data will be excluded.  
 
Secondary Acceptability Endpoint:  Provider -reported likelihood of recommending MedViewer to future 
patients.   
 
• Measurement/observation:  This measure will be assessed using a single Likert -type item among 
providers in a self -reported questionnaire administered to providers by study team member  in 
the endline questionnaire. Providers will be asked to rate their likelihood of recommending 
MedViewer, if av ailable for regular use, to other patients in the future.  
 
• Scale:  This item will be rated on a 4 -point scale ( definitely would not recommend to definitely 
would recommend ). 
 
• Statistical analysis:  We will calculate the proportion of providers reporting each response 
category (count/denominator and percent), respectively.  
 
• Statistical procedures:  
o Covariates and factors: Not applicable.  
o Rationale for covariates: Not applicable.  
o Details to check assum ptions: Not applicable.  
 
• Planned presentation of results:  Results will be presented as a count/denominator and 
percentage for each of the four response categories.  
 
• Populations for Analysis:  Per-Protocol delivery provider cohort.  
 
• Missing data:  A complete -case analysis will be used; those with missing data will be excluded.  
 
Secondary Acceptability Endpoint  Patient -reported likelihood of agreeing to future MedViewer use.  
 
• Measurement/observation:  This measure will be assessed among patients in the self-reported 
post -visit questionnaire administered by th e study team member  after the participant has 
received and discussed their MedViewer report with their provider, (or completed their visit 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  68 without a discussion).  This will be measured using a Likert -type item. Participants will be asked 
to rate their future likelihood of agreeing to MedViewer use if recommended by a provider  in 
the future .  
 
• Scale:  These items will be rated on a 4-point scale (definitely would not use to definitely would 
use).  
 
• Statistical analysis:  For each item, we will calculate the proportion of patients reporting each 
response category (count/denominator and percent), respectively.  
 
• Statistical procedures:  
o Covariates and factors: Not applicable.  
o Rationale for covariates: Not  applicable.  
o Details to check assumptions: Not applicable.  
 
• Planned presentation of results:  Results will be presented as a count/denominator and 
percentage.  
 
• Populations for Analysis:  Per-Protocol delivery patient cohort.  
 
• Missing data:  A complete -case an alysis will be used; those with missing data will be excluded.  
 
Secondary Acceptability Endpoint . Patient comprehension of MedViewer report as perceived by 
patients and providers, respectively.  
 
• Measurement/observation : In the post -visit questionnaire following the MedViewer report 
discussion, patients will be asked to rate their comprehension of  the information presented in 
report. Providers will complete a parallel item in their post -visit questionnaire to assess their 
view of how well p atients understood the information in the MedViewer report. Patient 
comprehension of the report will also be assessed qualitatively: during the patient IDIs, we will 
conduct a cognitive interview to assess patient comprehension of adherence information 
presented in MedViewer report.  
 
• Scale:  The patient item will be rated on a 4-point scale (very difficult to understand to very easy 
to understand). The provider item will be rated on a 5 -point scale (understood poorly to 
understood excellently).  Qualitative r esponses will have no scaling.  
 
• Statistical analysis:  Questionnaire items: for each item, we will calculate the proportion of 
patients and reporting each response category (count/denominator and percent), respectively. 
We will calculate similar proportions for provider responses regarding their perception of  each 
patient’s comprehension, as a proportion of patients. In depth interview: we will summarize the 
extent to which patients understood the content of the reports and describe the primary 
content and formatting features of the report which were poorly un derstood by participants, if 
applicable.  
 
• Statistical procedures:  
o Covariates and factors: Not applicable.  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  69 o Rationale for covariates: Not applicable.  
o Details to check assumptions: Not applicable.  
 
• Planned presentation of results:  Results will be presented as  a count/denominator and 
percentage. Cognitive interview results will be summarized narratively.  
 
• Populations for Analysis:  Questionnaire items: Per -protocol delivery patient and provider 
cohorts; IDI questions: IDI patient sub -sample.  
 
• Missing data:  A com plete -case analysis will be used; those with missing data will be excluded.  
 
Secondary Appropriateness Endpoint: Perceived usefulness of MedViewer to promote ART adherence.  
We anticipate a mean score across three item s each rated on a  5-point usefulness scale of 4.0 or higher.  
 
• Measurement/observation:  Perceived usefulness will be measured in the patient post -visit 
questionnaire administered by the study team member following the MedViewer discussion; 
provider post -visit questionnaire following each visit with an enrolled patient; patient and 
provider endline questionnaires; and in the patient and provider IDIs.  Participants will be asked 
to rate their agreement with statements regarding MedViewer’s usefulness in promoting: 1) 
adherence over the next 30 days; 2) adherence motivation; 3) skills  and strategies to avoid 
missed doses.  
 
• Scale:  These items will be rated on a Rated on a 5-point scale ( not at all useful to extremely 
useful).  
 
• Statistical analysis:  For each item, we will calculate the proportion of patients and providers 
reporting each response category (count/denominator and percent), respectively.  
 
• Statistical procedures : 
o Covariates and factors: Not applicable.  
o Rationale for covariates: Not applicable.  
o Details to check assumptions:  Not applicable.  
 
• Planned presentation of results:  Results will be presented as a count/denominator and 
percentage.  
 
• Populations for Analysis:  Per-protocol delivery patient and provider cohorts.  
 
• Missing data:  A complete -case analysis will be used; those with missing data will be excluded.  
 
Secondary Appropriateness Endpoint: Perceived impact of MedViewer use on patient -provider 
communication and relationship.  
 
Patients : We anticipate a mean score of 4.0 or higher on one  item rated on a 5 -point 
comparative satisfaction scale (much less satisfied than usual to much more satisfied than usual) 
of 4.0 or higher.  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  70 Providers : We anticipa te a mean score of 4.0 or higher on one ite m rated on a 5 -point scale 
(very negatively affected relationships to very positively affected relationships).  
 
• Measurement/observation : In the post -visit questionnaires administered to patients following 
the MedV iewer I, patients will be asked to rate the comparative satisfaction with  the patient -
provider interaction during the MedViewer visit as compared to a typical visit. In the 
questionnaires administered to providers at  endline, providers will be asked to rat e the effect of 
using MedViewer on their relationships with their patients . During the patient and provider IDIs, 
participants will be asked to discuss the anticipated effect of regular MedViewer use on patient -
provider communication and relationships.  
 
• Scale:  The patient questionnaire item will be rated on a 5 -point scale ( much less satisfied than 
usual to much more satisfied than usual ). The provider questionnaire item will be rated on 5 -
point scale ( very negatively affected relationship s to very positively affected relationships ). IDI 
questions will have no scaling.  
 
• Statistical analysis:  Questionnaire items: for each item, we will calculate the proportion of 
patients and providers reporting each response category (count/denominator and percent), 
respectively. IDI questions: N/A; for analytic methods, see section 9.5.  
 
• Statistical procedures:  
o Covariates and factors: Not applicable.  
o Rationale for covariates: Not applicable.  
o Details to check assumptions: Not applicable.  
 
• Planned presentation of results:  Results will be presented as a count/denominator and 
percentage; Qualitative results will be summarized and presented thematically.  
 
• Populations for Analysis:  Per-protocol patient and enrolled provider cohorts.  
 
• Missing data:  Ques tionnaire items: Per -Protocol delivery patient and provider cohorts; IDI 
questions: IDI patient sub -sample.  
 
9.4.4  SAFETY ANALYSES  
 
Adverse Events Definitions and Reporting Requirements   
 
An adverse event is defined as any untoward medical occurrence in a clinical research participant 
administered an investigational product and which does not necessarily have a causal relationship with 
the investigational product.  As such, an AE can be an unfavorable or unintended sign (including an 
abnormal laboratory finding, for example), symptom or disease temporally associated with the use of an 
investigational product, whether or not considered related to the product.  This definition is applied to al l 
the study groups and is applied to all groups beginning from the time of sequential assignment. The term 
“investigational product” for this study refers to all study products listed in this protocol. Study 
participants will be instructed to contact the s tudy site staff to report any AEs they may experience at any 
time between the study interval. In the case of a life -threatening event, they will be instructed to seek 
immediate emergency care. Where feasible and medically appropriate, participants will be encouraged to 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  71 seek evaluation where the study clinician is based, and to request that the clinician be contacted upon 
their arrival. Sites will obtain written permission from the participant to obtain and use records from non -
study medical providers to com plete any missing data element on a CRF related to an adverse event.  All 
participants reporting an untoward medical occurrence will be followed clinically, until the occurrence 
resolves (returns to baseline) or stabilizes.  
 
The site clinicians  will deter mine AE resolution or stabilization in their best clinical judgment but may seek 
PSRT medical consultation regarding follow -up or additional evaluations of an AE.  Study site staff will 
document in source documents all AEs reported by or observed in enroll ed study participants regardless 
of severity and presumed relationship to study product. Study staff also will record all AEs on case report 
forms.  
 
Serious Adverse Events  
 
Serious adverse events (SAEs) will be defined by the Manual for Expedited Reporting of Adverse Events 
to DAIDS (Version 2.1, dated March 2017) as AEs occurring at any dose /intervention  that:  
 
• Results in death  
• Is life -threatening  
• Results in persistent or significant disability/incapacity  
• Is a congenital anomaly/birth  defect    
• Requires inpatient hospitalization or prolongation of existing hospitalization  
 
The following are examples of hospitalization that will not be considered to be AEs:  
 
• Protocol -specified admission (e.g. for procedure required by study protocol)  
• Admission for treatment of target disease of the study, or for pre -existing condition (unless it is 
a worsening or increase in frequency of hospital admissions as judged by the c linical 
investigator)  
• Diagnostic admission (e.g. for a work -up of an existing condition such as persistent pretreatment 
lab abnormality)  
• Administrative admission (e.g. for annual physical)  
• Social admission (e.g. placement for lack of place to sleep)  
• Elective admission (e.g. for elective surgery)  
 
Important medical events that may not result in death, be life -threatening, or require hospitalization 
may be considered a serious adverse drug experience when, based upon appropriate medical judgment, 
they ma y jeopardize the patient or subject and may require medical or surgical intervention to prevent 
one of the outcomes listed above.  
   
Study staff will report all AEs that meet serious adverse event (SAE) reporting requirements according to 
the DAIDS -defined “standard” reporting requirements.  Information on all AEs will be included in reports 
to the US FDA, and other applicable governmen t and regulatory authorities.  Study staff will report 
information on all AEs and SAEs to the IRB in accordance with all applicable regulations and 
requirements.   
 
Social Harms Reporting   
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  72  
Although study sites make every effort to protect participant priv acy and confidentiality, it is possible that 
participants' involvement in the study could become known to others, and that social harms may result.  
For example, participants could be treated unfairly or discriminated against, or could have problems being 
accepted by their families and/or communities. Social harms that are judged by the Investigator of Record 
to be serious or unexpected will be reported to the responsible site IRB at least annually, or according to 
their individual requirements. In the even t that a participant reports social harm, every effort will be made 
by study staff to provide appropriate care and counseling to the participant, and/or referral to appropriate 
resources for the safety of the participant as needed.  While maintaining parti cipant confidentiality, study 
sites may engage their CABs in exploring the social context surrounding instances of social harm.  
 
9.4.5  BASELINE DESCRIPTIVE STATISTICS  
 
We will conduct descriptive statistics to characterize the samples of patient and provider participants.  
 
First,  we will describe the sample characteristics of patient participants according to the following 
demographic characteristics: self -rated health; hair coloring  and other treatments , extensions; number 
of visits in the ID Clinic  in the past year; years/months since became a patient in the ID Clinic ; time to 
travel from home to clinic; age; sex assignment at birth and gender identity ; sexual orientatio n; 
race/ethnicity ; current marital status ; education level; income in past year ; current employment status ; 
health insurance status and type ; and method of paying for ART. 
 
Second, we will compare, among those who are eligible  for a screening visit , those agreeing and not 
agreeing to participate with regard to their age (continuous), gender ( including but not limited to the 
following genders: male/female/trans  male to female/trans female to male ), viral load strata, and 
race/ethnicity  (assessing all racial options as indicated in the baseline questionnaire)  as well as recording 
reasons for non -participation, using a χ2 test (categorical) or a Wilcoxon rank -sum test (continuous). If 
expected cell counts are below 5 a Fisher’s exact test will be used rather than a χ2 test.  
 
Third , we will characterize the enrolled patient IDI sub sample with regard to their self -reported a ge, sex, 
gender identity,  race, ethnicity, marital status, educational level, income, employment status, insurance 
status, self -reported last 30 -day adheren ce, duration of diagnosis,  involvement in medical care, length of 
time it takes for them to get to t he clinic,  hair treatments,  as well as, from chart review, their last viral 
load and CD4 count.  
 
9.4.6  PLANNED INTERIM ANALYSES  
 
No interim analyses are planned.  
 
9.4.7  SUB -GROUP ANALYSES  
 
For sub -group analyses, the primary endpoints (feasibility, acceptability, and appropriateness) will be 
analyzed by viral load strata, and by current gender  and self -reported race/ethnicity , and for the post -
COVID modification subsample . Key, emergent qualitative themes for subgroups  will be described , as 
well as drug exposure in blood  and hair samples during the intervention .  
 
We will present listings of individual participant -level data for the primary endpoints.  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  73 9.4.8  EXPLORATORY ANALYSES  
 
Exploratory analyses will be conducted to provide supplemental information regarding MedViewer 
intervention feasibility, acceptability and appropriateness to further inform modifications to the testing 
of the intervention in a larger trial.  A separate f ull analysis plan will be developed for exploratory 
endpoints but a general description of our approach is provided below.  
 
Exploratory  Feasibility Endpoints :  
 
 
• Patient -reported maximum out -of-pocket cost willing to pay for MedViewer .  The amount that 
patient s would be willing to pay out of pocket for MedViewer in the future will be measured in 
two ways. First, using the post -visit and endline questionnaire s, patients will report the 
maximum dollar amount that the they would be willing to pay out -of-pock et for one use of the 
MedViewer test (adapted from Jonas et al., 2010 and Grutters et al., 2009 willingness to pay 
measures)  [52,53] . We will report summary statistics, including the mean (with 95% CI), 
standard deviation, median, range and 2 5th to 75th percentile of the amount of money patients 
reported being wi lling to pay. The distribution of maximum willing to pay out -of-pocket costs 
will be displayed using boxplots by viral load strata . 
 
• Cost of MedViewer delivery per patient.  This will be measured as a continuous variable using 
the study tracking form which will keep record of staff and study activity time. Specifically, this 
will be the total cost of MedViewer program delivery (based upon administrative cost data that 
will in clude the cost of sample collection kits, cost of lab analytes, processing and equipment, 
costs for utilizing CTRC and clinic exam rooms, records of staff time spent on intervention 
procedure) , and for patients undergoing remote sample collection, the cost  of staff travel (e.g. 
mileage, fuel, etc.,) to collect the samples from participants . Staff time will be estimated based 
on time log assessments made during 4 randomly selected weeks per year.  The total costs will 
be divided by the number of patients to whom the MedViewer intervention was delivered. 
Providers will indicate the estimated additional/reduced time in minutes spent with each 
patient due to the use of the MedViewer report; a sum of the total administrative cost data and 
total costs of staff tim e spent on intervention procedure as assessed using recorded (i.e., 
logged) staff time, reports from providers indicating the estimated additional/reduced time in 
minutes they spent with each patient due to the use of the MedViewer report and salary data. 
The total cost divided by the number of patients to whom the MedViewer was delivered will be 
the estimated cost of delivery per person.  
 
• Compatibility of MedViewer with  current clinic practices.  Qualitative assessment of provider 
perceptions. IDI questions will ask about perceived ease of delivering and discussing MedViewer 
results during typical appointment and perceived level of disruption to clinic flow by MedViewer 
procedures.  
 
 
Exploratory Acceptability Endpoints :  
 
• Patient -reported reasons for declining participation in the MedViewer intervention receipt of 
MedViewer  (declining or withdrawing participation).  This information will be collected using two 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  74 data sources: the study pre-screen ing form (reasons for declining participation) and the study 
termination  form (reasons for withdrawing participation). A list of reasons will be available for 
the study team member  to selec t why the participant declined or withdrew participation, and an 
option  to write in a reason will also be provided.  We will describe the number of people 
nominating each reason for declining/withdrawing participation.  
 
• Reasons  would/would not agree to (patient -reported) or recommend (provider -reported) future 
MedViewer use . Through in -depth interviews, we will elicit explanations of the reported 
likelihood of agreeing to (patients) or recommending (providers) future MedViewer use. 
Participants will be further asked to discuss the primary reasons for this attitude toward futur e 
MedViewer use. For data collection and analytic procedures, see section 9.5.  
 
• Patient comprehension of report. Will also explore patient comprehension of the MedViewer 
report qualitatively during individual IDIs with the subset of patients. As described in 9.5, these 
interviews will be administered by a trained  team member  who will use a semi -struct ured 
interview guide.  
 
• Acceptability of specific components of MedViewer procedure (a -d): 
a. Sufficiency of provider training & materials. Assessed by provider -reported self -
efficacy, knowledge and perceived quality rated on a 5 -point scale). We anticipate 
80% or more of providers will have a mean score of 4 or greater. Additional 
qualitative assessment and description.  
 
b. Sufficiency of patien t education (video): Assessed by 4 knowledge questions – we 
anticipate that 90% of patients will correctly answer each question; 2 self -efficacy 
questions rated on a 5 -point response scale - we anticipate 80% or more of patients 
will have a mean score of 4  or greater. Additional qualitative assessment and 
description.  
 
c. Provider satisfaction with results delivery (person, discussion format, and content), 
with specific items to be assessed by provider on 5 -point scale. We expect 80% or 
more of providers will score 4 or greater on each item. Additional qualitative 
assessment and description.  
 
d. Patient satisfaction with results delivery (person, discussion format and content), 
wait time, hair sample collection and MedViewer report, with specific items to be 
asses sed by patients on a 5 -point scale. We expect 80% or more of patients will 
have a mean score of 4 or greater. Additional qualitative assessment and 
description.  
 
 
Exploratory Adherence -Related Endpoints : 
 
• ART adherence measure by self -report ( open -ended self -report of missed doses over the past 3  
days,  7 days , and 30 days ). 
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  75 • Adherence information (qualitative assessment of information/ understanding gained of patient 
adherence resulting from use of MedViewer).  Assessed during follow -up patient study visit for 
IDI subsample.  
 
• Adherence motivation (quantitative and qualitative assessment of adherence motivation 
resulting from use of MedViewer).  Assessed during follow -up patient study visit for IDI 
subsample.  
 
• Adherence behavioral skills (quantitative and qualitative assessment of adherence behavioral 
skills and self -efficacy resulting from use of MedViewer) . Assessed during follow -up patient visit 
for IDI subsample .  
 
Exploratory Endpoints for Assessment of Accuracy of Hair as an Adherence Measure : 
 
• ARV concentrations  in blood collected for first patient study visit  and follow up patient study 
visit, when  applicable  (blood sample analysis) . 
 
• Patient viral load assessed with a  clinical care visit linked to a patient -provider MedViewer visit  
(within the last 6 months)  and abstracted from the medical record by study staff . 
 
• log 10 antiretroviral drug concentrations in hair  collected for first study visit and follow -up patient 
study visit , when  applicable . We will explore the relationship between log 10 ARV hair 
concentrations and viral load strata. In analyses of the association between VL group and log 10 
ARV hair concentrations using one -way ANOVA we will pre -specify that the impact of race -
ethnicity (as well as additional potential measured confounder s) will be explored with a general 
linear model.  
 
 
9.5 QUALITATIVE DATA COLLECTION AND ANALYSES  
 
IDI participants will complete an interview approximately one hour in length to discuss the interview 
topics pertaining to the relevant endpoints noted above. IDIs will be conducted by trained research staff 
experienced in qualitative research. Interviews will be guided by the use of a semi -structured interview 
guide which will include open -ended questions corresponding to each qualitative endpoint. Interviewers 
will be allowed the flexibility to probe patient responses and pursue discussion diverging from the initial 
interview questions if it is relevant to the endpoints of interest. Each interview will be digitally recorded 
and transcribed verbatim to text for analysis.  
 
Analysis  
 
All interviews will be digitally recorded and transcribed. Data will consist of four key steps: 1) Reading 
for Content:  We will begin with data reading until content becomes intimately familiar. As data are 
reviewed, emergent themes will be noted. 2) Codin g: A list of structural codes related to the interview 
questions will be developed. Code definitions will be documented in a codebook. Qualitative research 
assistants will be trained to apply the codes using software for qualitative analysis. The codebook will be 
piloted with 5 interview transcripts: each transcript will be double coded to reconcile code application, 
and codes and rules for their application were modified as needed. To ensure inter -coder reliability, 10% 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  76 of data will be double -coded. Indepe ndent coders will review areas of discrepancy until complete 
agreement is achieved on coded text; 3) Data reduction:  We will summarize participant responses 
pert aining to each interview topic and describe variation in responses between individuals or among  
subgroups. We will work with the data related to each code to identify principal sub -themes that reflect 
finer distinctions in the data; 4) Data display:  Matrices and tables that categorize and display data will be 
used to help facilitate comparisons (e.g . across viral load strata).  
 
10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS  
 
10.1 REGULATORY, ETHICA L, AND STUDY OVERSIGHT CONSIDERATIONS  
 
10.1.1  INFORMED CONSENT PROCESS  
 
The investigators will obtain informed consent from each patient  before starting any study procedures 
according to the standards set forth in the ICH Good Clinical Practice guidelines and per unit SOPs. The 
process will includ e reviewing consent forms with  potential patient s in a confidential setting and 
explaining all risks and benefits associated with participation of the study. This involves reading over the 
IRB-approved consent form with the patient  in a private space, soliciting questions from the patient, 
allowing the patient  ample time alone to review the form, soliciting questions again, and then offering 
the patient  the opportunity to sign the consent form  or provide verbal consent for follow -up IDI study 
visits using an IRB -approved verbal consent process . To ensure understanding, study staff  will ask 
questions of the patient s regarding study procedures. The consent forms will use language that is 
sufficiently simple for lay persons to comprehend. Patient s will not be coerced into participating. Chi ldren 
under the age of 18 years, decisionally impaired adults and non -English speakers will not be enrolled in 
this study.  Each patient  will be provided with a photocopy of all documents that they  sign. The informed 
consent process will cover all elements  of informed consent required by research regulations. In addition, 
the process specifically will address the following topics of importance to this study : 
 
• The unknown safety and unproven efficacy of the study intervention s 
• The importance of patient s in both study groups to the success of the study  
• The importance of adherence to the study visit and procedures schedule  
• The potential medical risks of study participation (and what to do if such risks are experienced)  
• The potential social harms associated with study participation (and what to do if such harms are 
experienced)  
• The limited benefits of study participation  
• The distinction between research and clinical care  
• The right to withdraw from the study at any time  
 
The informed consent pro cess will include an assessment , through a series of questions, of each potential 
patient ’s understanding prior to enrollment and sequential assignment of concepts identified by the 
protocol team as essential to the informed consent decision.  Patient s who are not able to demonstrate 
adequate understanding of key concepts after exhaustive educ ational efforts will not be enrolled in the 
study.   
  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  77 10.1.1.1  CONSENT/ASSENT AND OTHER INFORMATIONAL DOCUMENTS PROVIDED TO 
PARTICIPANTS  
 
One IRB -approved informed consent document will be reviewed with all patients on study.  All patients 
will also review and sig n a HIPAA form approved by the IRB.  During the consent process, the pa tient 
participants  will watch the short , IRB -approved  video, as noted above, describing the MedViewer and 
what to expect.  
 
 
10.1.1.2  CONSENT PROCEDURES AND DOCUMENTATION  
 
Our informed consent p rocess begins with the initial patient participant contact and provider participant 
contact and continues until study completion.  
 
Most of our initial patient contact will be through phone contact, during which an IRB -approved phone 
screening questionnaire will be administered.  If the patient agrees and passes the screening, they will 
provide basic demographic data needed to schedule their appointment in the clinical research 
management system (CRMS) and this is done under an IRB -approved limi ted HIPAA waiver.  Full HIPAA 
and informed consent occur during the first patient visit.  
 
Most of our initial provider contact will be through email, during which an IRB -approved email invitation 
to attend the provider training and participate in the study will be sent.  If the provider is willing to 
participate , they will schedule their traini ng with the research team and complete informed consent 
process  prior to  the training .  Full informed consent and screening will occur prior to  the provider 
training . 
 
10.1.2  STUDY DISCONTINUATION AND CLOSURE  
 
The study may be discontinued at any time by the NIAI D, site investigators, site IRBs, or other 
government or regulatory authorities. For any study that is prematurely terminated or temporarily 
suspended, the PI will promptly inform study patients, the IRB, and the sponsor providing the reason(s) 
for the ter mination or temporary hold.  
 
When a study is prematurely terminated, refer to Section 7, Study Intervention Discontinuation and 
Participant Discontinuation/Withdrawal , for handling of enrolled study participants.  
 
Circumstances that may warrant termination or suspension include, but are not limited to:  
• Determination of unexpected, significant, or unacceptable risk to pa tients  or to provider 
participants  
• Demonstration of efficacy that would warrant stopping    
• Insufficient compliance to protocol r equirements  
• Data that are not sufficiently complete and/or evaluable  
• Determination that the primary endpoint has been met  
• Determination of futility  
 
Study may resume once concerns about safety, protocol compliance, and data quality are addressed , 
and satis fy the sponsor, IRB and/or Food and Drug Administration ( FDA). 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  78  
10.1.3  CONFIDENTIALITY AND PRIVACY  
 
Confidentiality will be maintained by storing all specimens for current and future use with a unique 
identifying number, which will be linked to the subject’s name, social security number, address, 
telephone number, and hospital medical record (MR) number.  The principal investigators and study 
staff will be the only people with access to the identifying information.  Any information provided to 
other people working on this study will be given with the study ID number, not other identifying 
information.  The records will be secured in a locked file cabinet in a locked room in a badge access only 
office suite of the principal investigator.  
 
All electronic data for this study will be stored on a dedicated University server which contains extensive 
protections and securities.  
 
Participant confidentiality and privacy is strictly held in trust by the participating investigators, their 
staff, and the sponsor(s) and their interventions. This confidentiality is extended to cover testing of 
biological samples and genetic tests in addition to the clinical information relating to participants.  
Therefore, the study protocol, documentation, data, and all othe r information generated will be held in 
strict confidence. No information concerning the study or the data will be released to any unauthorized 
third party without prior written approval of the sponsor.  
 
All research activities will be conducted in as pri vate a setting as possible.  
 
The study monitor, other authorized representatives of the sponsor, representatives of the Institutional 
Review Board ( IRB), regulatory agencies may inspect all documents and records required to be 
maintained by the investigato r, including but not limited to, medical records (office, clinic, or hospital) 
and pharmacy records for the participants in this study. The clinical study site will permit access to such 
records.  
 
The study participant’s contact information will be securel y stored at each clinical site for internal use 
during the study. At the end of the study, all records will continue to be kept in a secure location for as 
long a period as dictated by the reviewing IRB, Institutional policies, or sponsor requirements.  
 
Certificate of Confidentiality  
 
To further protect the privacy of study participants, a Certificate of Confidentiality will be issued  by the 
National Institutes of Health ( NIH).  This certificate protects identifiable research information from 
forced disclos ure. It allows the investigator and others who have access to research records to refuse to 
disclose identifying information on research participation in any civil, criminal, administrative, legislative, 
or other proceeding, whether at the federal, state, or local level. By protecting researchers and 
institutions from being compelled to disclose information that would identify research participants, 
Certificates of Confidentiality help achieve the research objectives and promote participation in studies 
by helping assure confidentiality and privacy to participants.  
  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  79 10.1.4  FUTURE USE OF STORED SPECIMENS AND DATA  
 
Data collected for this study will be analyzed. Any blood sample specimens will be stored in the secure 
lab of the Principal Investigator at the address  noted previously in this protocol.  No data will be 
transmitted outside of study staff.  All samples will be destroyed in according with Environmental Health 
and Safety policies and local SOPs one year after the results have been published. No samples will be 
stored long term.  
 
10.1.5  KEY ROLES  AND STUDY GOVERNANCE  
Provide the name and contact information of the Principal Investigator and the Medical Monitor.  
Principal Investigator  Medical Office r 
Angela Kashuba , BScPhm, PharmD, 
DABCP , FCP, Professor  Cynthia  Gay, MPH, MD, Associate 
Professor  
 
Division of Pharmacotherapy and 
Experimental Therapeutics , 
UNC Eshelman School of Pharmacy  Division of Infectious Diseases, 
Department of Medicine  
UNC School of Medicine  
Address : CB# 7569, 3318 Kerr Hall,  
310 Pharmacy Lane  
Chapel Hill NC, 27599 -7569, USA  Address : 130 Mason Farm Rd. 
(Bioinformatics), CB# 7030  
Chapel Hill, NC 27599 -7030, USA  
Phone Number : 919-966-9998  Phone Number : 919-843-2726  
Email : akashuba@unc.edu  Email : cynthia_gay@med.unc.edu  
 
 
10.1.6  SAFETY OVERSIGHT  
 
A multi -tiered safety review process will be followed for the duration of this study.  The study site 
investigators are the first layer of this tiered system and are responsible for the initial evaluation and 
reporting of safety information at the participant level, and for alerting the Protocol Safety Review Team 
(PSRT) if unexpected concerns arise.   The PSRT will consist of the following study site investigators: Angela 
Kashuba, PharmD (Principle Investigator ), Cindy Gay, MD (Medical Officer) , Amanda Poliseno ( Project 
Manager ) along with the Biostatistician.  
 
10.1.7  CLINICAL MONITORING  
 
Clinical site monitoring is conducted to ensure that the rights and well -being of trial participants  are 
protected, that the reported trial data are accurate, complete, and verifiable, and that the conduct of 
the trial is in compliance with the currently approved protocol/amendment(s), with International 
Conference on Harmonisation Good Clinical Practice  (ICH GCP), and with applicable regulatory 
requirement(s) : 
 
 
• Onsite monitoring will occur at regular intervals.  Comprehensive source monitoring will occur.  
Database monitoring will be targeted at 10% of data entry.  
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  80 • Monitoring follow up clarifications will be completed within 14 business days as noted in our 
local SOPs.   
 
10.1.8  QUALITY ASSURANCE AND QUALITY CONTROL  
 
 Quality Control and Quality Assurance  
 
The study site will conduct quality control and quality assurance p rocedures in accordance with 
Requirements for Clinical Quality Management Plans at DAIDS Funded and/or Supported Clinical 
Research Sites available at:  
(http://www 3.niaid.nih.gov/research/resources/DAIDSClinRsrch/PDF/QMPPolicy.pdf ).  
 
Data Review  
Upon completion of a study or study interval, all study related documentation should be incorporated in 
the Study Folder (Data Packet or Ancillary Records). The Study Folder may consist of folders, 3 ring 
binders, accordion files, or other filing system, a s appropriate.  
All analysts are responsible for ensuring the lab notebooks are completely filled according to SOP -0318 
“Using CPAC Lab Notebooks”.  
 
The data packet will be reviewed and approved by the QC officer and Lab Director or Assistant Director 
to verify accuracy and completeness of the lab notebooks and data packets. Checklists have been 
generated that define specific items that require review by the QC officer as well as the Lab Director or 
Assistant Lab Director. Separate checklists a re used for Tier 1 (Research), Tier 2 (Qualified Methods), and 
Tier 3 (Validated Methods/ Proficiency Testing /Therapeutic Drug Monitoring ) studies. Checklists are also 
included for the review of Validated Method SOPs (200 Series), Analytical Validation Repo rts (400 
Series), and Qualified Method SOPs (700 Series).  
 
Data Reporting  
 
Manifest : Once the analysis is complete for a study, the results should be entered into the study 
Manifest. At a minimum, the Manifest should contain the following:  
 
• Run ID  
• Sampl e ID  
• CPAC ID  
• Species  
• Matrix  
• Time point  
• Analyte  
• Concentration  
• Comments  
 
Security : After the data packet has been reviewed and approved by the QC officer and Lab 
Director or Assistant Director, the manifest should be locked to prevent any data changes, and 
then may be released to the Sponsor.  
 
Quality Assurance : 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  81 • All analyses must be reviewed and approved by the QC officer and Lab Director or 
Assistant Director prior to reporting results.  
• All analysts responsible for performing any bioanalytical tests have been trained in all 
applicable procedures.  
• Hardcopies of test results will be kept in CPAC for 2 years. Hardcopies will then be 
transferred to an archive facility and kept up to 7 years.  
• Following completion of every run, the instrument data and result tables are copied to 
the secure network (M Drive) for stora ge. Backups are also performed nightly by the 
Information Technology department for the Department of Pharmacotherapy and 
Experimental Therapeutics.  
• Training records are kept in the Annual Training and Continuing Education binder.  
 
Arch iving Procedures  
 
Upon completion of a study or study interval, all study related documentation should be included in the 
study folder. A study folder should be created for each study and contain the following: Sample receipt 
records, sample processing forms, sample dispos al records, analytical run records, and sample analysis 
report.  
Conditions for archiving:  
• A dedicated archive facility  
• An individual responsible  
• An index of the archive contents  
• Records of entry and data examined  
• Data should be logged into the archive wi thin a reasonable period of time  
• Appropriate data protection measures  
 
Record Retention Policy : The following table lists the documents that should be retained at CPAC for 
the retention period of 7 years after the close -out date. Arrangements may be made w ith the Sponsor 
for storage or disposal after 7 years.  
• Study specific data, chromatograms, reports  
• Contracts and agreements  
• Patient chart records  
 
The following table lists the documents that should be retained at CPAC for up to 20 years.  
• Bioanalytical Methods  
• Standard Operating Procedures  
• Analytical Validation Reports  
• Lab notebooks  
• Equipment calibration and maintenance records  
• Proficiency testing records  
• Audit inspection reports  
• Employee training records  
 
Study Coordination : All procedures, documentation, subject contact, data management, clinical 
monitoring, personnel training and regulatory requirements will be performed in accordance to policies 
governed by the University of North Carolina Clinical Pharmacology and Analytical C hemistry Laboratory. 
These policies are located in department  and study specific  SOPs.  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  82 10.1.9  DATA  HANDLING  AND RECORD  KEEPING   
 
 
10.1.9.1  DATA COLLECTION AND  MANAGEMENT RESPONSIBILITIES  
 
The study site will maintain source data/documents in accordance with Requirements for Source 
Documentation in DAIDS Funded and/or Sponsored Clinical Trials 
(http://www3.niaid.nih.gov/LabsAndResources/resources/DAIDSClinRsrch/PDF/S ource DocPolicy.pdf ).  
 
The investigator will maintain, and store securely, complete, accurate and current study records 
throughout the study. The investigator will retain all study records for at least three years following the 
completion of the study, unless directed otherwise by the National Institutes of Health (NIH). Study 
records must be maintained on site for the entire period of study implementation.  
 
10.1.9.2  STUDY RECORDS RETENTION  
 
Study documents should be retained for a minimum of 2 years after the last approval of a marketing 
application in an  International Conference on Harm onization ( ICH) region and until there are no pending 
or contemplated marketing applications in an ICH region or until at least 2 years have elapsed since the 
formal discontinuation of clinical de velopment of the study intervention . These documents should be 
retained for a longer period, however, if required by local regulations. No records will be destroyed 
without the written consent of the sponsor, if applicable. It is the responsibility of the sponsor to inform 
the investigator when these documents no longer need to be retained . 
 
10.1.10  PROTOCOL DEVIATIONS  
 
A protocol deviation is any noncompliance with the clinical trial protocol, International Conference on 
Harmonisation Good Clinical Practice ( ICH GCP) , or Manual of Procedures ( MOP ) requirements. The 
noncompliance may be either on the part of the participant, the investigator, or the study site staff. As a 
result of deviations, corrective actions are to be developed by the site and impl emented promptly.  
 
These practices are consistent with ICH GCP:  
• 4.5 Compliance with Protocol, sections 4.5.1, 4.5.2, and 4.5.3  
• 5.1 Quality Assurance and Quality Control, section 5.1.1  
• 5.20 Noncompliance, sections 5.20.1, and 5.20.2.  
 
It is the respons ibility of the site investigator to use continuous vigilance to identify and report 
deviations within 14 working days of identification of the protocol deviation, or within 14 working days 
of the scheduled protocol -required activity.  All deviations must b e addressed in study source 
documents, reported annually to our local IRB and NIH.   The site investigator  is responsible for knowing 
and adhering to the  reviewing IRB requirements.  
 
10.1.11  PUBLICATION AND DATA SHARING POLICY  
 
This study will  be conducted in accordance with the following  publication and data sharing  policies and 
regulations:  
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  83 National Institutes of Health ( NIH) Public Access Policy, which ensures that the public has access to the 
published results of NIH funded research. It requi res scientists to submit final peer -reviewed journal 
manuscripts that arise from NIH funds to the digital archive PubMed Central  upon acceptance for 
publication.  
 
This study will comply with the NIH Data Sharing Policy and Policy on the Dissemination of NI H-Funded 
Clinical Trial Information and the Clinical Trials Registration and Results Information Submission r ule. As 
such,  this trial will be  registered at ClinicalTrials.gov , and results information from this  trial will be 
submitted to ClinicalTrials.gov.  In addition, every attempt will be made to publish results in peer -
reviewed journals.  Data from this study may be request ed from other researchers 1 year after the 
completion of the primary endpoint by contacting the lead contacts nota ted through ClinicalTrials.gov .  
 
In addition, this study will comply with the NIH Genomic Data Sharing Policy , which  applies to all NIH -
funded research that generates large -scale human or non -human genomic data, as well as the use of these 
data for subse quent research. Large -scale data include genome -wide association studies (GWAS), single 
nucleotide polymorphisms (SNP) arrays, and genome sequence, transcriptomic, epigenomic, and gene 
expression data .] 
 
10.1.12  CONFLICT OF  INTEREST  POLICY  
The independence of this  study from any actual or perceived influence, such as by the pharmaceutical 
industry, is critical.  Therefore , any actual conflict of interest of persons who have a role in the design, 
conduct, analysis, publication, or any aspect of this trial will be disclosed and managed. This is required 
by our local research offices at the onset of IRB submission and no less than annually. Furthermore, 
persons who have a perceived conflict of interest will be required to have such conflicts managed in a 
way that is appropriate to their participation in the design and conduct of this t rial.   
 
 
10.2 ADDITIONAL CONSIDERATIONS  
N/A  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  84 10.3 ABBREVIATIONS  
 
AE Adverse Event  
ACTG  AIDS Clinical Trials Group  
ANOVA  Analysis of Variance  
ART  Antiretroviral therapy  
ARV  Antiretroviral  
CAPI  Computer Assisted Personal Interviewing  
CASI  Computer Assisted Self  Interviewing  
CD4 Cluster of Differentiation 4  
CDC Centers for Disease Control and Prevention  
CFAR  Center for AIDS Research  
CFR Code of Federal Regulations  
COC  Certificate of Confidentiality  
CONSORT  Consolidated Standards of Reporting Trials  
CPAC  Clinical Pharmacology and Analytical Chemistry  
CQMP  Clinical Quality Management Plan  
CRF Case Report Form  
CTRC  Clinical and Translational Research Center  
DAIDS  Division of Acquired Immunodeficiency Syndrome i  
EAE Expedited Adverse Event  
EDTA  Ethylene diamine tetraacetic acid  
ENLIGHTEN  Establishing Novel AntiretroviraL Imaging for Hair to Elucidate Nonadherence  
FAQ  Frequently Asked Questions  
FDA Food and Drug Administration  
GC-MS Gas Chromatography -Mass Spectrometry  
GCP Good Clinical Practice  
GWAS  Genome -Wide Association Studies  
HIPAA  Health Insurance Portability and Accountability Act  
HIV Human Immunodeficiency Virus  
ICH International Conference on Harmonisation  
ID Infectious Disease  
ID Number  Identification Number  
IDI In-Depth Interview  
IGHID  Institute for Global health and Infectious Diseases  
IR Infra -red 
IRB Institutional Review Board  
LC-MS/MS  Liquid Chromatography -Triple Quadruple  
MALDESI  Matrix -Assisted Laser Desorption Electrospray Ionization  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  85 MO Medical Officer  
MOP  Manual of Procedures  
MSI Mass Spectrometry Imaging  
NIAID  National Institute of Allergy and Infectious Diseases  
NIH National Institutes of Health  
OHRP  Office for Human Research Protections  
PBPK  Physiologically Based Pharmacokinetic  
PI Principal Investigator  
PO Program Officer  
PrEP  Pre-Exposure Prophylaxis  
PSRT  Protocol Safety Review Team  
QA Quality Assurance  
QC Quality Control  
RA Research Assistant  
RNA  Ribonucleic Acid  
RSC Regulatory Support Center  
SAE Serious Adverse Event  
SAP Statistical Analysis Plan  
SNP Single Nucleotide Polymorphisms  
SOE Schedule of Events  
SOP Standard Operating Procedure  
TDM  Therapeutic Drug Monitoring  
UNC  University of North Carolina at Chapel Hill  
UP Unanticipated Problem  
US United States  
VL Viral Load  
WHO  World Health Organization  
 
  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  86 10.4 PROTOCOL  AMENDMENT  HISTORY  
The table below is intended to capture changes of IRB -approved versions of the protocol, including a 
description of the change and rationale. A Summary of Changes table for the current amendment is 
located in the Protocol Title Page.  
 
Version  Date  Descrip tion of Change  Brief Rationale  
1.1  18Feb2020  Protocol language update  Improved clarity  
2.0 20Aug2020  Incorporates LOA #1, changes to 
study procedures  Study procedures changed to 
remote operations due to 
COVID -19 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  87   
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  88 11 REFERENCES   
 
[1]  Agot K, Taylor D, Corneli AL, Wang M, Ambia J, Kashuba ADM, et al. Accuracy of Self -Report and 
Pill-Count Measures of Adherence in the FEM -PrEP Clinical Trial: Implications for Future HIV -
Prevention Trials. AIDS Behav 2015;19:743 –51. doi:10.1007/s10461 -014-0859 -z. 
[2]  Baxi SM, Liu A, Bacchetti P, Mutua G, Sanders EJ, Kibengo FM, et al. Comparing the novel method 
of assessing PrEP adherence/exposure using hair samples to other pharmacologic and traditional 
measures. J Acquir Immune Defic Syndr 2015;68:13 –20. doi:10.1097/QAI.0000000000000386.  
[3]  Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al. Tenofovir -based 
preexposure prophylaxis for HIV infection among African women. N Engl J Med 2015;372:509 –18. 
doi:10.1056/NEJMoa1402269.  
[4]  Haberer JE, Baeten JM, Campbell J, Wangisi J, Katabira E, Ronald A, et al. Adherence to 
antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of 
serodiscordant couples in East Africa. PLoS Med 2013;10:e1001511. 
doi:10.1371/ journal.pmed.1001511.  
[5]  Rosen EP, Thompson CG, Bokhart MT, Prince HMA, Sykes C, Muddiman DC, et al. Analysis of 
Antiretrovirals in Single Hair Strands for Evaluation of Drug Adherence with Infrared -Matrix -
Assisted Laser Desorption Electrospray Ionizatio n Mass Spectrometry Imaging. Anal Chem 
2016;88:1336 –44. doi:10.1021/acs.analchem.5b03794.  
[6]  Pack AP, Golin CE, Hill LM, Carda -Auten J, Wallace DD, Cherkur S, et al. Patient and clinician 
perspectives on optimizing graphical displays of longitudinal medi cation adherence data. Patient 
Educ Couns 2019. doi:10.1016/j.pec.2018.12.029.  
[7]  Hill LM, Golin CE, Pack AP, Carda -Auten J, Wallace DD, Cherkur S, et al. Using real -time adherence 
feedback toenhance communication about adherence to antiretroviral therap y: Patient and 
clinicianperspectives. JANAC 2019.  
[8]  Springfield AC, Cartmell LW, Aufderheide AC, Buikstra J, Ho J. Cocaine and metabolites in the hair 
of ancient Peruvian coca leaf chewers. Forensic Sci Int 1993;63:269 –75. 
[9]  Agius R, Kintz P, Europea n Workplace Drug Testing Society. Guidelines for European workplace 
drug and alcohol testing in hair. Drug Test Anal 2010;2:367 –76. doi:10.1002/dta.147.  
[10]  Jurado C, Sachs H. Proficiency test for the analysis of hair for drugs of abuse, organized by the  
Society of Hair Testing. Forensic Sci Int 2003;133:175 –8. 
[11]  Appenzeller BMR, Tsatsakis AM. Hair analysis for biomonitoring of environmental and 
occupational exposure to organic pollutants: state of the art, critical review and future needs. 
Toxicol Le tt 2012;210:119 –40. doi:10.1016/j.toxlet.2011.10.021.  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  89 [12]  Hickey MD, Salmen CR, Tessler RA, Omollo D, Bacchetti P, Magerenge R, et al. Antiretroviral 
concentrations in small hair samples as a feasible marker of adherence in rural Kenya. J Acquir 
Immune D efic Syndr 2014;66:311 –5. doi:10.1097/QAI.0000000000000154.  
[13]  Adams JL, Sykes C, Menezes P, Prince HMA, Patterson KB, Fransen K, et al. Tenofovir diphosphate 
and emtricitabine triphosphate concentrations in blood cells compared with isolated peripheral  
blood mononuclear cells: a new measure of antiretroviral adherence? J Acquir Immune Defic 
Syndr 2013;62:260 –6. doi:10.1097/QAI.0b013e3182794723.  
[14] Tests for drugs of abuse. Med Lett Drugs Ther 2002;44:71 –3. 
[15]  Pergament D. It’s Not Just Hair: Histor ical and Cultural Considerations for an Emerging 
Technology. Chicago -Kent Law Review 1999;75.  
[16]  Barry JA, Robichaud G, Bokhart MT, Thompson C, Sykes C, Kashuba ADM, et al. Mapping 
antiretroviral drugs in tissue by IR -MALDESI MSI coupled to the Q Exacti ve and comparison with 
LC-MS/MS SRM assay. J Am Soc Mass Spectrom 2014;25:2038 –47. doi:10.1007/s13361 -014-0884 -
1. 
[17]  Bokhart MT, Rosen E, Thompson C, Sykes C, Kashuba ADM, Muddiman DC. Quantitative mass 
spectrometry imaging of emtricitabine in cervical tissue model using infrared matrix -assisted laser 
desorption electrospray ionization. Anal Bioanal Chem 2015;407:2073 –84. doi:10.1007/s00216 -
014-8220 -y. 
[18]  Thompson CG, Bokhart MT, Sykes C, Adamson L, Fedoriw Y, Luciw PA, et al. Mass spectrometry 
imagin g reveals heterogeneous efavirenz distribution within putative HIV reservoirs. Antimicrob 
Agents Chemother 2015;59:2944 –8. doi:10.1128/AAC.04952 -14. 
[19]  Vogliardi S, Tucci M, Stocchero G, Ferrara SD, Favretto D. Sample preparation methods for 
determinati on of drugs of abuse in hair samples: A review. Anal Chim Acta 2015;857:1 –27. 
doi:10.1016/j.aca.2014.06.053.  
[20]  Olds PK, Kiwanuka JP, Nansera D, Huang Y, Bacchetti P, Jin C, et al. Assessment of HIV 
antiretroviral therapy adherence by measuring drug con centrations in hair among children in rural 
Uganda. AIDS Care 2015;27:327 –32. doi:10.1080/09540121.2014.983452.  
[21]  Coetzee B, Kagee A, Tomlinson M, Warnich L, Ikediobi O. Reactions, beliefs and concerns 
associated with providing hair specimens for medic al research among a South African sample: a 
qualitative approach. Future Virol 2012;7:1135 –42. doi:10.2217/fvl.12.100.  
[22]  Barfod TS, Hecht FM, Rubow C, Gerstoft J. Physicians’ communication with patients about 
adherence to HIV medication in San Francisc o and Copenhagen: a qualitative study using 
Grounded Theory. BMC Health Serv Res 2006;6:154. doi:10.1186/1472 -6963 -6-154.  
[23]  Fehringer J, Bastos FI, Massard E, Maia L, Pilotto JH, Kerrigan D. Supporting adherence to highly 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  90 active antiretroviral therapy and protected sex among people living with HIV/AIDS: the role of 
patient -provider communication in Rio de Janeiro, Brazil. AIDS Patient Care STDS 2006;20:637 –48. 
doi:10.1089/apc.2006.20.637.  
[24]  Golin CE, Smith SR, Reif S. Adherence counseling practices of generalist and specialist physicians 
caring for people living with HIV/AIDS in North Carolina. J Gen Intern Med 2004;19:16 –27. 
[25]  Krummenacher I, Cavassini M, Bugnon O, Schneider MP. An interdisciplinary HIV -adherence 
program combining motivational i nterviewing and electronic antiretroviral drug monitoring. AIDS 
Care 2011;23:550 –61. doi:10.1080/09540121.2010.525613.  
[26]  Nachega JB, Morroni C, Zuniga JM, Schechter M, Rockstroh J, Solomon S, et al. HIV treatment 
adherence, patient health literacy, and  health care provider -patient communication: results from 
the 2010 AIDS Treatment for Life International Survey. J Int Assoc Physicians AIDS Care (Chic) 
2012;11:128 –33. doi:10.1177/1545109712437244.  
[27]  Reif S, Smith SR, Golin CE. Medication adherence pr actices of HIV/AIDS case managers: a 
statewide survey in North Carolina. AIDS Patient Care STDS 2003;17:471 –81. 
doi:10.1089/108729103322395500.  
[28]  Smith SR, Golin CE, Reif S. Influence of time stress and other variables on counseling by 
pharmacists about antiretroviral medications. Am J Health Syst Pharm 2004;61:1120 –9. 
[29]  Valverde E, Beer L, Johnson C, Blair JM, Mattson CL, Sanders C, et al. Pre vention counseling 
practices of HIV care providers with patients new to HIV medical care: medical monitoring project 
provider survey, 2009. J Int Assoc Provid AIDS Care 2014;13:127 –34. 
doi:10.1177/2325957413516496.  
[30]  Wilson IB, Laws MB, Safren SA, Lee Y, Lu M, Coady W, et al. Provider -focused intervention 
increases adherence -related dialogue but does not improve antiretroviral therapy adherence in 
persons with HIV. J Acquir Immune Defic Syndr 2010;53:338 –47. 
doi:10.1097/QAI.0b013e3181c7a245.  
[31]  Amico  KR. Standard of Care for Antiretroviral Therapy Adherence and Retention in Care from the 
Perspective of Care Providers Attending the 5th International Conference on HIV Treatment 
Adherence. J Int Assoc Physicians AIDS Care (Chic) 2011;10:291 –6. 
doi:10.117 7/1545109711406734.  
[32]  Amico KR, Mugavero M, Smith L, Crane H, Quinlivan E, Roytburd K, et al. A brief provider survey 
to characterize retention and adherence standard of care support for patients in HIV care 2014.  
[33]  Thompson MA, Mugavero MJ, Amico KR, Cargill VA, Chang LW, Gross R, et al. Guidelines for 
improving entry into and retention in care and antiretroviral adherence for persons with HIV: 
evidence -based recommendations from an International Association of Physicians in AIDS Care 
panel. Ann In tern Med 2012;156:817 –33, W. doi:10.7326/0003 -4819 -156-11-201206050 -00419.  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  91 [34]  Bachman Desilva M, Gifford AL, Keyi X, Li Z, Feng C, Brooks M, et al. Feasibility and Acceptability 
of a Real -Time Adherence Device among HIV -Positive IDU Patients in China. A IDS Res Treat 
2013;2013:957862. doi:10.1155/2013/957862.  
[35]  Finocchario -Kessler S, Catley D, Thomson D, Bradley -Ewing A, Berkley -Patton J, Goggin K. Patient 
communication tools to enhance ART adherence counseling in low and high resource settings. 
Patie nt Educ Couns 2012;89:163 –70. doi:10.1016/j.pec.2012.03.020.  
[36]  Golin CE, Earp J, Tien H -C, Stewart P, Porter C, Howie L. A 2 -arm, randomized, controlled trial of a 
motivational interviewing -based intervention to improve adherence to antiretroviral therapy 
(ART) among patients failing or initiating ART. J Acquir Immun e Defic Syndr 2006;42:42 –51. 
doi:10.1097/01.qai.0000219771.97303.0a.  
[37]  Kohnert K -D, Heinke P, Vogt L, Salzsieder E. Utility of different glycemic control metrics for 
optimizing management of diabetes. World J Diabetes 2015;6:17 –29. doi:10.4239/wjd.v6.i 1.17.  
[38]  Mistry N, Keepanasseril A, Wilczynski NL, Nieuwlaat R, Ravall M, Haynes RB, et al. Technology -
mediated interventions for enhancing medication adherence. J Am Med Inform Assoc 
2015;22:e177 -93. doi:10.1093/jamia/ocu047.  
[39]  Reich WA. Medication  adherence feedback intervention predicts improved human 
immunodeficiency virus clinical markers. Int J Nurs Pract 2013;19:577 –83. doi:10.1111/ijn.12100.  
[40]  Tanenbaum ML, Leventhal H, Breland JY, Yu J, Walker EA, Gonzalez JS. Successful self -
management among non -insulin -treated adults with type 2 diabetes: A self -regulation 
perspective. Diabet Med 2015;32:1504 –12. doi:10.1111/dme.12745.  
[41]  Golin CE, Groves J, Carda -Auten J, Gould M, White B, Pence B, et al. Accessing and Adhering to 
Medical Care after  Prison Release: IndividualsMotivating to Participate in Adherence, Care and 
Treatment (imPACT) Trial 2013.  
[42]  Golin CE, Davis RA, Przybyla SM, Fowler B, Parker S, Earp JA, et al. SafeTalk, a multicomponent, 
motivational interviewing -based, safer sex co unseling program for people living with HIV/AIDS: a 
qualitative assessment of patients’ views. AIDS Patient Care STDS 2010;24:237 –45. 
doi:10.1089/apc.2009.0252.  
[43]  Golin CE, Earp JA, Grodensky CA, Patel SN, Suchindran C, Parikh M, et al. Longitudinal ef fects of 
SafeTalk, a motivational interviewing -based program to improve safer sex practices among people 
living with HIV/AIDS. AIDS Behav 2012;16:1182 –91. doi:10.1007/s10461 -011-0025 -9. 
[44]  Golin CE, Patel S, Tiller K, Quinlivan EB, Grodensky CA, Boland M. Start Talking About Risks: 
development of a Motivational Interviewing -based safer sex program for people living with HIV. 
AIDS Behav 2007;11:S72 -83. doi:10.1007/s10461 -007-9256 -1. 
[45]  Gardner LI, Marks G, O’Daniels CM, Wilson TE, Golin C, Wright J, et  al. Implementation and 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  92 evaluation of a clinic -based behavioral intervention: positive steps for patients with HIV. AIDS 
Patient Care STDS 2008;22:627 –35. doi:10.1089/apc.2007.0210.  
[46]  Lewis CL, Golin CE, DeLeon C, Griffith JM, Ivey J, Trevena L, et al.  A targeted decision aid for the 
elderly to decide whether to undergo colorectal cancer screening: development and results of an 
uncontrolled trial. BMC Med Inform Decis Mak 2010;10:54. doi:10.1186/1472 -6947 -10-54. 
[47]  Patel SN, Golin CE, Marks G, Groden sky CA, Earp JA, Zeveloff A, et al. Delivery of an HIV 
prevention counseling program in an infectious diseases clinic: implementation process and 
lessons learned. AIDS Patient Care STDS 2009;23:433 –41. doi:10.1089/apc.2008.0189.  
[48]  Sheridan SL, Golin C,  Bunton A, Lykes JB, Schwartz B, McCormack L, et al. Shared decision making 
for prostate cancer screening: the results of a combined analysis of two practice -based 
randomized controlled trials. BMC Med Inform Decis Mak 2012;12:130. doi:10.1186/1472 -6947 -
12-130.  
[49]  Thrun M, Cook PF, Bradley -Springer LA, Gardner L, Marks G, Wright J, et al. Improved prevention 
counseling by HIV care providers in a multisite, clinic -based intervention: Positive STEPs. AIDS 
Educ Prev 2009;21:55 –66. doi:10.1521/aeap.2009.21.1 .55. 
[50]  Proctor E, Silmere H, Raghavan R, Hovmand P, Aarons G, Bunger A, et al. Outcomes for 
implementation research: conceptual distinctions, measurement challenges, and research 
agenda. Adm Policy Ment Health 2011;38:65 –76. doi:10.1007/s10488 -010-0319 -7. 
[51]  Fisher JD, Fisher WA, Misovich SJ, Kimble DL, Malloy TE. Changing AIDS risk behavior: effects of an 
intervention emphasizing AIDS risk reduction information, motivation, and behavioral skills in a 
college student population. Health Psychol 1996;1 5:114 –23. doi:10.1037/0278 -6133.15.2.114.  
[52]  Jonas DE, Russell LB, Chou J, Pignone M. Willingness -to-pay to avoid the time spent and 
discomfort associated with screening colonoscopy. Health Econ 2010;19:1193 –211. 
doi:10.1002/hec.1545.  
[53]  Grutters JPC , Anteunis LJC, Chenault MN, Joore MA. Willingness to pay for a hearing aid: 
comparing the payment scale and open -ended question. J Eval Clin Pract 2009;15:91 –6. 
doi:10.1111/j.1365 -2753.2008.00959.x.  
[54]    Gilliland WM, et al. M Developing IR -MALDESI Mass  Spectrometry Imaging of HIV Medications in Hair as a  
Clinical Tool for Measuring  Patient Adherence. Abstract 294793, TP279. Annual Meeting of the American  
Society for Mass Spectrometry, San Diego, CA, 2018.  
 
 
 
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  93 APPENDICES  
 
APPENDIX A. INTERVENTION MATERIALS  
 
A.1 PROVIDER TRAINING  MATERIALS  
 
ENLIGHTEN PILOT STUDY
PROVIDER TRAINING
1Establishing Novel antiretrovira LImagin G
for Hair To Elucidate Non-adherence
FOR INVESTIGATIONAL USE ONL Y
 
TRAINING OBJECTIVES
2FOR INVESTIGATIONAL USE ONL YUnderstand:
What the MedViewer test does
How to interpret MedViewer reports (patient and provider versions)
Ways to talk to your patients about their MedViewer reports
How study activities will be incorporated into clinic flow
Study purpose and provider and patient activities
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  94 
WHAT IS MEDVIEWER?
NOVEL APPROACH to quantify daily, longitudinal ART drug 
concentrations in hair
Infra -red (IR) matrix -assisted laser desorption electrospray ionization 
(MALDESI) technology for mass spectrometry imaging (MSI)
5 strands scalp hair >1cm in length 
CONCRETE adherence feedback
Results show days of likely missed ART doses over past several weeks
Can be used by patients and providers together to identify possible patterns 
of missed doses of ART
3
FOR INVESTIGATIONAL USE ONL Y
 
4 FOR INVESTIGATIONAL USE ONL Y
 
ENLIGHTEN STUDY AIMS
1. Develop mass spectrometry technology (MedViewer) for ART drugs
2. Develop and validate mathematical benchmarks for IR -MALDESI MSI adherence monitoring
3. a. Formative study (2016 -2018) informed MedViewer video and report development
5FOR INVESTIGATIONAL USE ONL Y3. b. Feasibility Pilot : In the setting of real -time clinical monitoring, investigate: 
•Feasibility
•Acceptability
•Appropriateness
… of using MedViewer to provide feedback on longitudinal medication 
adherence patterns
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  95 
January 2020 –[Month] 2021
January 2020: initiate provider recruitment
January 2020 -[Month] 2021: visits with enrolled patients (~2 -3 per 
provider)
[Month] 2021 –[Month] 2021: ~ 5-minute endline questionnaire (online) and 
in-depth interview (if not already completed)
6FOR INVESTIGATIONAL USE ONL YPILOT STUDY DURATION 
PATIENT PARTICIPANTS
7•Age >18 and HIV -positive 
•Has a scheduled appointment with a provider enrolled in study
•Has documentation of HIV viral loads over the last 2 years
•Has been a UNC ID patient for >90 days
•Attended >1 clinic visit in last year
•On Dolutegravir or Emtricitabine ≥ 90 days
•≥ 1 cm hair not treated in last 4 weeks
Low VL (n=25)
(undetectable*)High VL (n=25)
(detectable**)Patient participants (n=50)
< 40 c/mL 40 to <1000 c/mL ≥1000 c/mL
FOR INVESTIGATIONAL USE ONL Y*all HIV RNA results below 
the limit of viral 
quantification over the 
previous 2 years 
**at least one HIV RNA 
above the limit of viral 
quantification within 
previous 2 years
PATIENT INFORMATIONAL VIDEO 
8
FOR INVESTIGATIONAL USE ONL Y
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  96 
•Pre-screening by phone
•Informed consent, brief video, in -person screening
•Hair sample (and blood sample for some)
•Baseline questionnaireBEFORE VISIT WITH 
PROVIDER 
(with research staff)
•Receive MedViewer report from provider
•Discuss MedViewer report with provider
•Discuss adherence strategies and motivators (optional ) DURING VISIT WITH 
PROVIDER
(with provider/pharmacist)
•Following visit: Brief post -visit questionnaire 
•~4 weeks post -visit: subsample (n=30) will complete in -depth 
interview, endline questionnaire. AFTER VISIT WITH 
PROVIDER 
(with research staff)
9FOR INVESTIGATIONAL USE ONL YPATIENT PARTICIPANT ACTIVITIES 
Prior to study 
completion:
•Receive MedViewer reports 
for participating patientBEFORE VISIT 
WITH PATIENT
•Review and discuss 
MedViewer reports with 
patientDURING VISIT 
WITH PATIENT
•Complete brief post -visit 
questionnaire (emailed to you 
after visit)AFTER VISIT 
WITH PATIENTDay of each patient 
study visit:
10Prior to patient 
study visits:
FOR INVESTIGATIONAL USE ONL Y•Informed 
consent
•Training 
session
•Baseline 
questionnaire•In-depth interview 
(after seeing ≥ 2 
enrolled patients or 
close of patient 
enrollment)
•Endline 
questionnaire  
(within 1.5 months 
after close of patient 
enrollment)PROVIDER PARTICIPANT STUDY ACTIVITIES
 
MEDVIEWER REPORTS
11FOR INVESTIGATIONAL USE ONL Y
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  97 
12Calendar report:
•Recommended for use 
by patients
•Days with likely 
missed doses 
indicated
FOR INVESTIGATIONAL USE ONL Y
13Bar-chart report:
•Recommended for use 
by providers
•Shows daily ART drug 
levels
•Contains information 
about specificity and 
sensitivity of test to 
detect missed doses 
of ART
FOR INVESTIGATIONAL USE ONL Y

Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  98 
14
COMMUNICATION AID AND FAQ
One -page reference sheet with possible strategies to discuss 
MedViewer results and ART adherence with patients (see 
attachment)
One -page FAQ sheet to clarify potential questions or concerns about 
MedViewer and the ENLIGHTEN study (see attachment)
15FOR INVESTIGATIONAL USE ONL Y 
COMMUNICATION AID: INTERPRETING 
MEDVIEWER REPORTS
Assay still in development, so no clinical decisions should be made on the 
basis of the report
Interpret reports in collaboration with your patient
Consider the limitations of the report:
Designed to under -rather than over -report likely missed doses
Precision bars represent variability across a patient’s 5 hair strands
Days in the reports might not represent exact dates of successful and missed doses. Rather, 
the dates indicated can provide an approximation to help identify patterns of missed doses
16FOR INVESTIGATIONAL USE ONL Y
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  99 
FAQ: ACCURACY OF MEDVIEWER REPORTS
Test sensitivity and specificity
MedViewer ROC curves based on evaluation of DTG and FTC in hair strands 
collected after DOT
Adherence cut -off values of MedViewer signal abundance:
Maximize likelihood that a daily concentration is not misclassified as a missed dose 
(specificity) 
Still achieves reasonable likelihood of identifying missed doses                               
(sensitivity)
Sensitivity and specificity values included on provider report
17FOR INVESTIGATIONAL USE ONL Y 
If MedViewer reports are not ready before the patient’s scheduled 
appointment with their provider: 
A research staff member will notify the provider before the appointment
The provider will determine, with patient input, whether to:
Delay the scheduled visit until later that day when the MedViewer report is ready OR
Schedule a separate visit to review the report with the patient within 4 weeks OR
Request that the UNC ID Clinic HIV pharmacist discuss the reports with the patient 
within 4 weeks
18FOR INVESTIGATIONAL USE ONL YIF DELAYS OCCUR WITH REPORT
 
POST -VISIT PROVIDER SURVEY
5 Questions:
1. Did you show your patient their MedViewer report during the visit? (If 
not→Reasons)
2. How much time did you spend discussing the report with your 
patient? (If none →Reasons)
3. How useful would you say that the MedViewer report was for helping 
you understand this patient’s ART adherence ?
4. How useful would you say it was for helping you have a productive 
conversation with this patient about their ART adherence ?
5. How well would you say your patient understood the information in 
their MedViewer report? 
19FOR INVESTIGATIONAL USE ONL Y
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  100 
WHAT’S NEXT FOR YOU?
Study activitie s Research team will…
Baseline questionnaire send you a link via email following this training
Review MedViewer report 
with patient(s) during 
routine clinic visitdeliver the MedViewer report to you before each 
patient’s scheduled visit ( either in -person or via 
secure email)
Post -visit questionnaire(s)send you a link via email after each patient 
MedViewer visit
In-dept h interview contact you to schedule the interview
Endline questionnaire send you a link via email before study close
20 
QUESTIONS?
21FOR INVESTIGATIONAL USE ONL Y
 
BASELINE QUESTIONNAIRE
Please complete your questionnaire as soon as possible.
You will receive an email with the link. 
22FOR INVESTIGATIONAL USE ONL Y
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  101 
THANK YOU!
[Study Contact Name] 
[Email]
[Phone number]
23FOR INVESTIGATIONAL USE ONL Y[Study Contact Name] 
[Email]
[Phone number][Study Contact Name] 
[Email]
[Phone number][Study Contact Name] 
[Email]
[Phone number] 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319      13 May 2021  
A.2 PATIENT VIDEO  STORYBOARD  
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  
MedViewer Patient Education Video Storyboard  
 
 
Notes about video:   
• The video will be approximately 8 minutes in length and include a diverse group of real and animated individuals in terms of race/ ethnicity 
and age.  
• Closed captioning will be available for participants who feel they would benefit from that.  
• The video wi ll open with the UNC  Center  for AIDS Research logo, followed by a title.  
• The video will include the following disclaimer information:  
o Text to appear on screen after the  title screen and before Frame 1:  “The MedViewer test described in this video is for 
investigational use only. No clinical decisions will be made using MedViewer results.”  
o Voiceover to accompany text on screen : “The MedViewer test described in this video is for investigational use only. By this we 
mean that the MedViewer test is still being developed and studied. Therefore, medical providers will not make any clinical 
decisions based on MedViewer results.”  
o Text to be added to the top of  MedViewer report shown in the video and used in the study:  “For investigational use only”  
o Text to be written on final screen after Frame 8:  “The MedViewer test described in this video is for investigational use only. No 
clinical decisions will be made using MedViewer results.”  
o Small watermark to go in botto m left corner of the screen throughout the entire video:  “For investigational use only”  
• Participants will watch the video on tablets with headphones in a private room of the CTRC before signing the informed consen t form to 
participate in the study.  
• The co nsent form will provide instructions to show the video during the section titled: “What will happen to me if I participate in  this 
research?”  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  103 FRAME 1: Purpose of video  
VIDEO: FILMED IN THE ID CLINIC 
  AUDIO SCRIPT  CAST  
• Show both Provider #1 and Patient #1 standing 
together inside the ID Clinic.  
• Then, Provider #1 and Patient #1 will alternate 
speaking directly to the camera.  
• The tone should be natural and welcoming.  
 
 
 • Hi! I’m <Patient #1> and I come to the infectious disease clinic for care 
and management of my HIV. (Patient #1)  
• And I’m <Provider #1>. I work here in the infectious disease clinic.  We 
have some exciting information for you. (Provider #1)  
• You and I already know that to stay healthy while living with HIV, we 
need to take antiret roviral medicine (or ART) every day. Now, 
researchers at the University of North Carolina have developed a test 
called MedViewer that can measure the amount of ART in our bodies 
over time. The test can help us, and our health care providers, know if 
we are  getting enough ART to keep staying healthy. (Patient #1)  
• We’d like to tell you a little bit more about this. We hope that by the 
end of this video, you’ll understand the MedViewer test and how it can 
improve how you and your provider manage your HIV. (Pro vider #1)  • Provider #1  
• Patient #1  
 
 
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  104 FRAME 2: How ARVs are processed in the body and end up in the hair  
VIDEO   
MOSTLY ANIMATION WITH NARRATION AND SOME 
FILMING IN THE ID CLINIC   AUDIO SCRIPT  CAST  
• Show a short shot of Patient #1 saying the first line. 
Patient #1 will then narrate the rest of the frame – which 
will be animated.  
• A text slide will indicate this frame is covering:  
“How ART is processed in the body and ends up in the 
hair”. Music will accompany it.  
• Animation will show a patient ingesting ART pills and 
those pills being absorbed in body, ending in hair. 
Accompanying text will point out key points.  • To begin, let’s look at what happens when you take your 
medicine.  
• When you swallow a pill, like ART, it travels to your stomach, 
where it dissolves into tiny particles.  
• These particles continue into your intestines, and then cross 
into your bloodstream. Your blood carries the medicine all 
over your body, helping to figh t the HIV virus.  
• Small amounts of medicine even travel into your hair.  
• The new MedViewer test will measure the amount of ART in 
your hair and this represents how much ART is in your body.   • Patient #1  
 
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  105 FRAME 3: Introduction to test, purpose of test, an d what test is measuring  
VIDEO   
MIX OF FILM AND ANIMATION: FILMING IN THE ID CLINIC  AUDIO SCRIPT  CAST  
• Begin with Provider #1 speaking directly to the camera for the first bullet.  
• Patient #1 will then speak directly to the camera for the second bullet.  
• Patient #1 will then narrate while animated images pop up to show 
comparisons between the VL and MedViewer tests (the sub -bullets).  
o Comparison 1: virus vs. ART  
▪ Show a vile of blood on the left hand  side of the 
screen. Next to it, show an animated image for a 
virus. Use text to highlight the fact that the VL test 
measures the amount of VIRUS in the body.  
▪ Next, show a sample of 4 hairs and a provider with 
tweezers on the left of the screen. Next to i t (on the 
right) show a bottle of medication/ pills. Use text to 
highlight the fact that the MedViewer test measures 
the amount of ART in the body.   
o Comparison 2: single vs. longitudinal measure  
▪ On the left show someone getting their blood drawn 
and then show a calendar with Viral Load on ONE day. 
Viral Load should be written on the bottom right of 
the frame.  
▪ Then, show someone on the left and an image of a 
full calendar representing the fact that MedViewer 
can detect many time points. Show a person with 
short hair and a couple of weeks highlighted on the 
calendar. Then, show a person with long hair and a 
whole month highlighted. MedViewer should be 
written on the bottom right of these frames.   
o Length of hair: Show a video image of Patient #1 stating that  you 
must have 1cm of hair. Show a ruler and a pea to provide a visual 
of the length.  • Health care providers, like me, want to make 
sure your body is getting enough ART to fight 
HIV. The MedViewer test, along with your HIV 
viral load, will help you and you r doctor 
manage your HIV better than ever before. 
(Provider #1)  
• Because you may be familiar with the viral 
load test already, I’ll tell you how MedViewer 
is different. (Patient #1)  
o First, the viral load test uses a BLOOD 
sample to measure the amount of 
VIRUS in your body. MedViewer uses 
a HAIR sample to measure the amount 
of ART in your body.  
o Second, the viral load test only shows 
the amount of virus at ONE point in 
time – when you provided the sample. 
But, MedViewer shows the amount of 
ART in your body at  MANY points in 
time.  
▪ If you have very short hair, 
MedViewer will show the past 
couple of WEEKS; if you have 
long hair it will show a 
MONTH.  
• But, to be able to use MedViewer, you have to 
have scalp hair that’s at least 1cm long. That’s 
about the width of a pea.  (Patient #1)  
 • Provider #1  
• Patient #1  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  106 FRAME 4: Hair sample collection process  
VIDEO  
ALL FILMED: IN THE ID CLINIC  AUDIO SCRIPT  CAST  
• Patient #1 will continue to do all the narration here. The first 
shot should show him talking to the camera in front of a closed 
clinic room door.  
• Next, show a health provider (Provider #2) talking to a patient 
(Patient #2) while Patient #1 narrates.  Then, show Provider #2 
picking up tweezers.  
o The camera should see Patient #2 appearing calm and 
interested – and agreeing to having her hair plucked.  
• The camera will then show Provider #2 selecting 4 strands of 
hair to pluck from the back of Patient #2’s head. The camera 
will remain zoomed in until  the provider plucks the hair – all 
five strands at one time.  
• The next shot will be a close -up of the provider securely 
attaching the plucked hair to foil with an ID label that has a 
unique ID# printed on it. The label will also indicate the distal 
and sca lp ends of the hair for the lab.  
• The last shot will be a close -up of Provider #2 folding the foil 
and placing the foil -wrapped hair into a secure container.  • Let’s see a close -up of how this new test works!  
• A trained staff member will select hair from the  back of 
your head and use clean tweezers to gently pluck it. He 
or she will pluck about five strands.  
• Once the hair is collected, the staff member will attach 
the hair to a foil sheet using a sticky label with a unique 
ID number. Your name or any other i dentifying 
information about you, will NOT  be on the label.  
• The staff member will fold the foil and place it in a 
secured container.  • Patient #1  
• Provider #2  
• Patient #2  
 
 
 
 
 
 
 
 
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  107 FRAME 5: Lifespan of hair sample collection, test, sample disposal, and results  
VIDEO  
ALL ANIMATION WITH NARRATION  AUDIO SCRIPT  CAST  
• To introduce this frame, a slide will ask “What happens next?” and music 
will accompany it.  
• Patient #1 will continue to do the narration for this frame.  
• For each bullet point, animation will show:  
o Sample carried/transported into the UNC hospital  
▪ Image of researcher walking to lab with a sealed 
container and sample being received by the analyst  
o Sample being examined in the lab  
▪ Image of analyst (in a lab coat) putting hair into a 
representation of the MedViewer machine  
o Sample being destroyed  
▪ Image of hair sample being incinerated  
o 2 hours  
▪ An animated view of the reception/ waiting room and 
a clock counting 2 hours  
o Results sent by secure email to the ID Clinic  
▪ Image of analyst and results, and then a secure email 
being sent and received (we see research staff member 
in the clinic delivering a confidential folder to a 
provider)  
o Provider discussing results with patient  
▪ Image of patient and provider talking across from each 
other  
o Provider and patient talking amicably together in a clinic room  • Then, the trained staff member will carry 
it to the UNC testing lab, and deliver it to 
the analyst .  
• The analyst will place the hair in the 
equipment to run the test.  
• Once the test is done, the analyst will 
permanently dispose of the hair.  
• Your provider will the n review your results 
with you.  
 • Patient #1  
 
 
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  108 FRAME 6A [BAR GRAPH RESULTS OPTION]: How provider will review results with the patient and how results will be used  
VIDEO  
MIX OF FILM AND ANIMATION: FILM IN THE ID CLINIC  AUDIO SCRIPT  CAST  
• The first shot should be a quick image of Patient #2 and 
Provider #3 sitting down talking together in a clinic 
room, talking about the MedViewer results.  They should 
be referring to and looking at a copy of the results so it’s 
clear what they are discussing.  
• Then, show Patient #2 speaking directly into the came ra 
for the first bullet.  
• The second bullet point, should show the results with 
animation highlighting specific features of the report 
that correspond to what the patient is discussing.  
• The last bullet should show Patient #2 and Provider #3 
discussing the  results in a clinic room.  
 • Hi! I’m <name> and I’m a patient as well. My provider and I just 
went over my MedViewer results, and I would like to share 
them with you. (Show patient)  
• The results look like this. These are all the days that the 
MedViewer detected and measured the amount of medicine 
in my body. Over here is a key that explains what we’re looking 
at. The blue areas show the days when I had enough ART in my 
body. But there are also some areas that are white and blank. 
These are days I did not have enough medicine in my body.  
(Show bar graph version of results)  • Patient #2  
• Provider #3  
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  109 FRAME 6B [CALENDAR RESULTS OPTION]: How provider will review results with the patient and  how results will be used  
VIDEO  
MIX OF FILM AND ANIMATION: FILM IN THE ID CLINIC  AUDIO SCRIPT  CAST  
• The first shot should be a quick image of Patient #2 and 
Provider #3 sitting down talking together in a clinic 
room, talking about the MedViewer results.  They should 
be referring to and looking at a copy of the results so it’s 
clear what they are discussing.  
• Then, show Patient #2 speaking directly into the camera 
for the first bullet.  
• The second bullet point, should show the results with 
animatio n highlighting specific features of the report 
that correspond to what the patient is discussing.  
• The last bullet should show Patient #2 and Provider #3 
discussing the results in a clinic room.  
 • Hi! I’m <name> and I’m a patient as well. My provider and I just 
went over my MedViewer results, and I would like to share 
them with you. (Show patient)  
• The results look like this. These are all the days that the 
MedViewer detected and measured the amount of medicine 
in my body. Over here is a key th at explains what we’re looking 
at. The blue areas show the days when I had enough ART in my 
body. But, there are also some areas that are white and blank. 
These are days I did not have enough medicine in my body.  
(Show calendar graph version of results)  • Patient #2  
• Provider #3  
 
  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  110 FRAME 7: Addressing potential concerns  
VIDEO  
MIX OF FILM AND ANIMATION: FILM IN THE ID 
CLINIC OR ELSEWHERE  
 AUDIO SCRIPT  CAST  
• First shot should be of Patient #1 in the reception 
area of the ID Clinic.  
• Patient #1 will do the narration for the full frame, 
except the questions.  
• The questions will be asked by diverse, animated, 
individuals. For each question, show an animated 
individual on the screen.   
• For each answer, show images previously shown 
in the video:  
• 1) Hair being plucked while a patient smiles/ 
seemingly not bothered  
• 2) The bar or calendar results graphs 
previously used in the video – which 
animated highlights showing days HIV 
medicine was detected.  
• 4) The research member receiving a secure 
email, p rinting results, putting them into a 
folder labelled “Confidential”, and delivering 
them to a provider  
• The last shot will show the ID number from 
the results.  • So now that you know what MedViewer is and what it does, 
we want to address some questions you m ay have. (Patient 
#1) 
1) Does it hurt? (Animated individual)  
• No! It doesn’t. A clinically trained staff member will pluck 
several strands of hair. You may feel a brief pinch from 
the plucking, but it’s not painful.  (Patient #1)  
2) What information about me will  this test collect? (Animated 
individual)  
• MedViewer will only measure and report information on 
HIV medicines in your body. (Patient #1)  
3) Should I be concerned about confidentiality and privacy? 
(Animated individual)  
• The research team will do everything pos sible to protect 
your confidentiality and privacy. The staff member and 
your provider are the only people who will see both your 
results and your name – everyone else will only see your 
unique ID number.  (Patient #1)  
 • Patient #1  
 
 
  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  111 FRAME 8: Summary of information covered  
VIDEO  
MIX OF FILM AND ANIMATION: FILM IN ID CLINIC OR ELSEWHERE  
 AUDIO SCRIPT  CAST  
• The first shot will be of Patient #1 in the clinic – just for the first 
bullet.  
• Patient #1 will then narrate the rest of the bullets.  
• Subsequent shots should reuse images previously seen in 
the video.  
▪ Image of hair strands and tweezers with text 
indicating MedViewer measures ART in the 
body – with ART underlined  
▪ Image of Provider #2 plucking hair from 
Patient #2 who is smiling/ relaxed  
▪ Image of hair being taken to the lab for testing  
▪ Image of hair being incinerated  
▪ Image of results being securely delivered to 
the provider  
▪ Image of two hours on a clock  
▪ Image of patient with short hair and a 
calendar showing ART detection for a couple 
of weeks  
▪ Image of a patient with longer hair and a 
calendar showing ART detection for a month  
▪ Image of Patient #2 and Provider #2 discussing 
results in a clinic room  
• The last frame should be a images of all the people who 
were filmed as part of this video: P rovider #1, Provider #2, 
Provider #3, Patient #1 and Patient #2  
 
 • Now, let’s review! (Show Patient #1 speaking; 
narrate sub -bullets)  
• MedViewer is a test that measures 
the amount of ART in your body using 
hair samples.  
• A trained staff member will pluck a 
small number of strands of hair from 
your head and take them to the lab 
for testing.  
• After testing, all hair samples will be 
permanen tly disposed of, and your 
results will be sent securely to the 
clinic.  
• Remember, the results will show amounts of 
ART in your body over the past couple of 
weeks or a month, depending on the length of 
your hair.  
• With this information, you and your 
provider can see how you are taking 
your medication.  
• We hope you’ve enjoyed hearing about 
MedViewer. If you have any questions, please 
feel free to ask your health care providers. 
Thanks for listening!  • Patient #1  
 
 
  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  112  
A.3 PROVIDER COMMUNICATION AIDS  
MedViewer Communication Aid  
MEDVIEWER REPORTS  
• Reports show days with likely missed ART dose(s) during the weeks prior to hair sample collection.  
• Two versions:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
•  Look over both the calendar and bar chart versions before discussing results with your patient.  
 
INTERPRETING MEDVIEWER REPORTS  
• This assay is still in development, so no clinical decisions should be made on the basis of the report.  
• Interpret MedViewer rep orts in collaboration with your patient. Use both the reports and your patient’s memory to understand your 
patient’s medication -taking.  
• Consider the limitations and levels of measurement certainty represented in the report:  
o The reports have been designed t o under - rather than over -report likely missed doses.  
o Precision bars for each day in bar chart represent variability across each patient’s 5 hair strands.  
o Days in the reports may not represent exact dates of successful and missed doses  (see FAQ).  
USING MEDVIEWER REPORTS WITH YOUR PATIENTS  
 
First step to use with each patient:  MEDVIEWER CURRENTLY FOR 
INVESTIGATIONAL USE ONLY  
Calendar version  
• Days with likely missed 
doses indicated.  
• Recommended for patients.  Bar chart version  
• Daily ART levels detected in hair 
and adherence threshold indicated.  
• Recommended for providers . 

Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  113 REVIEW & CHECK  
MedViewer results with 
patient  • Review and explain MedViewer report results to your patient.  
• Check in with patient to see how well patterns of missed doses generally 
align with patient’s recollection.  
o If patient corroborates, consider optional steps below.  
o If patient does not  corroborate, you may choose to conclude the 
conversation about the report.  
 
Optional additional steps:  
UNDERSTAND  
reasons for missed 
doses/successes  • Discuss causes  of successful and missed doses. Ask about:  
o Event -level causes of missed doses.  
o Chronic and psychosocial causes of missed doses.  
o Strategies that yielded success.  
STRATEGIZE   
to overcome challenges/ 
replicate successes  • Develop strategies with patient to overcome causes of missed doses.  
• Discuss ways to replicate adherence success.  
MOTIVATE   
to improve or maintain 
adherence  • Provide praise for good adherence.  
• Work with patient to set goals for adherence.  
  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  114 MedViewer Frequently Asked Questions (FAQs)   
Q: How will confidentiality of hair samples and MedViewer reports be ensured?  
A: All hair samples and MedViewer reports will be labeled with a unique participant ID that contains no identifying information about 
the patient. Once the MedViewer test is complete, all hair samples will be incinerated. The research team will store a copy of the 
MedViewer report in the secure research record after your appointment with the patient. Please securely dispose of the MedVie wer 
report and/or delete the email containing the report following your MedViewer discussion with the patient.  
Q: How will I  receive the MedViewer report during the pilot study?  
A: A study team member will deliver the MedViewer report either a) to your workstation at the ID Clinic or b) via secure email b efore 
your scheduled appointment with the patient participant. In the cas e that the report is delayed and not available before the 
appointment, there will be several possible options (see next question.)  
Q: What happens if the MedViewer report is not ready by the time I am scheduled to see the patient?  
A: If you do not receive the MedViewer report on time for the scheduled appointment with your patient, the research team will notify 
you before the appointment. You can then decide, with patient input, whether to a) delay seeing the patient until later that day when 
the report arr ives; b) meet with the patient at the scheduled appointment time and schedule a separate visit to review the MedViewer 
report within 4 weeks; or c) request that the clinic HIV care pharmacist discuss the MedViewer report with the patient within  4 weeks.  
Q: How does MedViewer compare to a viral load assay?  
A: While viral load results allow you to assess the impact of your patient’s ART regimen on viral suppression at a given point i n time, 
viremia may or may not be attributable to sub -optimal adherence to A RT and may only reflect recent adherence behavior. Similarly, 
an undetectable viral load may not reflect perfect adherence. The MedViewer report shows the level of drug absorbed by the bo dy on 
a daily basis over several weeks, providing a longitudinal indi cator of daily adherence. Once available for routine use, MedViewer 
can be used alongside viral load tests to guide patient counseling and treatment and offer another tool that can be used in 
conversations about adherence.  
Q: How accurate are MedViewer res ults?  
A: Test sensitivity and specificity:  Receiver operating characteristic (ROC) curves have been determined for MedViewer based on 
evaluation of dolutegravir (DTG) and emtricitabine (FTC) in hair strands collected following directly observed therapy. Ba sed on 
these results, adherence cut -off values of MedViewer signal abundance have been selected to maximize the likelihood that a daily 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319   13 May 2021  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  115 concentration is not misclassified as a missed dose (specificity) while still achieving reasonable likelihood of identif ying missed doses 
(sensitivity). Sensitivity and specificity values will be included on each provider report.  
Dates in report:  The dates of missed doses shown in the report might not correspond to exact dates of adherence behavior. Rather, 
the dates indica ted can provide an approximation to help identify patterns of missed doses.  
Q: How do different hair conditions affect the test results?  
A: MedViewer results are accurate and valid for hair treated more than 4 weeks prior to hair collection. Thus, patients are elig ible to 
participate if their most recent chemical hair treatment was more than 4 weeks prior to their study enrollment date. Howev er, patients 
who have received chemical hair treatment with bleach, dye or relaxers during the 4 weeks prior to their screening visit will  not be 
eligible to participate in the study. Other treatments such as hair straightening and moisturizing do not affe ct the detectable level of 
drug in hair measured by the MedViewer test.  
 
 
 
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319  20 August 2020  
 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  116 MEDVIEWER RESULTS REPORTS:  
Example provider report with hypothetical patient data:  
(Note: The provider report displayed below is an example of what the MedViewer provider report may  look like during the clinical trial. Final report displays to 
be used in the trial are being developed as additional pharmacokinetic data become available .)  
 
 
Example patient report with hypothetical patient data:  
(Note: The patient report displayed below is an example of what the MedViewer provider report may  look like during the clinical trial. 
Final report displays to be used in the trial are being develo ped as additional pharmacokinetic data become available.)  
 
 
 
  FOR INVESTIGATIONAL USE ONLY  
Summary Statistics:  
• Date of t est: February 3, 2019  
• Test sensitivity : 100% . Test  specificity : 73%  
• Drug tested: Dolutegravir  
• Drug concentration d etected:  Last 3 -4 weeks  
• Average c oncentration: 1.72 g/g hair  
• Days with optimal c oncentration: 13/24 (54%)  
• Average number of c ontiguous days b elow threshold: 2 (9%)  
 
 
 0.000.501.001.502.002.503.00
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31Median Drug Concentration from Four 
Hair Strands
𝝁g/ g hairART Medication in Hair Over Time
January 2019
Green Line : Daily dosing target Blue Bars : Days at or above daily dosing target    
Black Lines : Min/max values from four hair strands Gray Bars : Days below daily dosing targetSat  Sun Sat  Sun Sat  Sun Sat  Sun
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v.2.0 
Protocol 122319  20 August 2020  
  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  117   
Example patient report with hypothetical patient data:  
(Note: The patient report displayed below is an example of what the MedViewer provider report may look like during the clinical trial. Final report dis plays to be 
used in the trial are being developed as additional pharmacokinetic data become available.)   
 
Results Summary:  
• Your MedViewer test was conducted on February 3, 2019.  
• MedViewer detected ART medicine in your hair from the last 4 weeks.  Key:  
 
Blue:  Your body had ENOUGH 
ART medicine. Excellent! 
When your body has enough 
med icine, it can help make the 
virus  undetectable. It can also  
lower your risk of transmitting 
the virus to other people.  
 
White : Your body did NOT 
have enough medicine. Talk 
with your provider about how 
to make sure you get the right 
amount.  
 
Gray : MedViewer not 
conducted for these days.  
 
 FOR INVESTIGATIONAL USE ONLY  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v2.0 
Protocol 122319  20 August 2020  
 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  118 APPENDIX B. INFORMED CONSENT FORMS  
 
B.1 PATIENT STUDY VISIT 1 INFORMED CONSENT FORM  
 
 
IRB TEMPLATE  
Version 2.0 -12/5/2018  
 
**DO NOT CHANGE THIS FIELD -IRB USE ONLY**  
University of North Carolina at Chapel Hill  
Consent to Participate in a Research Study  
Adult Participants  (Verbal Consent)  
 
 
Consent Form Version Date:  v2.0 dated 15 October  2020  
IRB Study #  18-3360  
Title of Study : Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence 
(ENLIGHTEN)  
Principal Investigator : Angela Kashuba  
Principal Investigator Department : UNC Eshelman School of Pharmacy -Division of 
Pharma cotherapy and Experimental Therapeutics  
Principal Investigator Phone number : (919) 966 -9998  
Principal Investigator Email Address : akashuba@unc.edu  
Funding Source and/or Sponsor:  NIH National Institute of Allergy an d Infectious Diseases 
(NIAID)  
 
CONCISE SU MMARY  
MedViewer is the name of a new technology being developed at UNC to measure the amount of 
antiretroviral therapy (ART) medic ine in the body using hair . The purpose of this study is to 
determine if MedViewer is an acceptable, appropriate,  and convenie nt way to measure drug 
concentration s in hair  on the same day as a routine medical visit. Most participant s will be 
enrolled in this study for  one day; however, study activities may occur over multiple days if 
needed. Your clinic provider will also be a pa rticipant in this research study.  D uring the study 
visit, which will last several hours, participants will first provide  a hair sample  and complete a 
baseline survey. A small portion of patients may also be asked to provide a blood sample as well. 
The hai r sample will be sent to the laboratory for MedViewer testing and a report of the results 
will be sent to the medical provider. Then, the patient and provider will look at the MedViewer 
report and discuss the results, although since the MedViewer is still being developed, the results 
are for investigational research use only. Participation in this research is completely voluntary.  
You do not have to participate in this study in order to receive your regular health care, and there 
may be no direct benefit t o you. Risks of participation could include social harms or loss of 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v.2.0 
Protocol 122319  20 August 2020  
  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  119   
confidentiality. After the appointment with the provider, participants will complete a  short 
survey  to share how they felt about using MedViewer and talking about their results with their 
provider. Study participants will receive a $ 70.00 Visa® gift card, as well as parking tokens and 
food, as needed. A small subsample of participants will be asked to participate in a second  
virtual visit to complete an interview. This follow -up study visi t is discussed in more detail in a 
separate consent form.  
What are some general things you should know about research studies  
 
You are being asked to take part in a research study. To join the study is voluntary.  You may 
choose not to participate, or you may withdraw your consent to be in the study, for any reason, 
without penalty.  
 
Research studies are designed to obtain new knowledge. This new information may help people 
in the future.  You may not receive any direct benefit from being  in the research study. There also 
may be risks to being in research studies. Deciding not to be in the study or leaving the study 
before it is done will not affect your relationship with the researcher, your health care provider, 
or the University of Nort h Carolina -Chapel Hill. If you are a participant  with an illness, you do 
not have to be in the research study in order to receive health care.  
 
Details about this study are discussed below. It is important that you understand this information 
so that you c an make an informed choice about being in this research study.   
 
You will be given a copy of this consent form. You should ask the researchers named above, or 
staff members who may assist them, any questions you have about this study at any time.  
 
What is the purpose of this study?  
Over the last few decades, many new medic ines called antiretroviral  therapy  (ART) have been 
developed to treat Human Immunodeficiency Virus (HIV). The development of these medi cines  
has greatly increased the quality of health car e that can be offered to people living with HIV ; 
however, these medi cines  only work if patients take them continuously. Whether a patient is 
taking their ART medicine  continuously as prescribed is called adherence. Currently, to measure 
adherence we count pills and measure the amount,  or concentration , of the ART medicine  in 
blood. However, using blood  to measure adherence  only tells us about  the few days before the 
blood draw . There  is a need to find a way to measure adherence that could  give us this 
infor mation for a longer period of time between clinic visits.  
We are developing  a new technology called MedViewer, which , once finalized, will  allow us to 
measure  ART medic ine in hair using a laser attached to a detector in the laboratory. Using hair, 
we can p otentially  measure adherence for a longer period of time than we can with blood, and it 
is less invasive than taking a blood sample. In previous research studies, we developed  an initial 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v.2.0 
Protocol 122319  20 August 2020  
  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  120   
version of  MedViewer and tested it in hair from people across a variety of races, ethnicities, and 
genders as well as those that do and do not use chemicals to treat their hair. The purpose of this 
current study is to test if results from the MedViewer can be produc ed in real -time during a 
clinical setting, and if using MedViewer is acceptable and appropriate for patients and providers . 
Real-time is the term we use to describe the amount of time a patient spends in the clinic for a 
regularly scheduled appointment. Id eally, real -time would be two hours or less from the time the 
hair sample is collected. In this study, we will be comparing the concentrations of AR T medic ine 
in hair with the concentration s of the same AR T medicine  in blood. We will enroll  both patients 
and providers into this study. Providers will be trained on how to read the reports and how to use 
them as a discussion tool during patient visits.  
If you decide to participate in this study, we will collect a hair sample. We will also collect a 
blood sampl e from a small subset of patients. You will also complete a baseline survey. We will 
update your medical history and document any chemical treatments you use on your hair. At 
your regularly scheduled appointment, whether in person or virtual, you and your provider will 
go over the results of the hair analysis and discuss findings potentially related to your medication 
adherence. Because MedViewer is still being developed and studied, your provider will not make 
any clinical decisions based on the MedViewer results. At the end of this visit, you will be asked 
to complete a short survey about your opinions and experience with MedViewer, this will be 
done electronically either by videoconferencing or email. The information you share with us will 
help us improve  MedViewer for potential use in the future.  
We will also ask providers to complete surveys before and after reviewing the reports with their 
patients to learn about their experience using MedViewer and how useful they thought it was.  
We will be asking pat ients living with HIV and taking AR T medicines  to participate in this 
study. The AR T medicines  that we will be studying  are emtricitabine  and dolutegravir . These 
medicines are available in many combination pills, such as Truvada® , Biktarvy ®, and  Tivicay® , 
and several others.  
You are being asked to participate in this study because you are at least 18 years of age and meet 
our eligibility criteria.  
 
Are there any reasons you should not be in this study?  
 
You should not be in this study if you:  
• Are younger th an 18 years old  
• Are bald or have hair less than 1.0cm in length on the back of your head  
• Are not HIV -infected  
• Have a ny condition which, in the opinion of the investigator s, is likely to interfere with 
study procedures or  ability to affect drug absorption.  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v.2.0 
Protocol 122319  20 August 2020  
  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  121   
• Are not currently taking one of the  ART  medications under investigation  
• Have chemically treated your hair using dye, bleach, or relaxers in the last 28 days.  
 
How many people will take part in this study?  
 
If you decide to be in this study, you will be one of approximately 50 people in this research 
study. Any subject unable to complete samp le collection will be withdrawn, and a new 
participant will be enrolled as a replacement.  
 
How long will your part in t his study last?  
 
Your participation in this study will last approximately one day. A small subset of participant s 
will be enrolled into a cohort that completes a follow -up interview  and an  endline survey . If you 
participate in that cohort, there will be a separate consent that will review the details of that 
portion .   
 
What will happen if you take part in the study?  
 
Screening Visit  
The screening visit is designed to ensure that you should be in this study.  This visit will be 
conducted remotely via videoco nferencing if possible.  
Procedures that will take place during the screening visit include:  
• A review of the Informed Consent document that will cover all aspects of the research 
study, including risks and benefits. We will give you a chance to have all of your 
questions answered, review the forms in private, and sign if you choose.  
• As part of the consent, a  short video will be shown describing the hair collection process 
and explaining what the results  will look like and how they  will be shared with you . The 
MedViewer test is still being studied by researchers, and therefore is for investigational 
research use only. The video will show you how, once the MedViewer test is finalized, 
the results could be used to better understand your adherence behavior an d potentially to 
come up with strategies to help you improve or maintain adherence.  
• You will have a chance to have all your questions answered and sign the Informed 
Consent if you choose.   
If you choose to participate, and you continue to meet eligibility  requirements, the sampling 
portion of your visit will be  scheduled . 
 
Sampling Visit  (to be performed on the same day as the Screening Visit  if possible ) 
After informed consent, we will collect a sample of hair for analysis. This may be done at a 
remote lo cation to minimize clinic exposure. We will pluck 5 strands of hair from the back of 
your head  with tweezers , so that we can look at medication in the hair root . It will be chosen 
from a discrete location and be hidden as much as possible. On average, a person can lose about 
100 strands of hair per day.  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v.2.0 
Protocol 122319  20 August 2020  
  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  122   
After we collect the hair needed, we will have you complete a  short baseline survey to  obtain 
some basic information  and learn about how you take the  ART medic ine you have been 
prescribed. For a small subse t of participants, w e will also collect a sample of your blood through 
either a needlestick or a fingerstick to compare the amount of medication found in the blood with 
the amount of medication found in hair.  If you are having normal clinic labs drawn, we can have 
an additional tube drawn, about a half teaspoon (3mL), at the same time. Alternatively, we may 
be able to collect the blood through a fingerstick only (0.5mL). A finger stick is the term we use 
to describe pricking the tip of the finger to get a s mall amount of blood. You may have heard this 
term to describe how diabetic patients check their blood sugar. Your samples will only be used 
for research purposes and will not include any whole genome sequencing.  
During your regularly scheduled clinic appo intment, your provider will go over the results of the 
MedViewer hair analysis.  This may be done as part of an in person clinic visit or a virtual 
telehealth visit.  If you and your provider are not able to discuss the MedViewer reports, you and 
your provid er will decide whether to discuss the results at a later time or whether you would like 
to discuss your MedViewer results with the HIV clinic pharmacist. Remember, MedViewer is 
still being developed and researched, and it is currently for investigational u se only. If you do 
choose to participate your provider will not make any clinical decisions based on your 
MedViewer test results at this time.  
Follow -up 
At the completion of your clinic visit, you will complete a short computer -based survey about 
your exp erience in the study.  
 
Additional Study Activities  
A small subset of participant s (about 30 of the total 50 participants ) will be invited to complete 
an interview and brief survey about their experience with MedViewer at a later date. You are not 
required to participate in these additional study activities  in order to participate in the main study , 
and there is a separate consent form that will discuss the additional study activities in greater 
detail . 
  
What are the possible benefits from being in this study?  
 
Research is designed to benefit society by gaining new knowledge.   You will not benefit personally 
from being in this research study.  
  
 
What are the possible risks or discomforts involved from being in this study?  
Blood Draws  
Risks with blood draws include pain, bleeding, bruising, infection, or swelling at the site of the 
needle sticks , as well as the possibility of dizziness or fainting during needle sticks.  A finger 
stick is a bit uncomfortable and may cause some soreness and brui sing. Very rarely, the site can 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v.2.0 
Protocol 122319  20 August 2020  
  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  123   
become infected. These risks will be minimized by using an aseptic (clean) technique as well as 
having experienced nursing and lab staff perform blood draws .  
 
Medication Adverse Events  
 
Although HIV medications do cause some side effects, you are already receiving the antiretrovirals , 
and this study does not change your risk of having a drug -related side effect.  You will not be given 
any new med ications as part of this study.  
Hair  
There i s no foreseeable r isk with the donation of hair.  
Video  
Although the  short MedViewer intervention video is designed to introduce participant s to the 
investigational MedViewer test in an approachable manner, it is possible that participant s will 
experience discomfort or anxiety watching a video about providing a hair sample for conducting 
the MedViewer test and about antiretroviral medication circulating in their body depositing in 
their hair.  
 
Baseline and post -visit survey s 
Immediate known potential risks to participating in the survey s include the potential for 
participant s to feel uncomfortable or experience anxiety when being asked questions about their 
medication adherence and about their i nteractions with their provider.  
MedViewer assay and report  
It is possible that discussing the MedViewer report may alter participant -provider 
communication during the clinic visit, such that the participant  and/or the provider f eels 
uncomfortable. Participants may feel anxious or embarrassed reviewing their MedViewer report 
with the provider or pharmacist , or uncomfortable if the MedViewer results contradict self -
reported adherence. Additionally, the MedViewer report may lead to misunderstanding of or 
confusion about how you have been taking your medications  and potentially misinform 
conversations with your provider about your medication taking patterns . To minimize these 
concerns, your provider will also continue to monitor your medication adherence through the 
normal means with your standard clinic lab values.  Your provider will not make any clinical 
decisions based on MedViewer results because the MedViewer is currently for investigational 
use only. The results of this research will help to determine how, once fully developed, 
MedViewer could be used in a clinical setting.  
 
Social Harms  
 
There may be some social risks to participating in this study. You may feel embarrassed or 
uncomfortable with some the questions you will be asked, some of the procedures that will be 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v.2.0 
Protocol 122319  20 August 2020  
  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  124   
done, or some of the test results that you will receive. You may also ex perience stigma as a result 
of being involved in a clinical research study.  
 
Confidentiality  
 
Participation in clinical research includes the risks of loss of confidentiality and discomfort with 
personal nature of questions. Although the study site makes e very effort to protect participant 
privacy and confidentiality, it is possible that participants’ involvement in the study could 
become known to others and that social harms may result as a result of a loss of confidentiality.  
 
There may be uncommon or pre viously unknown risks. You should report any problems to the 
researcher.  
 
 
If you choose not to be in the study, what other treatment options do you have?  
 
You do not have to be in this research study in order to  continue to  receive treatment.  
 
What if we learn about new findings or information during the study?  
 
You will be given any new information gained during the course of the study that might affect 
your willingness to continue your participation.   
 
How will informati on about you be protected?  
 
The investigators will protect your privacy in the following ways:  
• All study records are kept in a locked drawer in a locked office under badge access  or stored 
electronically  on a secure internal computer network or server, acc essed using a password -
protected computer that can only be accessed by members of the study team.  
• Only the study team will have access to any personally identifiable information about  you. 
• No samples or study report forms will contain your name. You will b e assigned a study 
identification number that only contains your initials and a set of numbers. One study 
investigator will keep the  file that connects this number to you on a secure internal computer 
network.  
• All interviews will take place in a private ex amination room.  
• Identifiable phone messages will not  be left on your voicemail,  and you will only be 
contacted by study staff in a manner that you  agree upon.  
• All samples will be destroyed within 12 months of the study being published.  
• None of your samples will ever be used for commercial profit.  
 
No participants will be identified in any report or publication resulting from this study. Although 
every effort will be made to keep research records pri vate, there may be times when federal or state 
law requires the disclosure of such records, including personal information.  This is very unlikely, 
but if a disclosure is ever required, UNC -Chapel Hill will take any steps allowable by law to protect 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v.2.0 
Protocol 122319  20 August 2020  
  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  125   
the pri vacy of personal information. In some cases, your information in this research study could be 
reviewed by representatives of the University, research sponsors, or government agencies (for 
example, the NIH) for purposes such as quality control or safety.  
 
Under North Carolina law, confidentiality does not extend to certain communicable diseases, such 
as syphilis, gonorrhea, and chlamydia or other illnesses that put others at risk. If the researchers 
become aware that participants  have such an illness, they a re required to report it to state 
authorities.  
The study coordinator will keep the signed original consent form and a copy will be given to you. A 
copy of this informed consent will also be placed in your medical record.  
What is a Certificate of Confidentiality?  
To help us protect your privacy, the study team has obtained a Certificate of Confidentiality from 
the National Institutes of Health (NIH). With this certificate, the researchers cannot be forced to 
disclose any information that can be use d to identify you, even by court subpoena, in any federal, 
state, local or civil, criminal, administrative, legislative or other proceedings. The researchers would 
use the certificate to resist any demands for information that wo uld identify you, as descri bed. 
The Certificate cannot be used to resist a demand for information from personnel of the United 
States government that is used for auditing or evaluation of federally funded projects or for 
information that must be disclosed in order to meet the requir ements of the federal Food  and Drug 
Administration (FDA).  
 
You should understand that a Certificate of Confidentiality does not prevent you or a member of 
your family from voluntarily releasing information about yourself or your involvement in this 
researc h. If an employer, insurer, or other person receives your written consent to receive research 
information, then the researchers may not use the Certificate to withhold that in formation.  
The Certificate does not limit the researchers from disclosing informa tion that may include 
details about child abuse, homicidal or suicidal intent, or other information deemed appropriate. 
The researchers will not voluntarily release any information about you under this Certificate.   
What will happen if you are injured by this research?  
 
All research involves a chance that something bad might happen to you. If you are hurt, become 
sick, or develop a reaction from something that was done as part of this study, the researcher will 
help you get medical care, but the  University of North Car olina at Chapel Hill nor the National 
Institute of Health (NIH) has not set aside funds to pay you for any such injuries, illnesses or 
reactions, or for the related medical care. Any costs for medical expenses will be billed to you or 
your insurance company. You may be responsible for any co -payments and your insurance may 
not cover the costs of study related injuries. If you think you have been injured from taking part 
in this study, call Dr. Cindy Gay  at 919-216-2156 .  She will let  you know what you should 
do. By signing this form, you do not give up your right to seek payment or other rights if you are 
harmed as a result of being in this study . 
 
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v.2.0 
Protocol 122319  20 August 2020  
  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  126   
What if you want to stop before your part in the study is complete?  
 
You can withdraw from this study at any time, without penalty . The investigators also have the 
right to stop your participation at any time. This could be because you have had an unexpected 
reaction, or have failed to follow instructions, or because the entire stu dy has been stopped.  
 
Will you receive anything for being in this study?  
 
You will be receiving a $70.00 Visa® gift card for taking part in this study . You will also receive 
parking tokens and snacks/meals as needed for the duration of your participation i n this study. 
You will only be paid for the portions of the study that you complete.  If you do not complete the 
study, your payment will be adjusted:  
• You will receive $5.00 for the hair sample.  
• You will receive $15.00 for the blood sample.  
• You will receiv e $20.00 for the baseline survey.  
• You will receive $10.00 for the post -visit survey.  
You will also receive $20.00 on your Visa® gift card to cover any telephone minutes or internet 
data you may have purchased to complete this study visit.  
We do not reimbur se for childcare.  
 
We do our best to have your payment available on the day of your visit, but there may be times 
when this is not possible. We will get you payment as soon as possible after the visit , in the 
manner in which you prefer.  
 
Will it cost you a nything to be in this study?  
 
It will not cost you anything to be in this study. If by chance you ever receive a bill for study 
activities, please notify the study team right aw ay so this can be fixed.  
 
Who is sponsoring this study?  
 
This research is funde d by NIH National Institute of Allergy and Infectious Diseases (NIAID). 
This means that the research team is being paid by the sponsor for doing the study.  The 
researchers do not, however, have a direct financial interest with the sponsor or in the final 
results of the study.  
 
What if you have questions about this study?  
 
You have the right to ask, and have answered, any questions you may have about this research. If 
you have questions about the study (including payments), complaints, concerns, or if a rese arch-
related injury occurs, you should contact the researchers listed on the first page of this form.  
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v.2.0 
Protocol 122319  20 August 2020  
  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  127   
A description of this clinical trial will be available on www.clinicaltrials.gov, as required by U.S. 
Law. This website will not include information that  can identify you. At most, the website will 
include a summary of the results. You can search this website at any time.  
 
What if you have questions about your rights as a research participant?  
 
All research on human participant s is reviewed by a committee that works to protect your rights 
and welfare. If you have questions or concerns about your rights as a research subject, or if you 
would like to obtain information or offer input, you may contact the Institutional Review Board 
at 919 -966-3113 or by email to IRB_subjects@unc.edu.  
---------------------------------------------------------------------------------------------------------------------  
 
 
 
 
IRB Study #  18-3360  
 
Title of Study : Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence 
(ENLIGHTEN)  
 
Participant’s Agreement : 
I have asked all the questions I have at this time.   By giving my verbal consent, I voluntarily 
agree to participate in this research study.  I understand that my participation is voluntary and I 
can withdraw my consent to participate at any time.  
  
  
  
 
______________________________________________________  
Signature of Research Team Member Obtaining Consent   
____________________  
Date  
 
______________________________________________________  
Printed Name of Research Team Member Obtaining Consent    
 
  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v.2.0 
Protocol 122319  20 August 2020  
  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  128   
 
B.2 PATIENT STUDY VISIT 2 INFORMED CONSENT  
University of North Carolina at Chapel Hill  
Consent to Participate in a Research Study  
Verbal Consent - Adult Participants  - Patient participants (follow -up subsample)  
 
Consent Form Version Date:  Version 2.0, 15 October  2020  
IRB Study #  18-3360  
Title of Study : Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence 
(ENL IGHTEN)  
Principal Investigator : Angela Kashuba  
Principal Investigator Department : UNC Eshelman School of Pharmacy -Division of 
Pharmacotherapy and Experimental Therapeutics  
Principal Investigator Phone number : (919) 966 -9998  
Principal Investigator Email Add ress: akashuba@unc.edu  
Funding Source and/or Sponsor:  NIH National Institute of Allergy and Infectious Diseases 
(NIAID)  
 
CONCISE SUMMARY  
The study activities described in this consent are part of a larger research study at the UNC 
Infectious Diseases (ID) Clinic to learn about MedViewer, a test being developed to show how 
people take their antiretroviral therapy (ART) medicine over time. The MedViewer test uses a 
patient’s hair sample to create a report that shows whether ART doses were missed over the past  
several weeks. MedViewer is currently for investigational use only, so medical providers will not 
make any clinical decisions based on MedViewer results. Your participation is completely 
voluntary.  You are already enrolled as a participant in the larger ENLIGHTEN study. This 
consent form describes a second part of the study in which you may choose to participate. The 
purpose of this part of the study is to learn more about your experience with MedViewer. If you 
choose to participate, the additional study activities will be: doing an interview and a survey 
about your experience with MedViewer. These study activities should take about 1.5 to 2 hours, 
in total, to complete. If you choose to participate you will be one of about 30 patient participants 
in this part of the study. The information you share with us will be used to improve the 
MedViewer test and learn how it can be used in the medical clinics by patients and medical 
providers in the future, once the test is finalized. You do not have to participate in this study in 
order to receive your health care, and there may be no direct benefit to you. Risks of 
participation could include social harms or loss of confidentiality. For your participation in this 
study, you will receive up to $60.00 added to the Vi sa® gift card you received at your last visit. 
If you no longer have the card, we can provide you a new one by mail or in -person when you 
visit UNC Chapel Hill.  
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v.2.0 
Protocol 122319  20 August 2020  
  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  129   
What are some general things you should know about research studies?  
You are being asked to t ake part in a research study.  Participating in this part of the study is 
voluntary. You may choose not to participate, or you may withdraw your consent to be in the 
study, for any reason, without penalty.  
 
Research studies are designed to obtain new knowle dge. This new information may help people 
in the future.  You may not receive any direct benefit from being in the research study. There also 
may be risks to being in research studies. Deciding not to be in the study or leaving the study 
before it is done w ill not affect your relationship with the researcher, your health care provider, 
or the University of North Carolina at Chapel Hill. If you are a patient with an illness, you do not 
have to be in the research study in order to receive health care.  
 
Details  about this study are discussed below. It is important that you understand this information 
so that you can make an informed choice about being in this research study.   
 
You will be given a copy of this consent form.  You should ask the researchers named ab ove, or 
staff members who may assist them, any questions you have about this study at any time.  
 
What is the purpose of this study?  
Our study team is developing a new test called MedViewer. MedViewer measures the amount of 
antiretroviral (ART) medicine in a patient’s body each day, which can show how a patient takes 
their ART over time. Antiretroviral therapy, also known as ART, is medicine used to treat and 
suppress the Human Immunodeficiency Virus (HIV).  
 
This study is part of a larger study at the Unive rsity of North Carolina (UNC) Infectious Disease 
(ID) Clinic. You are already enrolled in this larger study, which involves having a hair sample 
collected and tested by MedViewer and receiving the results at your clinic visit with your 
medical provider. Be cause MedViewer is still being tested and finalized, your medical provider 
will not make any clinical decisions based on your MedViewer results.  
 
During this additional part of the study, we are conducting follow -up surveys and in -depth 
interviews with about 30 individuals who participated in the larger study.  By participating in the 
additional part of this study, we will be able to gather more information about your experience 
with the MedViewer test. The information you share with us w ill be used to improve MedViewer 
and help us learn how it can be used in the clinic with patients and medical providers. 
Participating in this part of the study is voluntary.  
Are there any reasons you should not be in this study?  
You should not participate  in this study if you are not enrolled in the main ENLIGHTEN study 
or if you were enrolled in the main study and did not have a hair sample collected and tested by 
MedViewer. You should also not participate in this part of the study if you do not have 1.0 cm of 
caput hair.  
 
How many people will take part in this study?  
You are one of about 50 patients participating in the main ENLIGHTEN study. If you decide to 
participate in this part of the study, you will be one of about 30 patients in this part of the st udy. 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v.2.0 
Protocol 122319  20 August 2020  
  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  130   
We will also interview about 15-30 medical providers who discussed MedViewer results with 
their patients.  
 
How long will your part in this study last?  
Today’s interview and survey will take approximately 1.5 to 2 hours.   
 
What will happen if you take  part in this part of the study?  
This part of the study will include the following activities:  
• In- depth interview:  A trained member of our research team will conduct an individual, 
in-depth interview with you either over the phone or over videoconferencin g. During the 
interview, the research staff member will ask you some questions about your experience 
with MedViewer. The goal of these questions is to understand how you felt about having 
your hair sample collected, receiving the MedViewer report, and talk ing about the report 
with your medical provider. There are no right or wrong answers. We simply want to 
know what you thought of your experience with MedViewer so we can improve it for 
potential future use.  
o To help assure that we get the best understanding possible from your answers, the 
interview will be audio -recorded with your permission. You will be asked at the 
end of this consent form to indicate if you give your permission to be recorded 
during the int erview.  
o If you do not want us to audio record the interview, we will take typed notes 
instead.  The typed notes will be stored on a password -protected server. A printed 
copy of the notes will be stored with your other study materials in your study 
chart i n a locked drawer in a secure room to which only the research team has 
access. We will not write your name - we will only write your unique ID number 
but not any information that can identify you.  
o If you do give us permission to audio record, after the in terview is finished, all 
audio files will be stored on the same  secure internal computer network that can 
only be accessed using a password -protected computer by members of the study 
team. This audio recording will be transcribed (typed) by a secure profes sional 
transcription service. All identifying information will be removed from the 
transcript. Your name will not be included on the transcript - only a unique 
participant ID number (an identification number unique to you that only contains 
your initials a nd a set of numbers) will be used. Once analysis of the interviews is 
completed, the digital audio file will be stored on a password -protected secure 
server.  
• Survey: During the survey, you will answer a set of questions about your experiences 
with MedView er and asked to mark your responses on an electronic survey form sent to 
you through a secure email link.  Alternatively, we can read the questions to you over the 
phone or videoconferencing and enter your responses on the electronic form.  Your 
responses will only be recorded with your unique ID number. Any information that can 
identify you will not be recorded.  
What are the possible benefits from being in this study?  
Research benefits society by providing new knowledge. Although there may be no direct benefits 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v.2.0 
Protocol 122319  20 August 2020  
  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  131   
from being in the study, we believe your participation will help us improve the MedViewer test 
so that it can be used to support people living with HIV in the fu ture with taking their ART 
medicine as prescribed by their medical provider.  
  
What are the possible risks or discomforts involved from being in this study?  
Survey and in -depth interview:  
Immediate  known risks to participating in the surveys and in -depth i nterviews include the 
potential for you to feel uncomfortable or experience anxiety when being asked questions about 
how you take your ART medicine or your MedViewer results. To minimize these risks, the study 
team will conduct the surveys and interviews i n a neutral and non -judgmental manner. You can 
also stop participating at any time or skip any questions that make you feel uncomfortable.  
 
Social Harms  
There may be some social risks to participating in this study. You may feel embarrassed or 
uncomfortab le with some of the questions you will be asked, some of the procedures that will be 
done, or some of the test results that you will receive. It is possible that you may also experience 
stigma as a result of being involved in a clinical research study.  
 
Confidentiality  
Participation in clinical research includes the risks of loss of confidentiality and discomfort with 
the personal nature of questions. Although the study site makes every effort to protect participant 
privacy and confidentiality, it is possible that a participant ’s involvement in the study could 
become known to others and that social harms may result from a l oss of confidentiality.  
 
There may be uncommon or previously unknown risks. You should report any problems to the 
researcher.  
 
What if we learn about new findings or information during the study?  
You will be given any new information gained during the cou rse of the study that might affect 
your willingness to continue your participation.   
  
How will information about you be protected?  
Your privacy will be protected in the following ways:  
• Interview notes and all other study records will be stored in a locked drawer in a 
designated, secure room  or electronically on a secure internal computer network or server  
that can only be accessed using a password -protected computer by members of the study 
team.  
• Audio files and notes from the interviews will be store d on a secure internal computer 
network or server that can only be accessed using a password -protected computer by 
members of the study team.  
• Only the study team will have access to any personally identifiable information about  you.  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v.2.0 
Protocol 122319  20 August 2020  
  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  132   
• No study records will contain your name. You will be assigned a unique study ID number 
that only contains your initials and a set of numbers. One study investigator will keep 
the file that connects this number to you on a secure internal computer network. It will be 
kept separa te from the audio files, interview notes, transcripts, surveys, and other study 
records.  
• All interviews will be conducted securely over videoconferencing or by telephone. Study 
staff will be in a private area with a closed door and will ask that you find a  quiet, private 
area in which to participate in the interview and survey.  
 
Participants will not be identified in any report or publication about this study.  
Although every effort will be made to keep research records private, there may be times when 
federal or state law requires the disclosure of such records, including personal information. This 
is very unlikely, but if disclosure is ever required, UNC at Chapel Hill will take steps allowable 
by law to protect your personal information. In some cases, y our information in this study could 
be reviewed by representatives of the University, research sponsors, or government agencies 
(such as the National Institute of Health (NIH)). This would be for purposes such as quality 
control or safety.  
Under North Car olina law, confidentiality does not extend to certain communicable diseases, such 
as syphilis, gonorrhea, and chlamydia or other illnesses that put others at risk. If the researchers 
become aware that participants have such an illness, they are required to  report it to state 
authorities.  
The study coordinator will keep the signed original consent form and a copy will be given to you. A 
copy of this informed consent will also be placed in your medical record.  
What is a Certificate of Confidentiality?  
To help us protect your privacy, the study team has obtained a Certificate of Confidentiality from 
the NIH. With this certificate, the researchers cannot be forced to disclose any information that can 
be used to identify you, even by court  subpoena, in any federal, state, local or civil, criminal, 
administrative, legislative or other proceedings.  The researchers would use the certificate to resist 
any demands for information that would identify you, as described.  
The Certificate cannot be used to resist a demand for information from personnel of the United 
States government that is used for auditing or evaluation of federally funded projects or for 
information that must be disclosed in order to meet the requirements of the federal  Food and Drug 
Administration (FDA).  
 
You should understand that a Certificate of Confidentiality does not prevent you or a member of 
your family from voluntarily releasing information about yourself or your involvement in this 
research. If an employer, in surer, or other person receives your written consent to receive research 
information, then the researchers may not use the Certificate to withhold that information.  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v.2.0 
Protocol 122319  20 August 2020  
  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  133   
The Certificate does not limit the researchers from disclosing information that may include  
details about child abuse, homicidal or suicidal intent, or other information deemed appropriate. 
The researchers will not voluntarily release any information about you under this Certificate.   
What will happen if you are injured by this research?  
All re search involves a chance that something bad might happen to you. If you are hurt, become 
sick, or develop a reaction from something that was done as part of this study, the researcher will 
help you get medical care, but the University of North Carolina at Chapel Hill nor the NIH  has 
not set aside funds to pay you for any such injuries, illnesses or reactions, or for the related 
medical care. Any costs for medical expenses will be billed to you or your insurance company. 
You may be responsible for any co -payments and your insurance may not cover the costs of 
study related injuries. I f you think you have been injured from taking part in this study, call Dr. 
Cindy Gay  at 919-216-2156 .  She will let you know what you should do.  By signing this form, 
you do not g ive up your right to seek payment or other rights if you are harmed as a result of 
being in this study . 
 
What if you want to stop before your part in the study is complete?  
You can withdraw from this study at any time, without penalty.  The investigators also have the 
right to stop your participation at any time. This could be because you have had an unexpected 
reaction, or have failed to follow instructions, or because the entire study has been stopped.  
 
Will you receive anything for being i n this study?  
You will receive up to $60.00, in the form of a Visa® gift card, for participating in this part of 
the study. You will only be paid for the parts of the study that you complete. If you do not 
complete the study, your payment will be adjusted based on the parts you complete:  
• You will receive $30.00 for the in -depth interview conducted today.  
• You will receive $10.00 for the survey conducted today.  
You will also receive $20.00 on your Visa® gift card  to cover any telephone minutes or internet 
data you may have purchased to complete this study visit.  
   
Will it cost you anything to be in this study?  
It will not cost you anything to be in this study except your time.  
 
What if you are a UNC student?  
You may choose not to be in the study or to stop b eing in the study before it is over at any 
time.   This will not affect your class standing or grades at UNC -Chapel Hill.   You will not be 
offered or receive any special consideration if you take part in this research.  
 
What if you are a UNC employee?  
Takin g part in this research is not a part of your University duties, and refusing will not affect 
your job.   You will not be offered or receive any special job -related consideration if you take part 
in this research.  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v.2.0 
Protocol 122319  20 August 2020  
  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  134   
Who is sponsoring this study?  
This research  is funded by NIH National Institute of Allergy and Infectious Diseases (NIAID). 
This means that the research team is being paid by the sponsor for doing the study. The 
researchers do not, however, have a direct financial interest with the sponsor or in th e final 
results of the study.   
 
What if you have questions about this study?  
You have the right to ask, and have answered, any questions you may have about this research. If 
you have questions about the study (including payments), complaints, concerns, or  if a research -
related injury occurs, you should contact the researchers listed on the first page of this form.  
A description of this clinical trial will be available on www.clinicaltrials.gov, as required by U.S. 
Law. This website will not include informa tion that can identify you. At most, the website will 
include a summary of the results. You can search this website at any time.  
 
What if you have questions about your rights as a research participant?  
All research on human volunteers is reviewed by a comm ittee that works to protect your rights 
and welfare.  If you have questions or concerns about your rights as a research subject, or if you 
would like to obtain information or offer input, you may contact the Institutional Review Board 
at 919 -966-3113 or by email to IRB_subjects@unc.edu.  
 
  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v.2.0 
Protocol 122319  20 August 2020  
  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  135   
 
IRB Study #  18-3360  
Title of Study : Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence 
(ENLIGHTEN)  
 
Participant’s Agreement : 
I have asked all the questions I have at this time.   By giving my verbal consent, I voluntarily 
agree to participate in this research study.  I understand that my participation is voluntary and I 
can withdraw my consent to participate at any time.  
  
  
  
 
______________________________________________________  
Signature  of Research Team Member Obtaining Consent   
____________________  
Date  
 
______________________________________________________  
Printed Name of Research Team Member Obtaining Consent    
 
Participant’s Agreement to be Audio Recorded  
 
__________ OK to record me during the interview  
(Research Team Member Initials)  
__________ NOT OK to record me during the interview  
(Research Team Member Initials)  
 
 
  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v.2.0 
Protocol 122319  20 August 2020  
  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  136   
B.3 PROVIDER INFORMED CONSENT FORM  
IRB TEMPLATE  
Version 2.0 -12/5/2018  
 
**DO NOT CHANGE THIS FIELD -IRB USE ONLY**  
 
University of North Carolina at Chapel Hill  
Consent to Participate in a Research Study  
Verbal Consent - Adult Participants  – Provider participants  
 
Consent Form Version Date:  Version 2.0, 18 August 2020  
IRB Study #  18-3360  
Title of S tudy : Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence 
(ENLIGHTEN)  
Principal Investigator : Angela Kashuba  
Principal Investigator Department : UNC Eshelman School of Pharmacy -Division of 
Pharmacotherapy and Experimental Therapeut ics 
Principal Investigator Phone number : (919) 966 -9998  
Principal Investigator Email Address : akashuba@unc.edu  
Funding Source and/or Sponsor:  NIH National Institute of Allergy and Infectious Diseases 
(NIAID)  
 
CONCISE SUMMARY  
 
The purpose of this research study is to determine the feasibility, acceptability and 
appropriateness of using an investigational clinical test, called MedViewer, as a clinical 
adherence -monitoring tool. The MedViewer test, being developed by our research team at UNC, 
measures the concentration of antiretroviral medication in a patient’s hair over time. MedViewer 
results have the potential to impact adherence counseling in a clinical setting in the future; 
however, since MedViewer is currently for investiga tional use only, no clinical decisions should 
be made using MedViewer results. This is research, and participation is completely voluntary. 
You may not receive a direct benefit. As part of this study, patient participants will provide a hair 
sample within three days before a routine in -person or telehealth clinic visit scheduled with their 
provider. Prior to the appointment time, the hair sample will be analyzed by the MedViewer test 
with the aim of producing the MedViewer reports and delivering the reports  to the provider 
before the patient’s appointment. For each participating patient, providers will receive a copy of 
their patient’s MedViewer reports to view and discuss with the patient during the appointment. 
Following the appointment, the patient and pr ovider will each complete a brief post -visit 
questionnaire. Before seeing any participating patients for the study, provider participants must 
attend a study training session. After the training, providers will complete a baseline 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v.2.0 
Protocol 122319  20 August 2020  
  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  137   
questionnaire. Part way t hrough the study, providers will complete an in -depth interview, and 
before study close, providers will complete a brief endline questionnaire. If you choose to 
participate, study activities may occur via videoconferencing, email, telephone, or in -person. In 
total, your active participation in the study may last up to 10 months. The greatest risks of 
participation include a loss of confidentiality  or feeling stressed or anxious about discussing 
MedViewer results with patients or possible disruptions to your  schedule related to study 
procedures. If you are interested in learning more about this study, please continue to read below.  
 
What are some general things you should know about research studies?  
You are being asked to take part in a research study.  To join the study is voluntary. You may 
choose not to participate, or you may withdraw your consent to be in the study, for any reason, 
without penalty.  
 
Research studies are designed to obtain new knowledge. This new information may help people 
in the future.  You may not receive any direct benefit from being in the research study. There also 
may be risks to being in research studies. Deciding not to be in the study or leaving the study 
before it is done will not affect your relationship with the res earcher or the University of North 
Carolina at Chapel Hill.  
 
Details about this study are discussed below.  It is important that you understand this information 
so that you can make an informed choice about being in this research study.   
 
You will be given  a copy of this consent form.  You should ask the researchers named above, or 
staff members who may assist them, any questions you have about this study at any time.  
 
What is the purpose of this study?  
The purpose of this research study is to investigate th e feasibility, acceptability, and 
appropriateness of using a clinical test called MedViewer as a clinical adherence -monitoring 
tool. The MedViewer test, being developed by our study team here at UNC, ultimately aims to:  
a) longitudinally quantify, in easy  to understand patient and provider reports, 
antiretroviral (ARV) concentrations in patient hair; and  
b) promote enhanced adherence counseling conversations between patients living with 
HIV and their medical providers through review and discussion of the MedViewer report 
during routine clinic visits.  
 
Although MedViewer is still in investigative stages, formative work with MedViewer has shown 
that MedViewer is able to quantify adherence over longer time periods and on a more granular 
level than other meas ures of adherence using blood samples. Yet, because MedViewer is still in 
investigative stages, no clinical decisions can be made based on MedViewer results at this time. 
Results from this study will help to determine how, once fully validated, MedViewer c ould be 
used in a clinical setting.  
 
You are being asked to be in this research study because you are a health care provider in the 
UNC Chapel Hill Infectious Diseases (ID) Clinic and you see HIV -positive patients at least 1 
half-day per week (i.e., at le ast 4 hours per week) for the UNC ID Clinic.  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v.2.0 
Protocol 122319  20 August 2020  
  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  138   
 
Are there any reasons you should not be in this study?  
You should not be in this study if you are:  
1. Not a health care provider (including attending physician, ID fellow, nurse practitioner, 
physician assistant,  or a designated HIV Care pharmacist)  who sees HIV -positive patients 
at least 1 half -day per week for the UNC ID Clinic; or  
2. Not willing or able to participate in any provider training sessions for this study or any 
form of make -up training session with the  research team.  
 
How many people will take part in this study?  
If you choose to participate in this study you will be 1 of approximately 15 -30 health care 
providers participating in this study. Additionally, approximately 50 patients from the UNC ID 
Clinic  will participate.  
 
How long will your part in this study last?  
Your active participation in this study will be up to 10 months, including:  
• Up to one month between the date of your enrollment and the date of the first provider 
training session: Providers w ho enroll prior the first provider training session may be 
enrolled for up to one month before the date of the first provider training, at which point 
patient enrollment for the study will begin. After patient enrollment begins providers who 
have completed  a study training can begin seeing patient participants for their 
MedViewer study visits.  
• Up to 7.5 months of patient study visits between completion of a provider study training 
session and the close of patient enrollment . Patients will be enrolled in the  study over 7.5 
months. Provider participants may see patients for their study visits for up to the full 7.5 
months if they have enrolled in the study prior to the start of patient enrollment. If a 
provider has not enrolled prior to initiation of patient e nrollment, they may enroll in the 
study at any point over the course of the 7.5 months of patient study visits. We expect 
provider participants will see an average of 2 -3 patient participants throughout the 
duration of the study though the exact number of patients may vary for each provider 
participant. During each patient study visit, you will receive the patient’s MedViewer 
results report to discuss with your patient during the routine clinic visit. Receipt of the 
MedViewer report, the MedViewer discussio n with the patient, and completion of a 5 -
item questionnaire after the patient visit is expected to add only several extra minutes to 
the routine clinic visit. You may also be invited to participate in an in -depth interview 
during this time period after yo u have seen at least two patient participants for the study.  
• Approximately 1.5 months to complete endline questionnaire and in -depth interview . 
After the close of patient enrollment in the study there will be a 1.5 -month period for you 
to complete the endl ine questionnaire. During this time, you will also complete an in -
depth interview, if you have not already done so during the 7.5 -month period of patient 
visits. The in -depth interview will take place after you have seen at least two patient 
participants o r within 1.5 months of the close of patient enrollment, whichever comes 
first. 
 
What will happen if you take part in the study?  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v.2.0 
Protocol 122319  20 August 2020  
  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  139   
This research study consists of several activities for provider participants. Study activities may 
occur via IRB -approved videoc onferencing, email, phone, or in -person, as appropriate.  
1. Study training and post -training questionnaire: First, you will be asked to attend an 
approximately 30 -60-minute study training session. This training will be offered on 
several different dates. The training will introduce you to the study materials and 
procedures and provide an opportunity to practice reviewing hypothetical MedViewer 
reports. Throughout the training, research staff will reiterate that MedViewer is currently 
for investigati onal use only and no clinical decisions can be made based on MedViewer 
results at this point. At the conclusion of the study training, you will be asked to complete 
a brief post -training baseline questionnaire (paper or electronic), assessing your 
satisfac tion with the training, understanding of the MedViewer test and study procedures, 
and comfort reviewing MedViewer reports with patients. Supplemental training will be 
offered to providers, as needed.  
2. Receiving and discussing MedViewer results reports with patients: After you 
complete a study training session, your patients can begin being recruited and enrolled in 
the study, at which point you will start to have clinic visits with patient participants. We 
expect during the approximately 7.5 -month period of recruitment and enrollment of 
patients in this research study, each provider will see, on average, 2 -3 patient participants. 
Before their scheduled visit with you, a trained clinical research team member will collect 
a hair sample (and in some cases a bloo d sample) from the patient participant. A team 
member will take the blood and hair samples to the MedViewer lab for testing. Once 
MedViewer results are generated, the trained team member will deliver either a printed 
copy of the MedViewer reports to you at  the ID Clinic or an electronic copy via secure 
email. You should not make clinical changes or decisions based on the results of the 
MedViewer test. During the regularly scheduled clinic appointment you and your patient 
will be able to review the MedViewer  reports together. This discussion is expected to 
take several minutes.  If for any reason you do not discuss the MedViewer reports with 
your patient during the routine clinic visit, you will have the option to schedule a follow -
up appointment to discuss t he MedViewer reports within four weeks of hair sample 
collection.  
3. Completing a brief post -visit questionnaire: After your clinic visit with each patient 
participant you will be asked to complete a brief 5 -item questionnaire that can be 
completed immediatel y or at any point during that workday. The purpose of the post -visit 
questionnaire is to identify whether you were able to discuss the MedViewer results with 
your patient and, if so, some aspects of that experience.  
4. In-depth interview: All participating pr oviders will also be asked to complete an in -
depth interview that will last approximately 30 -45 minutes. This will be scheduled at 
your convenience after you have received MedViewer reports for at least 2 patient 
participants or after the close of patient enrollment in the study, whichever comes first. 
The interview will be conducted via videoconferencing or phone call by a trained 
member of the research team, who will ask you questions about your experience 
receiving the MedViewer reports and discussing th em with patient participants. 
Specifically, interview topics will explore how useful and feasible you perceived 
MedViewer to be, your view of patient’s reactions to MedViewer, your satisfaction with 
different aspects of MedViewer, and its effects on clinic  flow and your relationship with 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v.2.0 
Protocol 122319  20 August 2020  
  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  140   
patients. The information you provide will be used to improve MedViewer so that it can 
help other patients in the future.  
o To help assure that we get the best understanding possible from your 
answers, the interview will b e audio -recorded with your permission. You will be asked at 
the end of this consent form to indicate if you give your permission to be recorded during 
the interview.  
o If you do not want us to audio record the interview, we will take notes that 
will be st ored with your other study materials in your study chart instead. We will not 
write your name or any information that can identify you - we will only write your unique 
ID number. The notes will be typed and stored on a password -protected server or in in a 
locked drawer in a secure room to which only the research team has access.  
o If you do give us permission to audio record, after the interview is 
finished, all audio files will be stored on the same secure internal computer network that 
can only be access ed using a password -protected computer by members of the study 
team. This audio recording will be transcribed (typed) by a secure professional 
transcription service. All identifying information will be removed from the transcript. 
Your name will not be inc luded on the transcript - only a unique participant ID number 
(an identification number unique to you that only contains your initials and a set of 
numbers) will be used. Once analysis of the interviews is completed, the digital audio file 
will be stored o n a password -protected secure server.  
 
5. Endline questionnaire: At the conclusion of patient enrollment in this study, we will ask 
you to complete an endline questionnaire. In the event that you must end your 
participation in the study before the close of p atient enrollment, the endline questionnaire 
may be completed at that time. The questionnaire will assess your thoughts about 
recommending MedViewer to future patients; your perceived level of confidence to use 
the MedViewer report; your satisfaction and p erceived usefulness for different aspects of 
the report; and who you think is most appropriate for delivering future MedViewer 
counseling.  
 
What are the possible benefits from being in this study?  
Research is designed to benefit society by gaining new knowledge. You will not benefit 
personally from being in this research study.  
  
What are the possible risks or discomforts involved from being in this study?  
 
Questionnaires :  
Immediate known risks to participating in the questionnaires include the potential for you to feel 
uncomfortable or experience anxiety when being asked questions about your patients’ 
medication adherence or about your adherence counseling practices. To minimize these risks the 
questionnaires are self -administered. You can also stop participating at any time or skip any 
questions that make you feel uncomfortable.  
MedViewer test and report :  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v.2.0 
Protocol 122319  20 August 2020  
  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  141   
It is possible that discussing the MedViewer report may alter patient -provider communication  
during the clinic visit, such that you or your patient may feel uncomfortable. You may also end 
up spending extra time with patients in order to discuss MedViewer report, which may prolong 
the appointment and delay your schedule for the day. As an objecti ve of this study is to assess 
whether the use of the report will prolong patient visits and whether it proves to be a feasible, 
useful, and acceptable tool, we may not be able to fully prevent this risk. To minimize it, 
however, we will obtain feedback aft er each patient visit about both patient and provider 
experiences with the tool.  
In-depth interviews :  
Risks relating to participation in the interviews includes the potential for you to feel 
uncomfortable or experience anxiety when being asked about your  patients’ medication 
adherence, your adherence counseling practices, and your opinions about your experiences using 
the MedViewer with your patients. To minimize these risks, the study team will conduct the 
interviews in a neutral and non -judgmental manne r. Also, you may stop participating at any time 
or skip any questions that make you feel uncomfortable.  
Social Harms:  
There may be social risks to participating in this study. You may feel embarrassed or 
uncomfortable with some of the questions you will be asked or discussing the results of the 
procedures and tests with your patient participants. You may also experience stigma from 
participating in this research study which could alter your relationships with patients and peers.  
Confidentiality : 
Participation in research includes the risks of loss of confidentiality. Although the study site 
makes every effort to protect participant privacy and confidentiality, it is possible that 
participants’ involvement in the study could become known to others. We discuss this in more 
detail below.  
There may be risks unknown to the study researchers. Because of this, you are encouraged to 
report any problems.  
 
What if we learn about new findings or information during the study?  
You will be given any new informatio n gained during the course of the study that might affect 
your willingness to continue your participation.   
 
How will information about you be protected?  
Your privacy will be protected in the following ways:  
• No study records will contain your name. You wil l be assigned a unique participant ID 
number that only contains your initials and a set of numbers. One study investigator will 
keep the  file that connects this number to you on a secure internal computer network. It will 
be kept separate from the audio fi les, transcripts, questionnaires and other study records.  
• Only the study team will have access to any personally identifiable information about  you.  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v.2.0 
Protocol 122319  20 August 2020  
  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  142   
• All interviews will be conducted securely over videoconferencing or by telephone. Study 
staff will be in a  private room with a closed door and will ask that you find a quiet, private 
area in which to participate in the interview.  
• All study records will be stored in a locked drawer in a designated, secure room or 
electronically  on a secure internal computer net work or server, that can only be accessed 
using a password -protected computer by members of the study team  
• Audio files from the interviews will be stored on a secure internal computer network or 
server, accessed using a password -protected computer, that can only be accessed by 
members of the study team.  
• All identifying information will be removed from the tran script. Your name will not be 
included on the transcript, only a unique participant identification (ID) number will be used.  
• If you choose only to have notes taken during the interview, we will only write a unique 
participant ID number that does not conta in any of your identifying information, including 
your name on the notes. These notes will be stored in a locked drawer in a secure room to 
which only the research team has access or electronically  on a secure internal computer 
network or server, that can only be accessed using a password -protected computer by 
members of the study team.  
• Neither you, nor any other participant, will be identified in any report or publication 
about this study.  
Although every effort will be made to keep research records privat e, there may be times when 
federal or state law requires the disclosure of such records, including personal information. This 
is very unlikely, but if disclosure is ever required, UNC -Chapel Hill will take steps allowable by 
law to protect your personal in formation. In some cases, your information in this study could be 
reviewed by representatives of the University, research sponsors, or government agencies such as 
the National Institutes of Health. This would be for purposes such as quality control or safe ty.  
The study coordinator will keep the signed original consent form and a copy will be given to you.  
What is a Certificate of Confidentiality?  
To help us protect your privacy, the study team has obtained a Certificate of Confidentiality from 
the Nationa l Institutes of Health (NIH). With this certificate, the researchers cannot be forced to 
disclose any information that can be used to identify you, even by court subpoena, in any federal, 
state, local or civil, criminal, administrative, legislative or othe r proceedings.  The researchers 
would use the certificate to resist any demands for information that would identify you, as 
described.  
The Certificate cannot be used to resist a demand for information from personnel of the United 
States government that is used for auditing or evaluation of federally funded projects or for 
information that must be disclosed in order to meet the requirements of the federal Food and Drug 
Administration (FDA).  
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v.2.0 
Protocol 122319  20 August 2020  
  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  143   
You should understand that a Certificate of Conf identiality does not prevent you or a member of 
your family from voluntarily releasing information about yourself or your involvement in this 
research.  If an employer, insurer, or other person receives your written consent to receive research 
information,  then the researchers may not use the Certificate to withhold that information.  
The Certificate does not limit the researchers from disclosing information that may include 
details about child abuse, homicidal or suicidal intent, or other information deemed  appropriate. 
The researchers will not voluntarily release any information about you under this Certificate.   
What if you want to stop before your part in the study is complete?  
You can withdraw from this study at any time, without penalty.  The investigat ors also have the 
right to stop your participation at any time. This could be because you have failed to follow 
instructions, or because the entire study has been stopped.  
 
Will you receive anything for being in this study?  
At the end of your total partici pation in the study, you will receive up to $80.00, in the form of a 
Visa® gift card, for taking part in this study. You will only be paid for the portions of the study 
that you complete. If you do not complete all of the study activities, your payment wil l be 
adjusted as follows:  
• You will receive $20.00 for attending the provider training session and completing the 
baseline questionnaire.  
• You will receive $30.00 total for completing the post -visit questionnaires for all 
MedViewer patient visits you conduct  over the duration of the study.  
• You will receive $20.00 for completing the in -depth interview.  
• You will receive $10.00 for completing the endline questionnaire.  
So, if you complete all components of this study you would receive $80.00 in the form of a 
Visa® gift card, in total.  
 
Will it cost you anything to be in this study?  
There will be no cost to you  to participate in the study, other than your time.  
 
What if you are a UNC employee?  
Taking part in this research is not a part of your University duties, and refusing will not affect 
your job.   You will not be offered or receive any special job -related consideration if you take part 
in this research.  
 
Who is sponsoring this study?  
This research is funded by NIH National Institute of Allergy and Infe ctious Diseases (NIAID). 
This means that the research team is being paid by the sponsor for doing the study. The 
researchers do not, however, have a direct financial interest with the sponsor or in the final 
results of the study.  
 
What if you have question s about this study?  
You have the right to ask, and have answered, any questions you may have about this research. If 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v.2.0 
Protocol 122319  20 August 2020  
  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  144   
you have questions about the study, complaints, concerns, or if a research -related injury occurs, 
you should contact the researchers listed  on the first page of this form.  
A description of this clinical trial will be available on www.clinicaltrials.gov, as required by U.S. 
Law. This website will not include information that can identify you. At most, the website will 
include a summary of the results. You can search this website at any time.  
 
What if you have questions about your rights as a research participant?  
All research on human volunteers is reviewed by a committee that works to protect your rights 
and welfare.  If you have questions or c oncerns about your rights as a research subject, or if you 
would like to obtain information or offer input, you may contact the Institutional Review Board 
at 919 -966-3113 or by email to IRB_subjects@unc.edu.  
 
  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v.2.0 
Protocol 122319  20 August 2020  
  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  145   
IRB Study #  18-3360  
Title of Study : Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence 
(ENLIGHTEN)  
 
Participant’s Agreement : I have asked all the questions I have at this time.  By giving my verbal 
consent, I voluntarily agree to participate in this research study. I understand that my 
participation is voluntary and I can withdraw my consent to participate at any time.  
  
  
 
______________________________________________________  
Signature of Research Team Member Obtaining Consent   
____________________  
Date  
 
______________________________________________________  
Printed Name of Research Team Member Obtaining Consent    
 
Participant’s Agreement to be Audio Recorded:  
 
__________ OK to record me during the interview  
(Research Team Member Initials)  
__________ Not OK to record me during the interview  
(Research Team Member Initials ) 
 
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 146 of 214 
 APPENDIX C . DATA COLLECTION INSTRUMENTS  
 
C.1 PATIENT BASELINE QUESTIONNAIRE  
Participant ID __ __ __ __ / __ __ __  
PATIENT BASELINE QUESTIONNAIRE  
ENLIGHTEN PILOT STUDY  
Introduction   
Thank you for joining us in the ENLIGHTEN Study!  
This survey will ask questions about your health, taking  your Human Immunodeficiency Virus (HIV) medicine, 
called antiretroviral therapy (ART), and your view s of MedViewer. When we say  MedViewer we are talking 
about the new investigational test that looks at the amount of ART in your body using hair and the report you 
will get from your medical provider.  
This survey should take about 20 minutes to complete. T he information you provide will be kept private. Your 
name will not be reported alongside any of the information you give us. Please feel free to be open and honest 
in responding to the questions - there are no right or wrong answers. If at any time you fe el uncomfortable, 
you may skip questions or stop the survey. Please let study staff know if you have questions or need help.  
Instructions:  First, we’d like to start by asking some general questions about your health. Please 
mark your responses to the following questions.  
 
SECTION 1: GENERAL HEALTH  
 
1. In general, how would you rate your health?  
⚪ Poor  
⚪ Fair 
⚪ Good  
⚪ Very good  
⚪ Excellent  
 
⚪ I prefer not to answer the question  
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 147 of 214 
 2. How long does it take you to get to the UNC ID clinic from your home by your typical mode of 
transportation (e.g. car, bus, walking, Medicaid van)?  
⚪ Less than 30 minutes  
⚪ Between 30 minutes and 1 hour  
⚪ Between 1 and 2 hours  
⚪ More than 2 hours  
 
⚪ I prefer not to answer the question  
 
SECTION 2: YOUR VIEWS ON THE MEDVIEWER VIDEO  
 
Now we’ll ask you some questions about the information in the MedViewer  video you just watched and  your 
views of the video.  
 
3. Please mark the best answer for each question about the MedViewer test.  
a. What is the MedViewer  test designed to measure?  
i. The amount of  ART medicine in the body over time  
ii. The amount of HIV virus in the body over time  
 
iii. Don’t know   
iv. I prefer not to answer the question  
 
b. What kind of sample does the MedViewer test use ? 
i. A blood sample from your arm  
ii. A hair sample from the back of your head  
 
iii. Don’t know   
iv. I prefer not to answer the question  
 
c. How will your sample be labeled?  
i. A unique ID number  
ii. Your name  
 
iii. Don’t know   
iv. I prefer not to answer the question  
 
d. What will happen to your hair sample after it has been analyzed?  
i. It will be kept by the resea rch team for additional testing  
ii. It will be permanently destroyed  
 
iii. Don’t know   
iv. I prefer not to answer the question  
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 148 of 214 
 e. How  can you and your provider use your MedViewer report?  
i. To see how you are doing with taking  your ART  medicine  
ii. To know how much HIV virus is in your body  
 
iii. Don’t know   
iv. I prefer not to answer the question  
 
f. Now we want to ask you some questions about how helpful you found the video.  
In terms of how much the video helped you understand what would happen to you if you took  
the MedViewer tes t, would you say the video was:  
⚪ Extremely helpful  
⚪ Very helpful  
⚪ Moderately helpful  
⚪ A little helpful  
⚪ Not at all helpful  
 
i. I prefer not to answer the question  
 
g. In terms of  how much the video helped you decide whether or not you wanted to take the 
MedViewer test , would you say the video was:  
⚪ Extremely helpful  
⚪ Very helpful  
⚪ Moderately helpful  
⚪ A little helpful  
⚪ Not at all helpful  
 
i. I prefer not to answer the question  
 
h. In terms of  how much the video helped you decide whether or not to be in this study , wo uld 
you say the video was:  
⚪ Extremely helpful  
⚪ Very helpful  
⚪ Moderately helpful  
⚪ A little helpful  
⚪ Not at all helpful  
 
i. I prefer not to answer the question  
 
i. In terms of  how much the video helped you understand how to interpret your MedViewer 
report, would you say the video was:  
⚪ Extremely helpful  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 149 of 214 
 ⚪ Very helpful  
⚪ Moderately helpful  
⚪ A little helpful  
⚪ Not at all helpful  
 
i. I prefer not to answer the question  
j. In terms of  how much the video helped you feel more comfortable about  having the 
MedViewer test , would you say the video was:  
⚪ Extremely helpful  
⚪ Very helpful  
⚪ Moderately helpful  
⚪ A little helpful  
⚪ Not at all helpful  
 
i. I prefer not  to answer the question  
 
k. In terms of  how much you enjoyed watching the video, would you say you:  
⚪ Enjoyed it A Lot  
⚪ Enjoyed it Some  
⚪ Enjoyed it A Little  
⚪ Did not Enjoy it at All  
 
⚪ I prefer not to answer the question  
 
4. How confident are you that you will be able to understand the information on your MedViewer report?  
⚪ Not at all confident  
⚪ A little bit confident  
⚪ Moderately confident  
⚪ Very confident  
⚪ Completely confident  
 
⚪ I prefer not to answer the question  
SECTION 3: ABOUT YOU  
5. How would you describe your sexual o rientation?  
⚪ Straight or heterosexual  
⚪ Lesbian, gay, or homosexual  
⚪ Bisexual  
⚪ Queer  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 150 of 214 
 ⚪ Asexual  
⚪ Pansexual  
⚪ Other (please specify): ________________________  
 
⚪ I prefer not to answer the question.  
 
6. What is your CURRENT marital status?  
⚪ Married  
⚪ Widowed  
⚪ Divorced or separated  
⚪ Living together, but not married  
⚪ Single, never married  
 
⚪ I prefer not to answer the question.  
 
7. What is the HIGHEST grade or level of school you have completed or the highest degree you have 
received?  
⚪ Middle school ( junior high school) or less  
⚪ Some high school, no diploma  
⚪ High school graduate / GED or equivalent  
⚪ Junior (2 -year) college  
⚪ Technical / Trade / Vocational school  
⚪ Some college (4 -year college or university)  
⚪ College graduate (4 -year college or univ ersity)  
⚪ Advanced Degree (After a 4 -year college)  
 
⚪ I prefer not to answer the question.  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 151 of 214 
  
8. Which of the following best describes the total yearly income from all legal sources before taxes in your 
household  IN THE PAST YEAR?  
⚪ Under $5,000  
⚪ $5,000 -10,000  
⚪ >$10,000 -20,000  
⚪ >$20,000 -$50,000  
⚪ >$50,000 -$100,000  
⚪ >$100,000  
 
⚪ I prefer not to a nswer the question.  
 
9. What is your current work status? (Check ALL that apply)  
☐ Employed part -time  
☐ Employed full -time  
☐ Unemployed  
☐ Take care of the home and/or family  
☐ Student  
☐ Retired  
☐ Unable to work due to disability  
☐ Other (specify) ______________  
 
⚪ I prefer not to answer the question.  
 
10. What kind of health insurance coverage do you have? (Check ALL that apply)  
☐ Medicaid  
☐ Medicare  
☐ Military insurance coverage  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 152 of 214 
 ☐ Private insurance pr ovided by employer or spouse/partner’s employer  
☐ Private insurance purchased by you directly (from an insurance company or through a health 
insurance exchange created as part of the Affordable Care Act/Obamacare)  
☐ None  
☐ Other: __________________________ _________________  
 
⚪ I prefer not to answer the question.  
 
11. How do you pay for your ART medicines? (Check ALL that apply)  
☐ AIDS Drug Assistance Program (ADAP)/ Ryan White  
☐ Medicaid  
☐ Medicare Part D  
☐ Military insurance coverage  
☐ A private health insurance plan (provided by an employer or purchased by you directly, either from 
an insurance company or through a health insurance exchange)  
☐ I pay for my ART medicines partly  out-of-pocket  
☐ I pay for my ART medicines completely  out-of-pocket  
☐ Other: ________________________  
 
⚪ I prefer not to answer the question.  
 
  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 153 of 214 
 SECTION 4: Taking Your ART  
12. Now thinking about the ART medicine you are taking…               
a. How sure are you that you can or cannot take the right amounts of medicine  at the right times  
over the next 30 days ?  
i. Very sure I cannot  
ii. Somewhat sure I cannot  
iii. Neither sure no r unsure  
iv. Somewhat sure I can 
v. Very sure I can  
 
vi. I prefer not to answer the question  
 
b. How sure are you that you can or cannot do better  with taking the right amounts of medicine 
at the right times over the next 30 days ?  
i. Very sure I cannot  
ii. Somewhat sure I cannot  
iii. Neither sure no r unsure  
iv. Somewhat sure I can  
v. Very sure I can  
 
vi. I do no t think I need to do better  
vii. I prefer not to answer the question  
 
c. How sure  are you that you can or cannot take the right amounts of your medicine at the right 
times even if you were very tempted not to  over the next 30 days ?  
i. Very sure I cannot  
ii. Somewhat sure I cannot  
iii. Neither sure no r unsure  
iv. Somewhat sure I can  
v. Very sure I can  
 
vi. I prefer not to answer the question  
 
13. Would you say that in the next 30 days, taking your ART is:  
⚪ Not at all important to you  
⚪ A little important to you  
⚪ Very important to y ou 
⚪ More important to you than just about anything  
 
⚪ I prefer not to answer the question  
 
  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 154 of 214 
 14. The following question relates to the reasons why you would take your ART every day at the right times. 
Different people have different reasons for taking their ART every day at the right times. We want to know 
how true each of the following reasons is for  you. Please indicate the extent to which each reason is true 
for you, using the 7 -point scale provide d, where 1 means not true at all and 7 means very true.  
 
The reason I would take my ART every day at the 
right times is:  1 
not true at 
all 2 3 4 
somewhat 
true  5 6 7 
very true  
a. Because I feel that I want to take 
responsibility for my own health.  ⚪ ⚪ ⚪ ⚪ ⚪ ⚪ ⚪ 
b. Because I would feel guilty or ashamed of 
myself if I did not take my ART regularly.  ⚪ ⚪ ⚪ ⚪ ⚪ ⚪ ⚪ 
c. Because I personally believe it is the best 
thing for my health.  ⚪ ⚪ ⚪ ⚪ ⚪ ⚪ ⚪ 
d. Because others would be upset with me if I 
did not.  ⚪ ⚪ ⚪ ⚪ ⚪ ⚪ ⚪ 
e. I really don't think about it.  ⚪ ⚪ ⚪ ⚪ ⚪ ⚪ ⚪ 
f. Because I have carefully thought about it and 
believe it is very important for many aspects of 
my life.  ⚪ ⚪ ⚪ ⚪ ⚪ ⚪ ⚪ 
g. Because I would feel bad about myself if I 
did not take my ART regularly.  ⚪ ⚪ ⚪ ⚪ ⚪ ⚪ ⚪ 
h. Because it is an important choice I really 
want to make.  ⚪ ⚪ ⚪ ⚪ ⚪ ⚪ ⚪ 
i. Because I feel pressure from others to do so.  ⚪ ⚪ ⚪ ⚪ ⚪ ⚪ ⚪ 
j. Because it is easier to do what I am told than 
think about it.  ⚪ ⚪ ⚪ ⚪ ⚪ ⚪ ⚪ 
k. Because it is consistent with my life goals.  ⚪ ⚪ ⚪ ⚪ ⚪ ⚪ ⚪ 
l. Because I want others to approve of me.  ⚪ ⚪ ⚪ ⚪ ⚪ ⚪ ⚪ 
m. Because it is very important for being as 
healthy as possible.  ⚪ ⚪ ⚪ ⚪ ⚪ ⚪ ⚪ 
n. Because I want others to see I can do it.  ⚪ ⚪ ⚪ ⚪ ⚪ ⚪ ⚪ 
o. I don't really know why.  ⚪ ⚪ ⚪ ⚪ ⚪ ⚪ ⚪ 
 
  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 155 of 214 
 Instructions for Question 15 (remote):  Please think of all the ART medicines you take together to answer the 
next question.  
15 (Remote). Percentage antiretroviral (ART) medicine taken in the past 30 days  
Please tell us your best guess about how much of your current antiretroviral medication you have taken in 
the past 30 days . Please write the percentage you have taken — you can write any number from 0% to 
100%.  
0% means you have taken none of your current antiretroviral medication , 50%  means you have taken 
half your current antiretroviral medication , 100%  means that you have taken every single dose  of your 
current antiretroviral medication in the past 30 days.  
Percentage ART medicine taken in the past 30 da ys: ______________%  
 
 
 
 
 
C.2 PATIENT POST -VISIT QUESTIONNAIRE  
Participant ID __ __ __ __ / __ __ __  
Patient Post -Visit Questionnaire  
ENLIGHTEN Pilot Study  
Instructions: Please read each question and mark your response(s).  
1. Who showed  you a copy of your MedViewer report at your visit?  
⚪ No one, I did not see a copy of my MedViewer report → Skip to Question 2  
⚪ My usual HIV medical provider  
⚪ The clinic pharmacist  
⚪ A clinic nurse  
⚪ Someone else, please specify _____________________________  
 
a. Did this person discuss  your MedViewer report with you at your visit today?  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 156 of 214 
 ⚪ Yes 
⚪ No 
 
b. How satisfied were you with the discussions you had with this provider during today’s 
MedViewer visit, compared with a usual visit?  
⚪ Much less satisfied than usual  
⚪ Somewhat less satisfied than usual  
⚪ Neither more nor less satisfied than usual  
⚪ Somew hat more satisfied than usual  
⚪ Much more satisfied than usual  
 
⚪ I prefer not to answer the question.  
 
2. How likely would you be to use MedViewer again in the future if your medical provider offered it to 
you?  
⚪ Definitely would not  use 
⚪ Probably would not use 
⚪ Probably would  use 
⚪ Definitely would  use 
 
⚪ Prefer not to answer  
 
3. How likely would you be to recommend using MedViewer to others if it were available?  
⚪ Definitely would not  recommend  
⚪ Probably would not  recommend  
⚪ Probably would  recommend  
⚪ Definitely would  recommend  
 
⚪ Prefer not to answer  
 
Now we’d like to ask you some questions about how you felt about your MedViewer report. (Skip this 
section (questions 4 to 6) if you did not receive the MedViewer report.)  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 157 of 214 
  
4. How difficult or easy was it to u nderstand the information in the MedViewer report?  
⚪ Very difficult  
⚪ Somewhat difficult  
⚪ Somewhat easy  
⚪ Very easy  
 
⚪ I prefer not to answer the question  
 
5. How closely did the information in the MedViewer report line up with how you remember taking 
your ART medicine?  
⚪ Did not line up at all with how I remember taking my ART medicine  
⚪ Lined up a little with how I remember taking my ART medicine  
⚪ Lined up pretty well with how I remember taking my ART medicine  
⚪ Lined up exactly with how I remember taking my ART medicine  
 
⚪ I prefer not to answer the question  
 
6. How useful do you think th e MedViewer report is for helping you feel motivated  to take your ART 
medicine over the next 30 days?  
⚪ Not at all useful to you  
⚪ A little bit useful  
⚪ Somewhat useful  
⚪ Very useful  
⚪ Extremely useful to you  
 
⚪ I prefer not to answer the question  
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 158 of 214 
 Now we’d like to ask you a couple questions about your satisfaction with different aspects of the 
MedViewer test. Please tell us how you would rate the following parts of the MedViewer experience:  
 
7. How satisfied or unsatisfied are you with the waiting time , from when your hair sample was 
collected to when you saw your medical provider?   
⚪ Very unsatisfied  
⚪ Somewhat unsatisfied  
⚪ Neither satisfied nor unsatisfied  
⚪ Somewhat satisfied  
⚪ Very satisfied  
 
⚪ I prefer not to answer the question.  
 
8. How satisfied or unsatisfied are you with the experience of having your hair plucked ?  
⚪ Very unsatisfied  
⚪ Somewhat unsatisfied  
⚪ Neither satisfied nor unsatisfied  
⚪ Somewhat satisfied  
⚪ Very satisfied  
 
⚪ I prefer not to answer the question.  
 
9. How satisfied or unsatisfied are you with the discussion you had with your medical provider today 
about your ART adherence  using the MedViewer report? (Skip if you did not receive the MedViewer 
repo rt.) 
⚪ Very unsatisfied  
⚪ Somewhat unsatisfied  
⚪ Neither satisfied nor unsatisfied  
⚪ Somewhat satisfied  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 159 of 214 
 ⚪ Very satisfied  
 
⚪ I prefer not to answer the question.  
 
10. How satisfied or unsatisfied are you with the format of the MedViewer report? (Skip if you did not 
receive the MedViewer report.)  
⚪ Very unsatisfied  
⚪ Somewhat unsatisfied  
⚪ Neither satisfied nor unsatisfied  
⚪ Somewhat satisfied  
⚪ Very satisfied  
 
⚪ I prefer not to answer the question.  
Finally, we have a couple of questions about how you feel about taking your ART.  
 
11. Thinking about the ART you are taking…  
a. How sure are you that you can or cannot take the right amounts of medicine at the right 
times  over the next 30 days ?  
⚪ Very sure I cannot  
⚪ Somewhat sure I cannot  
⚪ Neither sure nor unsure  
⚪ Somewhat sure I can  
⚪ Very sure I can  
 
⚪ I prefer not to answer the question.  
 
b. How sure are you that you can or cannot do better  with taking the right amounts of 
medicine at the right times over the next 30 days ?  
⚪ Very sure I cannot  
⚪ Somewhat sure I cannot  
⚪ Neither sure nor unsure  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 160 of 214 
 ⚪ Somewhat sure I can  
⚪ Very sure I can  
 
⚪ I do not think I need to do better  
⚪ I prefer not to answer the question  
 
c. How sure are you that you can or cannot take the right amounts of your medicine at the 
right times even if you were very tempted not  to over the next 30 days ?  
⚪ Very sure I cannot  
⚪ Somewhat sure I cannot  
⚪ Neither sure nor unsure  
⚪ Somewhat sure I can  
⚪ Very sure I can  
 
⚪ I prefer not to answer the question  
 
12. Would you say that in the next 30 days, taking your ART is:  
⚪ Not at all important to you  
⚪ A little important to you  
⚪ Very important to you  
⚪ More important to you than just about anything  
 
⚪ I prefer not to answer the question.  
13. Imagine that the MedViewer test became available as a routine clinical test (in addition to viral 
load testing). What is the most you would be willing to pay out of poc ket to get the MedViewer 
test?  
⚪ None. I am not willing to pay out of pocket for MedViewer.  
⚪ $10.00  
⚪ $25.00  
⚪ $50.00  
⚪ $100.00  
⚪ $150.00  
⚪ $250.00  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 161 of 214 
 ⚪ Other  
 
       ⚪ Don’t know  
       ⚪ I prefer not to answer the question.  
 
You have reached the end of the survey. Thank you for your time and attention.  
 
 
C.3 PATIENT IN -DEPTH INTERVIEW GUIDE  
Participant ID __ __ __ __ / __ __ __  
Patient In -Depth Interview Guide  
ENLIGHTEN Pilot Study  
Introduction: Thank you for meeting with me today. During our discussion, I would like to ask your 
opinions about MedViewer and about your first MedViewer study visit.  As you may remember, 
MedViewer is the new test to measure the amount of ART medicine in  the body by testing hair. There 
are no right or wrong answers to the questions I will ask you. Your opinion will help us learn more 
about how MedViewer can help doctors and people living with HIV. Everything you say here will be 
kept anonymous, and nothin g you say during this interview will affect your care at the clinic. Please 
feel free to interrupt me or let me know if you have questions at any time. This discussion should last 
about 45 -60 minutes.  
 
 
Interview Questions  
1. To begin, please tell me about t he day you came in for your MedViewer visit. What was that 
like?  
 
Section 1: Intervention components   
As I you may remember from your first study visit, there were a few study activities you did on the 
day you had the MedViewer test. You watched a short video to give you information about 
MedViewer. You gave a hair sample for MedViewer testing. And you pro bably received the 
MedViewer report and talked about it with your provider. I’d like to ask you about each of those 
things in more detail.  
 
2. Let’s begin with the video since it was the first thing you did. Generally, what did you think 
about the video?  
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 162 of 214 
 a. What did you like about it?  
b. What would you change about it?  
c. How useful or not useful do you think the video was?  
d. What additional information would you have wanted in the video?  
 
Thank you. Now, let’s talk about how it was to have a hair sample collected for MedViewer testing 
and the time it took to receive the results.  
 
3. Generally, what did you think about having your hair sample collected for MedViewer 
testing?  
 
a. How did it feel to have your hair plucked?  
b. What would you change about the collection procedure, if anything?  
c. How did you feel about having your hair sent to the lab for testing?  
d. How willing or unwilling would you be to provide a hair sample for MedViewer in 
the future?  Please explain.  
e. What concerns did you have about hair colle ction and MedViewer testing, if any?  
 
4. How did you feel about the amount of time you had to wait to receive your MedViewer 
results? Please explain.  
 
a. How long did you wait?  
b. How willing or unwilling would you be to wait that long again in the future for 
Med Viewer results? Please explain.  
c. Is there anything that would make it easier for you to wait that long?  
d. If dissatisfied, how long would you be willing to wait?  
 
Section 2: MedViewer results report  
Thank you. Now, I’d like to spend some time talking about t he MedViewer report.  
 
5. In your own words, what is the purpose of the MedViewer report?  
 
6. What did you like about the report?  
 
7. What did you not like about the report?  
 
8. In the MedViewer report you received from your provider, how much do you feel the 
information in the report lined up with how you actually took your ART medicine?  
a. Did the MedViewer report show what you expected it would? How/why?  
b. In what ways was it different than how you actually took your ART medicine?   
c. How much did specific dates m arked as missed doses on the report match up with 
the dates you remembered missing ART doses?  
 
This is a sample report – these are not yours or anyone else’s actual results. But this report does 
have the same features. ( Show sample report but don’t describ e the report – let participant describe 
it first .) 
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 163 of 214 
 9. Using your own words, please describe this SAMPLE results report to me.  
 
a. What do the colors mean?  
b. What do the dates represent?  
c. What are these boxes of text?  
 
10. Now I’d like to hear about your opinion of the report.  
a. What parts of the report are easy to understand?  
b. What parts of the report are more difficult to understand? Why?  
c. What changes would you make to the way the report looks or the information 
provided? ( Specify if need be that we are ask ing about the REPORT not these specific 
RESULTS. ) 
 
Section 3: Results discussion and effects  
Thank you. Let’s talk about what it was like to discuss your MedViewer results report with your 
provider and any changes in medication -taking strategies this discu ssion might have led to.  
 
11. Who provided your MedViewer report to you?  
a. How did you feel about having this person deliver the results to you?  
b. Is there someone else you would have preferred? Please explain.  
c. In what ways was your conversation with your provider different than a typical visit?  
 
12. Tell me about the conversation you and your provider had about your MedViewer report.  
 
a. What did you and  provider talk about?  
b. How was your conversation different or the same as a typical visit?  
c. How much did you like or not like having this conversation with your provider?  
d. What about the MedViewer conversation was helpful? What was not helpful?  
e. What did you l earn about how adherent you were to your ART medicine?  
f. Were there any missed days/periods that surprised you?  
g. How much did MedViewer results help you remember reasons you missed doses?  
h. What were reasons for missing doses that you and your provider talked  about?  
 
13. How much did you and your provider talk about strategies or ways you could make sure you 
take your ART medicine at the right times?   
a. Tell me about the strategies you identified?  
b. Have you followed the strategies you identified with your provider?  Why or why 
not?  
c. Do you think having more MedViewer tests, like the one you had that day, could 
help you to improve/continue these using these strategies? Please explain.  
 
14. In general, how did MedViewer affect your motivation to take your ART medicine at the 
right days/times, if at all?  
 
a. How did the MedViewer report  contribute your motivation?  
b. How did the discussion with your provider, using the MedViewer report , contribute 
to your motivation?  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 164 of 214 
 c. How would MedViewer affect your motivation if you used it on a regular basis?  
d. How could the MedViewer report or discussion be more motivating for you?  
 
15. How have you changed how you take your ART medicine since the MedViewer test?  
a. How u seful do you think MedViewer has been in helping actually take your doses 
regularly and on time? Please explain (why/how).  
 
Section 4: Additional thoughts about future MedViewer use  
Thank you. Let’s talk now about your thoughts about using MedViewer in t he future.  
 
16. Imagine that a medical provider recommended MedViewer to you again in the future, what 
are the main reasons you would or wouldn’t take the MedViewer test?  
 
17. If MedViewer became a regular part every visit with your provider, how would that affect 
your relat ionship with your provider? Please explain.  
 
18. If you get the MedViewer test and report regularly during your visits, what effect do you 
think it would have on your adherence to your ART medicine?  
 
Closing question:  
 
19. Do you have anything else you’d like to  share regarding your thoughts about MedViewer?  
 
Conclusion : Thank you for your time and thoughts today. This has been very helpful.  
 
C.4 PATIENT ENDLINE  QUESTIONNAIRE  
 
Participant ID __ __ __ __ / __ __ __  
PATIENT ENDLINE QUESTIONNAIRE  
ENLIGHTEN PILOT STUDY  
Instructions : Please read each que stion and mark your response(s) in the appropriate space.  
1. How useful do you think having the MedViewer test was for:   
a. Helping you feel motivated  to take your ART medicine over the LAST 30 days?  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 165 of 214 
 ⚪ Not at all useful to you  
⚪ A little bit useful  
⚪ Somewhat useful  
⚪ Very useful  
⚪ Extremely useful to you  
 
⚪ I prefer not to answer the question  
 
b. Helping you  take your ART medicine as prescribed  over the LAST 30 days?  
⚪ Not at all useful to you  
⚪ A little bit useful  
⚪ Somewhat useful  
⚪ Very useful  
⚪ Extremely useful to you  
 
⚪ I prefer not to answer the question  
 
c. Helping you to develop skills and strategies  to take your ART medicine over the LAST 30 
days?  
⚪ Not at all useful to you  
⚪ A little bi t useful  
⚪ Somewhat useful  
⚪ Very useful  
⚪ Extremely useful to you  
 
⚪ I prefer not to answer the question  
 
  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 166 of 214 
 2. Thinking about the ART you are taking…  
a. How sure are you that you can take the right amounts of medicine at the right times  over 
the next 30 days ?  
⚪ Very sure I cannot  
⚪ Somewhat sure I cannot  
⚪ Neither sure no r unsure  
⚪ Somewhat sure I can  
⚪ Very sure I can  
 
⚪ I prefer not to answer the question.  
 
b. How sure are you that you can do better  with taking the right amou nt of medicine at the 
right t imes over the next 30 days ?  
⚪ Very sure I cannot  
⚪ Somewhat sure I cannot  
⚪ Neither sure no r unsure  
⚪ Somewhat sure I can  
⚪ Very sure I can  
 
⚪ I do not think I need to do better  
⚪ I prefer not to answer the question  
 
c. How sure are you that you can take the right amount of your medicine at the right times 
even if you were very tempted not  to over the next 30 days ?  
⚪ Very sure I cannot  
⚪ Somewhat sure I cannot  
⚪ Neither sure no r unsure  
⚪ Somewhat sure I can  
⚪ Very sure I can  
 
⚪ I prefer not to answer the question  
 
3. Would you say that in the next 30 days, taking your ART is:  
⚪ Not at all important to you  
⚪ A little important to you  
⚪ Very important to you  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 167 of 214 
 ⚪ More important to you than just about anything  
 
⚪ I prefer not to answer the question.  
 
4. Imagine that the MedViewer test became available as a routine clinical test (in addition to viral 
load testing). What is the most you would be willing to pay out of pocket to get the MedViewer 
test?  
⚪ None. I am not willing to pay out of pocket for MedViewer.  
⚪ $10.00  
⚪ $25.00  
⚪ $50.00  
⚪ $100.00  
⚪ $150.00  
⚪ $250.00  
⚪ Other  
 
       ⚪ Don’t know  
       ⚪ I prefer not to answer the question.  
 
Instructions for Question 5 (remote):  Please think of all the ART medicines you take together to answer the next 
question.  
5 (Remote). Percentage antiretroviral (ART) medicine taken in the past 30 days  
Please tell us your best guess about how much of your current antiretroviral medication you have taken in 
the past 30 days . Please write the percentage you have taken — you can wr ite any number from 0% to 
100%.  
0% means you have taken none of your current antiretroviral medication , 50%  means you have taken 
half your current antiretroviral medication , 100%  means that you have taken every single dose  of your 
current antiretroviral me dication in the past 30 days.  
Percentage ART medicine taken in the past 30 days: ______________%  
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 168 of 214 
  
C.5 PROVIDER POST -TRAINING (BASELINE) QUESTIONNAIRE  
 
Participant ID __ __ __ __ / __ __ __  
 
Provider Post -Training Questionnaire  
ENLIGHTEN Pilot Study  
Instructions:  Please respond to each question by selecting or writing in your response(s) in the 
appropriate space.  
 
1. How would you rate the overall quality of this training on a scale of 1 (poor) to 5 
(excellent)?  
⚪ 1- Poor  
⚪ 2 - Fair 
⚪ 3 - Good  
⚪ 4 - Very Good  
⚪ 5 - Excellent  
  
2. How would you describe the amount of time used for the training?  
⚪ Too little  
⚪ Just right  
⚪ Too much  
 
2. After completing this training, how confident are you in your ability to :  
a. Accurately provide a brief description of the ENLIGHTEN pilot study?  
⚪ Not at all confident  
⚪ Slightly confident  
⚪ Moderately confident  
⚪ Very confident  
⚪ Completely confident  
 
b. Interpret patient and provider MedViewer reports?  
⚪ Not at all confident  
⚪ Slightly confident  
⚪ Moderately confident  
⚪ Very confident  
⚪ Completely confident  
 
c. Explain MedViewer reports to patients?  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 169 of 214 
 ⚪ Not at all confident  
⚪ Slightly confident  
⚪ Moderately confident  
⚪ Very confident  
⚪ Completely confident  
 
d. Utilize MedViewer reports to counsel patients on adherence?  
⚪ Not at all confident  
⚪ Slightly confide nt 
⚪ Moderately confident  
⚪ Very confident  
⚪ Completely confident  
 
3. After completing this training, how would you rate your level of knowledge of:  
a. Study activities for providers?  
⚪ Not at all knowledgeable  
⚪ Slightly knowledgeable  
⚪ Moderately knowledgeable  
⚪ Very knowledgeable  
⚪ Fully knowledgeable  
 
b. Study activities for patients?  
⚪ Not at all knowledgeable  
⚪ Slightly knowledgeable  
⚪ Moderately knowledgeable  
⚪ Very knowledgeable  
⚪ Fully knowledgeable  
 
4. What did you like about the training?  
___________________ __________________________________________________
___________________________________________ __________________________  
_____________________________________________________________________
___________________________________________ ________________________ __ 
 
5. What about the training could have been improved?  
_____________________________________________________________________
___________________________________________ __________________________  
_____________________________________________________________________
___________________________________________ _____ _____________________  
 
Establishing Novel Antiretroviral Imaging for Hair to  Elucidate Non-Adherence (ENLIGHTEN) Version v1.0 
Protocol 122319                                                         25 September 2019  
3DJHRI
6.Would you like to receive additional information about MedViewer or the 
ENLIGHTEN Pilot Study prior to seeing patients for their study visits? 
ؗYes…Go to 6a and 6b  
ؗNo… END SURVEY 
 
a.What additional information would yo u like to receive? (Select ALL that 
apply) 
Information about the MedViewer technology 
Information about the purpose of the ENLIGHTEN Pilot Study 
Guidance on interpreting patient and provider MedViewer reports 
Suggestions for using MedViewer reports to counsel patients on 
adherence 
Guidance on using the communication aids 
Information on patient study activities 
Information on provider study activities 
Other: _________________________________________ 
 
b.In what format would you like to receiv e that information? (Select ALL that 
apply) 
Additional group training session 
One-on-one training/conversation 
Other: __________________________________________ 
 
 
 
  
Establishing Novel Antiretroviral Imaging for Hair to  Elucidate Non-Adherence (ENLIGHTEN) Version v1.0 
Protocol 122319                                                         25 September 2019  
3DJHRI
 
 
C.6 PROVIDER POST-VISIT QUESTIONNAIRE 
Participant ID __ __ __ __ / __ __ __ 
Provider Post-Visit Questionnaire 
ENLIGHTEN Pilot Study  
Instructions:  Thinking about the most recent patient you sa w for a MedViewer visit, please respond to the 
following questions using a BLACK-INK PEN. Place the completed questionnair e in the blue deposit box. Thank 
you!  
 
Date of patient MedViewer visit:  ____ / ____ / ________     
    dd       mmm          yyyy 
 
1.Did you show your patient his/her/thei r MedViewer report during the visit?  
ؗNo….Go to Question 1a  
ؗYes…Go to Question 2  
 
1a. What were the reasons you did not sh ow your patient his/her/their MedViewer 
report? (Mark all that apply)  
Did not receive a MedVie wer report for this pa tient before the visit 
No time to show the MedViewer report during the visit 
The patient had other more pressi ng medical issues to address 
I did not think it would be beneficial to show the report. Please explain: 
____________________________________________________________ 
Technical difficulties. Please explain: ______________________________ 
Other: ______________________________________________________ 
END SURVEY  
 
2.How much time did you spend during  the visit discussing the MedViewe r report with your patient?  
a.0 minutes - I did not discuss the MedViewer report with the patient…Go to Question 2a  
b.< 1 minute…Go to Question 3  
c.2-5 minutes…Go to Question 3  
d.5-10 minutes…Go to Question 3  
e.10-15 minutes…Go to Question 3  
f.>15 minutes …Go to Question 3 
 
2a. What were the reasons you did not disc uss the MedViewer report with your patient 
during the visit? (Mark all that apply)  
No time to discuss the MedV iewer report during the visit 
The patient was not interested in discussing the MedViewer report 
The patient had other more pressi ng medical issues to address 
Establishing Novel Antiretroviral Imaging for Hair to  Elucidate Non-Adherence (ENLIGHTEN) Version v1.0 
Protocol 122319                                                         25 September 2019  
3DJHRI
I did not think it would be beneficial to discuss the report. Please explain: 
____________________________________________________________ 
Technical difficulties. Please explain: ______________________________ 
Other: ______________________________________________________ 
END SURVEY   
 
3.How useful would you say the MedVie wer report was for helping you understand this patient’s ART 
adherence? 
a.Not at all useful 
b.Slightly useful  
c.Moderately useful 
d.Very useful  
e.Extremely useful 
 
f.I prefer not to answer the question 
 
4.How useful would you say the MedViewer report  was for helping you have a productive 
conversation with this patien t about their ART adherence? 
a.Not at all useful  
b.A little bit useful  
c.Moderately useful 
d.Very useful  
e.Extremely useful 
 
f.I prefer not to answer the question 
 
5.How well would you say your pati ent understood the information in their MedViewer report?  
a.Not at all well 
b.Slightly well 
c.Moderately well 
d.Very well 
e.Excellently 
 
f.I prefer not to answer the question 
 
  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 173 of 214 
 C.7 PROVIDER IN -DEPTH INTERVIEW GUIDE  
______ _______________________  Participant ID __ __ __ __ / __ __ 
__ 
Provider In -Depth Interview Guide  
ENLIGHTEN Pilot Study  
Introduction  
 
Thank you for meeting with me today to discuss your experience with the MedViewer 
intervention and using MedViewer reports with patients at the ID Clinic. Specifically, I am 
interested in hearing your thoughts on: 1) the usefulness of  the MedViewer reports and 
discussions with your patients  using the reports ; 2) the extent to which the MedViewer 
intervention fits within routine clinical practice; and 3) future MedViewer use. Please feel 
free to ask questions at any time. There are no right or wrong answers. Your feedback will 
help us determine the future direction of MedViewer.  
 
Do you h ave any questions before we get started?   
 
Note: Bold  indicates essential topics to be covered during the interview.  
 
Interview Questions  
 
Section 1: Overall opinions  
First, I am interested in hearing your overall experience using MedViewer.  
 
1. To start, please walk me through a typical visit with a patient you saw for a 
MedViewer visit.  
 
Section 2: Use of MedViewer reports  
Thank you. Now, we’ll talk more about the  MedViewer reports . You may remember that 
you received two versions of the report for each patient. One was the “provider” report in a 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 174 of 214 
 bar graph format showing the concentration of ART medication detected each day. The 
other was the “patient” report that w as in a calendar format showing whether or not a 
missed dose of medication was detected.  
 
2. What do you think of the MedViewer reports for providers?  (Show or describe these 
to the provider as a reminder.)   
 
Probes:  
a. How did you use these, if at all?  
b. What aspects of the report were helpful ? 
c. What aspects of the report were difficult to understand or use ? 
d. What changes would you suggest?  
 
3. What do you think about the MedViewer reports for patients?  (Show or describe 
these to the provider as a reminder.)  
 
Probes:  
a. How did you use these reports, if at all?  
b. How well did you think your patients generally understood the reports?  
c. From your perspective, what aspects of the se report s were helpful for 
patie nts? 
d. From your perspective, w hat aspects of the se report s were difficult to 
understand for patients?  
e. What changes would you suggest  to further facilitate patient understanding 
of the report ?  
 
Section 3: Impact of MedViewer report on adherence counseling discussions  
Now I’d like to learn about the discussions you had with your patients  using the MedViewer 
reports.   
 
4. Please t ell me about the discussions you had with patients using the MedViewer 
reports.  
 
Probes:  
a. How did you explain the results to your patients?  
b. How did patients respond to seeing their MedViewer results?  
c. Was there any aspect of the results you had difficulty discussing with your 
patients?  
d. If applicable, how did your discussions differ for patients whose results 
showed mis sed doses vs. patients whose results showed none?  
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 175 of 214 
 5. In what ways did your discussions using MedViewer differ from typical discussions 
you ha ve with patients about adherence?  
 
Probes:  
a. What things did you discuss with the MedViewer results that you might not 
otherwise have discussed?  
b. Do you feel like visits using MedViewer were more beneficial or less 
beneficial for your patients than normal visits? What are the reasons for 
that?  
 
6. Now thinking specifically about using MedViewer reports for adherence counseling, 
overall, how did you find the MedViewer reports for counseling your patients about 
their adherence?  
a. How did you use the MedViewer re sults  to encourage adherence , if at all, 
in terms of problem solving, motivation, or behavioral skills ?  
 
7. If applicable , if you have seen any of your MedViewer patients since  they had a  
MedViewer study visit, did you observe or discuss any changes  in the patient’s 
adherence  related to their receipt of MedViewer results?  
 
Probes:  
a. Any observed or reported changes i n adherence?  
b. Any observed or reported changes in motivation or adherence strategies that 
you talked about?  
 
Section 4: Potential impacts of routine/future MedViewer use  
Thank you. I’d like to hear your thoughts about using MedViewer if it became available for 
routine  use. 
 
8. If MedViewer were available for routine use in the future, to what extent do you 
think it could be a useful tool to help your patients with adherence? What are the 
reasons for that?  
 
Probes:  
a. How would you decide whether to recommend MedViewer to patients?  
b. Are there patients for whom you would be more likely to recommend 
MedViewer? Please explain.  
c. How useful would routine use be for promoting adherence motivation  
among your patients?  
d. How useful would routine use be for promoting skills  to avoid missed doses? 
Are there certain types of patients for whom it might be more or less useful?  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 176 of 214 
  
9. If MedViewer were to be used routinely in the clinic, how do you anticipate it 
would affect your communication or relationships with patients, if at all?  
 
Probes:  
a. For what types of patients might it enhance communication or 
relationships?  
b. Are there specific patients for whom it is less worthwhile or even harmful? If 
so,  
please explain.  
 
10. If MedViewer became available for routine use, what type of provider (such as the 
physician, pharmacist, nurse or social worker, etc.) do you think should deliver the 
MedViewer report to patients for the purposes of adherence counseling? Why?  
 
Section 5: Training session and user support  
Next, I’d like to hear your thoughts on the provider training session and communication 
aid and FAQ you received.  
 
11. Now that you have used the MedViewer report with patients, how  well do you 
think the study training session prepare d you to use MedViewer reports with 
patients?  
 
Probes:  
a. What changes would you suggest for the training session, if any?  
b. How well did the training prepare you to interpret the MedViewer results?  
c. What further training/information would you have desired , if anything?  
 
12. How did you use the communication aid and FAQ sheet, if at all?  (Show or describe 
these to the provider as a reminder. )  
 
Probes:  
a. To what extent did these materials help you interpret MedViewer reports 
and explain them to patients?  
b. How helpful were these materials as a guide for counseling patients on 
adherence using MedViewer reports?  
c. What aspects of the communication aid and FAQ were helpful?  
d. What aspects about the communication aid and FAQ were difficult to 
understand or  use?  
e. What would you change about the communication aid and FAQ?  
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 177 of 214 
 Section 6: MedViewer impact on clinic flow  
Next, I’d like to hear your thoughts on the impact of the MedViewer intervention on clinic 
flow.  
 
13. On days when you had MedViewer visits with patients, how did MedViewer 
activities affect your overall clinic flow for the day?  
 
Probes:  
a. How easy or difficult was it to integrate MedViewer into your activities for 
the day?  
b. Did you experience or hear about any instances where the MedViewer 
intervention interrupted clinic flow?  If yes, can you tell me more about that?  
 
14. Logistically  speaking, how well di d discussi ng the MedViewer report  with your 
patients  fit into visit s with them ? 
 
Probes:  
a. How about f or visits conducted in the clinic versus virtually?  
b. What made it easy to deliver and discuss reports with patients? What made 
it challenging?  
 
Section 6: Concluding remarks  
Just a few final questions:  
 
15. Are there any other changes or improvements we have not discussed yet that could 
be made to MedViewer reports or how they are used?  
 
16. From  your perspective, is there anything else promisin g or beneficial about 
continued MedViewer use that we have not previously discussed?  
 
17. Do you have any other questions or final comments about the MedViewer 
intervention that you would like to share?  
 
Conclusion : Thank you for sharing your thoughts and time tod ay. 
 
  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 178 of 214 
  
C.8 PROVIDER ENDLINE QUESTIONNAIRE  
 
ENLIGHTEN Pilot Study  
Instructions:  Please indicate your responses to the following questions.  
 
1. After completing your MedViewer visits with patients, how confident are you in 
your ability to:  
a. Explain the MedViewer report to patients?  
⚪ Not at all confident  
⚪ Slightly confident  
⚪ Moderately confident  
⚪ Very confident  
⚪ Completely confident  
 
⚪ Prefer not to answer  
 
b. Use the MedViewer report to counsel patients on adherence?  
⚪ Not at all confident  
⚪ Slightly confident  
⚪ Moderately confident  
⚪ Very confident  
⚪ Completely confident  
 
⚪ Prefer not to answer  
 
2. How did using MedViewer with patients affect your relationships with them?  
⚪ Very negatively  
⚪ Somewhat negatively  
⚪ No change  
⚪ Somewhat positively  
⚪ Very positively  
 
⚪ Prefer not to answer  
 
3. How would you rate your overall satisfaction with adherence counseling 
discussions  using MedViewer?  
⚪ Very dissatisfied  
⚪ Somewhat dissatisfied  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 179 of 214 
 ⚪ Neither satisfied nor dissatisfied  
⚪ Somewhat satisfied  
⚪ Very satisfied  
 
⚪ Prefer not to answer  
 
4. In general, how useful would you say MedViewer is for the following things?   
a. Promoting ART adherence  among your patients  
⚪ Not at all useful  
⚪ Slightly useful  
⚪ Somewhat useful  
⚪ Very useful  
⚪ Extremely useful  
 
⚪ Prefer not to answer  
 
b. Developing strategies  with your patients to overcome adherence 
challenges  
⚪ Not at all useful  
⚪ Slightly useful  
⚪ Somewhat useful  
⚪ Very useful  
⚪ Extremely useful  
 
⚪ Prefer not to answer  
 
c. Motivating  your patients to adhere to ART after a clinic visit  
⚪ Not at all useful  
⚪ Slightly useful  
⚪ Some what useful  
⚪ Very useful  
⚪ Extremely useful  
 
⚪ Prefer not to answer  
 
5. How satisfied are you with the content  of the MedViewer report for providers ?  
⚪ Very dissatisfied  
⚪ Somewhat dissatisfied  
⚪ Neither satisfied nor dissatisfied  
Establishing Novel Antiretroviral Imaging for Hair to  Elucidate Non-Adherence (ENLIGHTEN) Version v1.0 
Protocol 122319                                                         25 September 2019  
3DJHRI
ؗSomewhat satisfied 
ؗVery satisfied 
 
ؗPrefer not to answer 
 
6.How satisfied are you with the form at of the MedViewer report for patients ?  
ؗVery dissatisfied 
ؗSomewhat dissatisfied 
ؗNeither satisfied nor dissatisfied 
ؗSomewhat satisfied 
ؗVery satisfied 
 
ؗPrefer not to answer 
 
7.If MedViewer were available for routine use, how likely would you be to 
recommend it to some of your  patients in the future?  
ؗDefinitely would not recommend 
ؗLikely would not recommend 
ؗLikely would recommend 
ؗDefinitely would recommend 
 
ؗPrefer not to answer 
 
8.If MedViewer were available for routine use, what would be your 
recommendation for the type of clinician that should discuss MedViewer results with patients? (Mark all that apply)  
MD/NP/PA-C 
Pharmacist 
Nurse 
Other: ______________________________ 
  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 181 of 214 
 APPENDIX D. BENCHMARKING  
D.1 BENCHMARKING OF IR -MALDESI MSI LONGITUDINAL ARV PROFILING IN HAIR 
STRANDS  
Benchmarking of IR -MALDESI MSI Longitudinal ARV Profiling  in Hair Strands  
As part of [STUDY_ID_REMOVED], we c onduct ed structured dose proportionality studies to develop mathematical 
benchmarks of real -time IR -MALDESI MSI  hair adherence monitoring for both PrEP and HIV treatment 
applications . We enroll ed 12 healthy volunteers into one of 3 drug arms. Our study schema is outlined in 
Figure 1. Subjects gave  informed consent and then under went  laboratory screening for safety. Subjects will 
return to the clinic within 2 weeks to start drug dosing. Dosing was divided into three 28 day phases: single 
dose, daily dose, and dose proportionality. Subjects were  randomly assigned to receive one of 3 dr ug 
regimens: TFV+FTC (Truvada®; TDF 300mg/FTC 200mg), DTG 50mg once daily, and MVC 300 mg once daily. 
Subjects visit ed the research center for hair collection (10 strands), blood collection (3mL), and PBMC 
collection (for the Truvada arm only) on days 3, 7 , 14, 21, and 28 of each phase. After the  single dose phase, 
study subjects initiate d daily dosing with their assigned ARV. One tablet per day was administered by directly 
observed therapy. After the daily dosing phase, subjects were  randomly assigned to o ne of three arms for final 
dose proportionality assessments. They either: 1) stop ped their medication (0 doses/week), 2) switch ed to 1 
dose/week, or 3) t ook 3 doses/week. This approach allow ed evaluation of dose -response in hair strands for 1, 
4, 12, and 2 8 doses per month (28 days). Here, we summarize benchmarking results for TFV+FTC and DTG.  
Sample Evaluation  and Determination of Longitudinal ARV Profiles  
An example of IR -MALDESI MSI evaluation of ARV disposition in hair strands can be seen in Figure 2  for a 
sample collected on Phase 3 Day 21 from a volunteer receiving 3 doses/week. Four hair strands from each 
volunteer were adhered to a glass slide and analyzed by IR -MALDESI  (Figure 2A ). MS images in Figure 2B and C  
show heatmaps corresponding to the meas ured signal abundance of an endogenous lipid and ARV, 
respectively. The endogenous lipid provides a chemical signature delineating the boundaries of each hair 
strand, and the IR -MALDESI response is consistent over the entire length of each hair strand in t he region of 
interest interrogated, corresponding to the proximal 15 mm of the cut hair strands . Unlike the uniformity of 
the endogenous response, the ARV heatmap shows distinct and localized bands of higher abundance within  
Figure 1  – Study schema for [STUDY_ID_REMOVED], a s ingle -center, open -label, 3 -arm, directly 
observed therapy, triple phase study . 
 
Phase 1 Phase 2 Phase 3
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 182 of 214 
 each strand. Average hair growt h is approximately 10 mm/month, such that the 15 mm long region of interest 
investigated in this example reflects roughly one and a half months of hair growth. This period of time 
captures the Phase 3 dosing response and the Phase 2 daily dosing response, along with the 7 day gap 
between study phases as denoted in Figure 2C. These features can be seen more clearly in the accompanying 
profiles associated with each hair strand shown in Figure 2D .  
Features of the ARV profiles are not in exactly the same position on each strand relative to the proximal strand 
end due to variability in the angled cutting of hair by scissors during sampling . We align profile features across 
strands using built -in algorithms of our custom MATLAB analysis software before evaluating a composite 
average profile for a sample.  
Assessment of Dose -Response in Hair Strands from Composite Profiles  
Summary ARV profiles for all 12 volunteers in each arm of [STUDY_ID_REMOVED] are shown in Figures 3  and 5 for FTC 
and DTG, respectively.  Profiles are shown in blue with accompanying 95% confidence intervals. Shaded 
regions denote portions of the longitudinal prof ile attributed to daily and differentiated dosing phases.  
Average signal abundances associated with each identified region from these profiles are shown in Figures 4  
and 6 for FTC and DTG, respectively.  For FTC and DTG, incorporation rates in hair were rap id enough to clearly 
discern regions of the Phase 3 Day 28 profiles associated with the Phase 3 differentiated dosing. For these two 
ARVs, receiver operating characteristic (ROC) curves were determined for classification of adherence based on 
average signa l abundances. Sensitivity and selectivity are separately plotted as a function of IR -MALDESI signal 
abundance cutpoint. Based on cutpoint selection, adherence can be evaluated for the longitudinal profiles. An 
example report for an individual on the DTG st udy transitioning from daily to 1x -week dosing (RSAU) is shown 
in Figure 7 , where an adherence cutpoint IR -MALDESI signal abundance of 2000 has been selected. Figure 7A  
shows the original profile for RSAU shown in Figure 5 for comparison to the bar graph f ormat of the provider 
report ( Figure 7B ) and the calendar format of the patient report ( Figure 7C ).  
Figure 2 – IR-MALDESI MSI evaluation of ARVs in hair strands. A) Optical image of four hair strands prepared 
for analysi s. B) Endogenous lipid response from sampled hair strands. C) ARV signal abundance, showing 
characteristic patterns associated with transition between daily and 3x per week dosing. D) Longitudinal 
profiles of ARV for each strand.  
 

Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 183 of 214 
 Emtricitabine   
 
Figure 3 – Phase 3 Day 28 longitudinal profiles for FTC measured by IR -MALDESI.  
 
 
Figure 4 – Dose -Response Summary for FTC based on IR -MALDESI longitudinal profiles.  

Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 184 of 214 
 Dolutegravir  
  
Figure 5 – Phase 3 Day 28 longitudinal profiles for DTG measured by IR -MALDESI.  
 
 
Figure 6 – Dose -Response Summary for DTG based on IR -MALDESI longitudinal profiles.  

Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 185 of 214 
  
   
Figure 7 –Example adherence assessment to DTG regimen in samples collected from the volunteer  RSAU. A) 
IR-MALDESI DTG profile in strands collected from RSAU. B) Bar graph format of the provider report based on an 
adherence cutpoint IR -MALDESI signal abundance of 2000. C) Calendar format of the adherence assessment for 
the patient report.  
1
11
16
25
Adherence
cutpoint
A)
B)C)
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 186 of 214 
 APPENDIX E. IR -MALDESI METHOD VALIDATION  
 
 
 
Laboratory Name:  Clinical P harmacology and Analytical Chemistry Laboratory  
 
Laboratory address:  School of Pharmacy  
1100 Genetic Medicine Building, CB 7361  
120 Mason Farm Road.  
UNC Chapel Hill  
Chapel Hill, NC 27599  
  
 
 
Approved by:   ______________________________________________   
 
Title:    Laboratory Director  
 
 
 
 
 
Reviewed by:_______________________________________________________  
 
Assistant Laboratory Director  
 
 
 
 
 
Reviewed by:_ ______________________________________________________  
 
Quality Assurance Auditor  
 
 
  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 187 of 214 
 1. INTRODUCTION  ................................ ................................ ................................ ..............................  4 
2. MATERIALS AND METHODS  ................................ ................................ ................................ ...........  5 
2.1 Reference Standards  ................................ ................................ ................................ ...........  5 
2.2 Reagents  ................................ ................................ ................................ ...............................  5 
2.3  Instrumentation and Supplies  ................................ ................................ .............................  6 
2.4 Preparation of Stock and Internal Standard Solutions, and Calibration Standards  .............  6 
2.4.1  Preparation of Internal Standard Stock Solutions  ................................ .................  6 
2.4.2  Preparation of Primary Analyte Standard Stock Solutions  ................................ .... 6 
2.4.3  Preparation of Calibration Standards by TM Sprayer  ................................ ............  6 
2.4.4  Preparation of Calibration Standards by Incubation  ................................ .............  7 
2.4.5  Preparation of Hair Samples with Internal Standards Using the TM Sprayer  .......  7 
3. VALIDATION  ................................ ................................ ................................ ................................ .... 8 
3.1 Experimental Design  ................................ ................................ ................................ ............  8 
4. RESULTS  ................................ ................................ ................................ ................................ ..........  9 
4.1 Verification of Calibration Model  ................................ ................................ .........................  9 
4.2 Lower Limit of Quantitation (LLOQ)  ................................ ................................ .....................  9 
4.3 Precision  ................................ ................................ ................................ .............................  10 
4.4 FTC, and DTG Analysis of Six Incurred Samples  ................................ ................................ . 10 
4.4.1  Accuracy of IR -MALDESI Quantitative Analysis of Incurred Samples  ..................  10 
4.4.2  Precision of IR -MALDESI Analysis of Incurred Samples  ................................ .......  11 
5. CONCLUSION  ................................ ................................ ................................ ................................  12 
6. REFERENCES  ................................ ................................ ................................ ................................ . 13 
  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 188 of 214 
  
LIST OF TABLES AND FIGURES  
 
TABLE 1.  CALIBRATION STANDARD CURVE SUMMARY  ................................ ......................  14 
TABLE 2.  REGRESSION SUMMARY  ................................ ................................ ......................  15 
TABLE 3.  QUANTITATIVE EVALUATION OF INCURRED SAMPLES ................................ ........  16 
TABLE 4.  INTRA - & INTER -DAY PRECISION OF INCURRES SAMPLES  ................................ ... 16 
 
FIGURE 1.  EXTRACTION OF HAIR -ASSOCIATED ION PEAKS USING MSiREADER  .............  Error! 
Bookmark not defined. 8 
FIGURE 2  GENERATION OF CALIBRATION STANDARDS USING THE TM SPRAYER ...............  19 
FIGURE 3.  REPRESENTATIVE MASS SPECTRA AND EXTRACTED ION CHROMATOGRAMS OF 
TARGETED ANALYTES IN INCURRED HAIR STRANDS  ................................ ...........  20 
FIGURE 4.  EXAMPLE OF A CALIBRATION CURVE  ....................  Error! Bookmark not defined. 1 
FIGURE 5.  EVALUATION OF INCURRED SAMPLES BASED ON CALIBRATION 
CURVES…………………………………………… …………………………………………………………… …23  
 
  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 189 of 214 
 E.1 INTRODUCTION  
 
A method for quantifying the levels of emtricitabine (FTC), and dolutegravir (DTG) in single strands 
of human hair has been validated using infrared matrix assisted laser desorption electrospray 
ionization (IR -MALDESI) mass spectrometry imaging (MSI).  An analyte -specific linear response range 
has been established.  The analytical range was selected based on screening of hair samples 
collected from subjects adherent to HIV treatment regimens containing FTC or DTG. Concentrations 
expected to be found in clin ical hair samples are anticipated to fall within the selected analytical 
range.   
 
IR-MALDESI MSI is an analytical technique that is based on the ambient ionization of material 
directly desorbed from the solid matrix of an individual hair strand without an y extraction or 
analytical separation steps. Creating analytical standards for unique, solid matrices such as hair 
represents a considerable challenge. The following is a brief description of the method used to 
validate the quantification of FTC or DTG in human hair:  
 
Calibration standards were prepared from blank (drug -free) hair matrix by two approaches: 1. spray 
deposition, and 2. incubation. In the former approach, a template was placed on top of blank hair 
adhered to a glass slide to mask deposition of  sprayed standards into discrete wells and total 
concentration of drug in each well was controlled based on the number of passes of a moving 
sprayer head. In the latter approach, standards were prepared by transferring drug -free hair 
(approximately 10 mg) into a vial containing 20 mL of analyte and solvent (50:50 Methanol:Water), 
and incubating for approximately 24 hours in a reciprocal shaking bath. Incubated standards were 
then rinsed with fresh solvent and stored at -20°C and used as needed for analysis.    
All hair samples were prepared for analysis by mounting hair strands onto a glass slide by VHB tape. 
For quantitative analysis, samples were sprayed with isotopically labeled internal standard solution 
containing FTC -d3 (FTC -IS). After air drying, sampl es were placed into the IR -MALDESI MSI source for 
evaluation. Target compounds generated by IR -MALDESI sample interrogation were detected on a 
Thermo Q Exactive Plus mass spectrometer. Acquisition was conducted using electrospray ionization 
in the positive  ion mode with a solvent of 0.2% Formic Acid in 50:50 Methanol:Water. The following 
ions were monitored:  
Analyte  Analysis Mode  Target 
peak  Peak identity  
FTC MS/MS  130.0412  [F+H]+  protonated fragment ion  
FTC-d3 MS/MS  133.0384  [F+H]+  protonated fragment ion  
DTG  Full MS  420.136555  [M+H]+  protonated parent ion  
     
Quantitation is based on the peak area of each sampling point associated with a hair strand defined 
during post -processing analysis in MSiReader software ( Figure 1 ).  
  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 190 of 214 
 E.2 MATERIALS AND METHODS  
E.2.1 REFERENCE STANDARDS  
The following reference standards were used for the preparation of calibration standards, quality 
control samples, and internal standard solutions:  
Compound  Source  Lot No.  Purity  Salt 
Correction  
FTC Toronto Research 
Chemicals, Inc.  8-SSR-128-1 0.980  1.00  
FTC-d3 Moravek  390-095-000-B-20150316 -
PVA 0.980  1.00  
DTG  Toronto Research 
Chemicals, Inc.  5-RTU-102.1  0.980  1.00  
 
E.2.2  Reagents  
 
 Description  Specification  
Acetonitrile (ACN)  HPLC grade  
Formic Acid  Certified ACS, 88%  
Water (H 2O) Hydro UltraPure H 2O System or HPLC grade  
Methanol (MeOH)  HPLC grade  
Human Hair  BioreclamanationIVT  
 
 
E.2.3   INSTRUMENTATION AND SUPPLIES  
 
Description  Supplier  
Q-Exactive Plus Mass Spectrometer  ThermoElectron  
TM Sprayer  HTX Technologies  
Pipettor  5000 µL adjustable; 1000 µL adjustable; 200 µL 
adjustable; 100 µL adjustable  
Reciprocal shaking bath  Precision  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 191 of 214 
  
E.2.4  Preparation of Stock and Internal Standard Solutions, and Calibration Standards  
E.2.4.1 PREPARATION OF INTERNAL STANDARD STOCK SOLUTIONS  
 
Typically, a 1 mg/mL stock solution of internal standard is prepared.  Due to the cost associated with 
isotopically -labeled internal standards, these compounds are typically ordered in 1mg  amounts.  The 
internal standard is then solvated by adding the appropriate amount of solvent directly to the vial 
received from the vendor.  The purity and salt corrections are figured into the calculation of the 
amount of solvent (50:50 Methanol:Water) r equired to result in a 1mg/mL solution for FTC -IS.  
These compounds are not weighed in our lab.  A completely accurate weighing is not critical for the 
internal standard component as it is only used as a constant mass addition to each sample.  The 
exact co ncentration of internal standard has no impact on the quantitation of DTG.  
 
E.2.4.2  PREPARATION OF PRIMARY ANALYTE STANDARD STOCK SOLUTIONS  
Typically, 1 mg/mL stock solutions are prepared for FTC or DTG.  The purity and any salt correction 
(listed on the c ertificate of analysis) are figured into the calculation of the amount of solvent (50:50 
Methanol:Water) required to result in a 1mg/mL solution.   
 
E.2.4.3  PREPARATION OF CALIBRATION STANDARDS  BY TM SPRAYER  
The amount of standard deposited onto the hair sample surface during spraying is determined by 
the following equation:  
Sample Concentration (ng/mm2) = # Spray Passes × Flow Rate × Standard Concentration  
Spray Head Velocity × Track Spacing 
The surface concentration is then converted to a per mass b asis ARV concentration (ng/mg) hair 
based on estimates for the depth of laser desorption and density of hair. Optical inspection of 
ablated hair strands yielded an estimated depth of 0.05 mm. Hair density was evaluated by placing 
95 mg of blank hair in a g lass graduated cylinder and adding 5 ml of water. The displacement of 1 ml 
resulted in an estimated hair density of 95 mg/ml.  
The primary stock solutions were used to make spraying solutions of 1 M in polypropylene plastic.  
The diluent used for this prepa ration was 50:50 Methanol:Water.  Solutions are stored at -80 °C and 
are stable for up to 91 days. Spraying of calibration standards was performed with the following 
conditions:  
 
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 192 of 214 
 Flow Rate  0.02  ml/min  
Concentration  1 M 
Head velocity  600 mm/min  
Track width  2 mm 
The number of passes was varied in each well of the templated mask, as shown in Figure 2 , to generate the 
desired range of concentrations for calibration . 
 
E.2.4.4  PREPARATION OF CALIBRATION STANDARDS  BY INCUBATION  
The primary stock solutions were used to make incubation solutions in polypropylene plastic.  The 
diluent used for this preparation was 50:50 Methanol:Water.  Solutions are stored at -80 °C and are 
stable for up to 91 days. Standards were prepared by trans ferring drug -free hair (approximately 10 
mg) into a vial containing 20 mL of spiked calibration solution and incubating for approximately 24 
hours in a reciprocal shaking bath. Incubated standards were then rinsed with fresh solvent and 
allowed to dry for 10 minutes before being stored at -20°C and used as needed for analysis.   
 
E.2.4.5  PREPARATION OF HAIR SAMPLES WITH INTERNAL STANDARDS USING THE TM 
SPRAYER  
Stable isotope labelled internal standards were sprayed onto prepared hair samples using the TM 
Sprayer with the following conditions:  
Flow Rate  0.02  ml/min  
Concentration  4 M 
Head velocity  600 mm/min  
Track width  2 mm 
# passes  6  
Spray configuration  Criss -cross  
 
E.3 VALIDATION  
E.3.1  EXPERIMENTAL DESIGN  
The validation procedure for FTC consisted of triplicate analytical runs to evaluate assay 
performance.  The standard curves were constructed from at least five calibration standard levels 
and analyzed using a linear regression algorithm with 1/x2 weighting to plot the peak area ratio of 
analyte to internal standard versus concentration.  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 193 of 214 
 The analytical procedure consisted of the following steps:  
 
Blank hair strands were adhered to a glass microscope slide and placed in the TM sprayer with a 
templated mask. FTC standards were sprayed over  the sample, increasing the numbers of spray 
passes in each well of the mask. After 10 minutes of drying, FTC -IS were sprayed onto the sample. 
An additional 10 minutes of drying was provided prior to analysis.  
 
Based on the observation that adherence of m ore hydrophyllic analytes (FTC, DTG) to blank 
hair strands was unacceptably variable between tests, particularly at lower calibration 
concentrations, calibration of DTG response was performed using incubated hair strands. 
LC-MS/MS evaluation of DTG concent rations in incubated hair strands was conducted to 
determine absorbed concentrations within the hair matrix.  
 
Typical mass spectra and extracted ion chromatograms from FTC and DTG from incurred 
samples, illustrating relevant concentration levels, are show n in Figure 3 . 
 
E.4 RESULTS  
E.4.1  VERIFICATION OF CALIBRATION MODEL  
All validations used peak area ratios of calibration standard to internal standard to construct 
calibration curves.  All calibration curves employed linear regression with 1/x2 weighting.  All 
correlation coefficients exceeded 0.95. Analytical results are reported in ng/mg.  
See Figure 4  for an example calibration curve for each analyte.   
Calibration curve details from individual validation experiments are presented below:  
Analyte  Calibration Range  
(ng/mg)  Calibration Curve  
Table  Regression Table  
FTC 1.4 to 111  1 2 
DTG  0.04 to 6.6  1 2 
 
 
E.4.2  LOWER LIMIT OF QUANTITATION (LLOQ)  
The LLOQ has been imputed at half the signal abundance of the lowest level of calibration based on 
the calibration slope and intercept.  
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 194 of 214 
  IS-corrected   
Slope  Intercept  R-
squared  LLOQ 
(ng/mg)    
FTC Yes  0.0063  0.0051  0.9971  0.270    
DTG  No  6.12E+04  -1.45E+03  0.9527  0.040    
   
As seen in the example chromatograms of Figure 3 , analysis shows no off -strand background 
response and no signal carryover. With little baseline noise present, a raw signal abundance of 1e3 
represents a standard limit of detection for the Q -Exactive Plus. For FTC and DTG, half the signal 
abundance of the lowest level of calibration exceeded 1e3.  
E.4.3  PRECISION  
Precision was determined by triplicate analysis of human hair matrix calibration concentrations  
representing the entire calibration range.  Precision is expressed as relative standard deviation 
(%RSD).  
% RSD =  
100%  values found  of mean deviation  standardx  
Data for IS -normalized FTC and DTG are summarized in the following table. Individual results can be 
found as indicated in the table listed.  
Analyte  %RSD  Table  
FTC 11.3% to 63.1%  1 
DTG  40% to 41%  1 
 
E.4.4  FTC AND DTG  ANALYSIS OF FIVE  INCURRED SAMPLES  
Also included in the evaluation of the method were replicate analyses of hair samples from six 
separate subjects.  Hair from two subjects on MVC regimens, three subjects on FTC, and one subject 
on a DTG regimen was utilized. LC -MS/MS conc entrations were also determined for all but one 
sample for which insufficient hair was available.  
IR-MALDESI MSI detected measurable signal abundance for all incurred samples within the linear 
calibration range, as shown in Figure 5 , and samples were quantified based on these calibrations.     
 
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 195 of 214 
 E.4.4.1  ACCURACY  OF IR -MALDESI QUANTITATIVE ANALYSIS OF INCURRED SAMPLES  
Accuracy, expressed as %Bias (mean % difference from nominal), was determined according to the 
following equation:  
 
% Bias =  
100%   value l theoretica  valuecal  theroreti -   values found  of mean x  
A summary of quantitative evaluation by LC -MS/MS and IR -MALDESI for incurred samples is 
provided in Table 5.  Bias ranged from -5 to 65%, but should be treated with some caution because 
analysis by each method cannot be conducted on tr uly matching samples. LC -MS/MS analysis was 
performed on 2 -5 mg of hair comprising 10s of strands evaluated in aggregate. IR -MALDESI MSI is 
performed on individual hair strands that may reflect differing levels of pigmentation or growth 
phase than the aver age over many strands. Nonetheless, the results of this test demonstrate good 
agreement between measurement approaches. No systematic bias in response is apparent over the 
relatively small number of samples investigated.  
 
E.4.4.2  PRECISION OF IR -MALDESI A NALYSIS OF INCURRED SAMPLES  
Additionally, precision was evaluated for repeated analysis of hair strands from two incurred 
samples.  
Analyte  Sample  %Intra -day Precision  %Inter -day Precision  Table  
FTC UCSF003  20% to 76%  35% 4 
DTG  DK010  25% to 42%  22% 4 
 
As incurred samples, these are not true replicate analyses due to expected biological variability but 
the measured precision demonstrates the reproducibility between separate hair samples from the 
same subject.  
 
  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 196 of 214 
 E.5 CONCLUSION  
A method to quantify the l evels of emtricitabine (FTC) and dolutegravir (DTG) in human hair 
has been validated over a linear concentration range relevant to incurred clinical samples.  
 
The method uses a linear regression algorithm with 1/x2 weighting.  During the validation, 
the co rrelation coefficient (r2) for all calibration curves exceeded 0.9 5.  The responses of 
blank human hair analyzed showed no interferences.  
 
Quantitative analysis of incurred samples by IR -MALDESI MSI showed good agreement with 
LC-MS/MS and consistency in r epeated measures of analytes in clinical samples.   
 
Based on these results, the method is available for use in determining the concentrations of 
emtricitabine and dolutegravir in human hair.  
E.6 REFERENCES  
 
• FDA Guidance for Industry Bioanalytical Method V alidation, May 2001  
 
• CPQA Guidelines for Chromatographic Method Development and Validation Based on (and 
including) FDA Guidelines Dated May 2001, Version 4, 2012  
 
• SOP-0342  Guidelines for performing bioanalytical assays  
 
• SOP-0343 Guidelines for validating  bioanalytical methods  
 
• SOP-0346  Data reporting, review and archiving  
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 197 of 214 
 TABLE 1. CALIBRATION STANDARD CURVE SUMMARY  
FTC        
  Std Level 
1 Std Level 
2 Std Level 
3 Std Level 
4 Std Level 
5 Std Level 
6 Std Level 
7 
  ng/mg  ng/mg  ng/mg  ng/mg  ng/mg  ng/mg  ng/mg  
Theoretical conc.  1.4 2.8 5.6 11.1  27.8  55.5  111.1  
                
Raw IR -MALDESI 
Response                
Run 1  2.50E+03  2.80E+03  1.35E+04  1.22E+04  4.65E+04  9.18E+04  1.45E+05  
Run 2  1.72E+03  1.81E+03  1.48E+04  1.82E+04  6.47E+04  1.40E+05  2.16E+05  
Run 3  6.03E+03  5.56E+03  6.70E+03  2.50E+04  6.22E+04  1.26E+05  2.36E+05  
                
Mean  3.42E+03  3.39E+03  1.17E+04  1.84E+04  5.78E+04  1.19E+05  1.99E+05  
SD 2.30E+03  1.94E+03  4.35E+03  6.39E+03  9.87E+03  2.47E+04  4.77E+04  
%RSD  67.3%  57.3%  37.3%  34.7%  17.1%  20.7%  24.0%  
                
IS-normalized  
IR-MALDESI 
Response                
Run 1  0.017  0.035  0.055  0.065  0.156  0.348  0.710  
Run 2  0.005  0.009  0.023  0.039  0.136  0.269  0.541  
Run 3  0.018  0.044  0.050  0.046  0.125  0.288  0.754  
                
Mean  0.013  0.029  0.043  0.050  0.139  0.302  0.668  
SD 0.007  0.018  0.017  0.014  0.016  0.041  0.113  
%RSD  54.3%  63.1%  40.4%  27.4%  11.3%  13.6%  16.9%  
 
  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 198 of 214 
 DTG         
  Std Level 
1 Std Level 
2 Std Level 
3 Std Level 
4 Std Level 
5 Std Level 
6 Std Level 
7 
  ng/mg  ng/mg  ng/mg  ng/mg  ng/mg  ng/mg  ng/mg  
Theoretical conc.  0.041  0.129  0.345  0.411  0.685  1.887  3.000  
                
Raw IR -MALDESI 
Response                
Run 1  1.38E+04  2.02E+04  2.70E+04  4.62E+04  8.25E+04  1.94E+05  3.44E+05  
Run 2          8.78E+04  1.42E+05    
                
Mean          8.52E+04  1.68E+05    
SD         3.44E+04  6.89E+04    
%RSD          40%  41%    
 
 
TABLE 2. REGRESSION SUMMARY  
  
 IS-corrected  Slope  Intercept  R-squared  LLOQ (ng/mg)  
FTC Yes 0.0063  0.0051  0.9971  0.270  
DTG  No 6.12E+04  -1.45E+03  0.9527  0.040  
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 199 of 214 
 TABLE 3. QUANTITATIVE EVALUATION OF INCURRED SAMPLES  
Sample 
ID Target  IR-MALDESI 
Concentration  LC-MS/MS 
Concentration  LC-MS/MS 
Sample Mass  Bias 
    ng/mg  ng/mg  mg % 
UCSF003  FTC 0.93  0.56  5.12  0.656  
UCSF023  FTC 1.88  1.23  5.10  0.528  
UCSF030  FTC 0.64  0.55  5.10  0.167  
DK010  DTG  1.07  1.23  5.77  -0.13  
      
 
TABLE 4.  INTRA - & INTER -DAY PRECISION OF INCURRED SAMPLES  
FTC UCSF 003     
Strand  Date of 
Analysis  IR-MALDESI 
Signal 
Abundance  Intraday Statistics  
1 3/14/2019  BLD Mean  9.85E+03  
2 3/14/2019  BLD SD 4.82E+03  
3 3/14/2019  9.10E+03  %RSD  49%  
4 3/14/2019  1.06E+04  n 2 
5 3/19/2019  7.84E+03  Mean  7.84E+03  
6 3/19/2019  BLD SD NA 
7 3/19/2019  BLD n 1 
8 3/20/2019  6.63E+03  Mean  6.48E+03  
9 3/20/2019  6.72E+03  SD 1.67E+03  
10 3/20/2019  7.30E+03  %RSD  26%  
11 3/20/2019  5.26E+03  n 4 
          
Interday  Mean  7.64E+03     
 Statistics  SD 3.04E+03     
  %RSD  40%     
  n 7     
  
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 200 of 214 
 DTG  DK010  
Strand  Date of 
Analysis  IR-MALDESI 
Signal 
Abundance  Intraday Statistics  
Mean  SD %RSD  
1 4/11/2019  2.39E+04        
2 4/11/2019  2.06E+04  2.22E+04  9.26E+03  42%  
3 4/12/2019  2.53E+04        
4 4/12/2019  2.21E+04        
5 4/12/2019  2.46E+04  2.40E+04  6.08E+03  25%  
        
Interday  Mean  2.33E+04      
 
Statistics  SD 5.20E+03      
  %RSD  22%      
  n 5       
 
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 201 of 214 
 FIGURE 1. EXTRACTION OF HAIR -ASSOCIATED ION PEAKS USING MSiREADER  
 

Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 202 of 214 
 FIGURE 2.  GENERATION OF CALIBRATION STANDARDS USING THE TM SPRAYER  
 
 

Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 203 of 214 
 FIGURE 3.  REPRESENTATIVE MASS SPECTRA AND EXTRACTED ION CHROMATOGRAMS OF 
TARGETED ANALYTES IN INCURRED HAIR STRANDS  
 
FTC 
 
DTG  
 
 

Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 204 of 214 
 FIGURE 4.  EXAMPLE OF A CALIBRATION CURVE  
 
 
FTC 
 y = 0.0063x + 0.0051
R² = 0.9971
00.10.20.30.40.50.60.70.8
0 20 40 60 80 100 120FTC Signal Abundance (IS Adjusted)
FTC  Concentration (ng/mg)
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
Page 205 of 214 
 DTG  
 

Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
 
206 FIGURE 5.  EVALUATION OF INCURRED SAMPLES BASED ON CALIBRATION CURVES  
 
 00.020.040.060.080.10.120.140.160.180.2
0 5 10 15 20 25 30 35 40FTC Signal Abundance (IS Adjusted)
FTC  Concentration (ng/mg)Calibration curve
UCSF003
UCSF023
UCSF030
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
 
207  
 
APPENDIX F. IR -MALDESI EVALUATION OF HAIR COLOR AND TREATMENT  
F.1 IR -MALDESI EVALUATION OF HAIR COLOR AND TREATMENT  
 
Influence of Hair Color and Treatments on Detection of Antiretrovirals by IR -MALDESI Mass 
Spectrometry Imaging  
 
1. Correlation Between Hair Color and ARV Response  
Hair samples collected from the 3 phase DOT study ([STUDY_ID_REMOVED]) were evaluated for emtricitabine 
(FTC) and dolutegravir (DTG) in combination with the m elanin biomarker pyrrole -2,3,5 -tricarboxylic acid 
(PTCA ). Four hair strands/subject were fixed to glass slides with double -sided tape, oxidized for 10 min 
in 1M NH 4OH in 10/45/45 H 2O2/H2O/MeOH (v/v/v) before analysis by IR -MALDESI MSI. Results are 
shown in Figure 1A. Relationships between the ARVs and the melanin biomarker were evaluated by 

Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
 
208 Pearson correlation coefficient, which indicated positive correlation for DTG with melanin (r DTG=0.42) 
and negative correlation for FTC with melanin (r FTC=-0.29). Scaling of the raw ARV IR -MALDESI response 
by PTCA response is shown in Figure 1B. For each of the investigated ARVs, the raw ARV response scaled 
by maximum value was compared to the PTCA -norm alized ARV response scaled by maximum value. 
Based on the relative standard deviation (RSD) of these distributions, PTCA scaling increased variability 
for IR -MALDESI measurement of FTC and DTG.  
 
Overall, PTCA correction of IR -MALDESI measurements in hair is not effective for reducing IR -MALDESI 
measurement variability of these ARVs . 
 
Figure 1 - A) IR -MALDESI measurements of ARV and melanin signal abundance in hair strands collected 
during [STUDY_ID_REMOVED]. B) Comparison of raw (solid) and PTCA -normalized (outli ned) ARV IR -MALDESI 
measurements, scaled by measurement maxima.    
 
2. Hair Treatment Influence on ARV Response  
Manual Manipulation of Hair Treatments .  
Hair strands collected from participants of [STUDY_ID_REMOVED], classified as adherent to varied ARV regimens 
based on plasma levels of <50 copies HIV RNA/mL, were used to test the influence of benchtop 
treatment with bleach (powder lightener from Wella), dye (brown hair dye from Wella), and relaxer 
(medium relaxer from Mizani). A cream developer was used with the bleach a nd dye (20 Volume, 

Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
 
209 ColorCharm, Wella) before application to hair strands. Prior to treatment, samples were fixed to a glass 
microscope slide by taping one end of the hair strand. Bleach powder and dye were mixed in a 1:2 ratio 
with the cream developer in a  centrifuge tube prior to application to the hair strands. The compounds 
were then applied to the hair strands using a pipette or spatula. The contact times were 30 min for the 
bleach and dye and 15 min for the relaxer. The hair strands were then washed th oroughly with water 
and dried with nitrogen. Finally the hair strands were transferred to double -sided tape (VHB Tape, 3M, 
St. Paul, MN) on a microscope slide for MSI analysis.  
MS images for hair strands from an individual on ART combining MVC and FTC are  shown in Figures 2 
and 3 . A total of 12 strands were analyzed: 3 strands each were treated with bleach (B), dye (D), and 
relaxer (R), with 3 strands left untreated (C). Error! Reference source not found. A shows an image c
orresponding to the endogenous ion cholesterol ( m/z 369.3516), and Error! Reference source n ot 
found. B shows the ion image corresponding to MVC ( m/z 514.3352).  Error! Reference source not 
found. C shows the average MVC intensity for each hair strand and each of the three treatments and 
control. The bleached strands appeared to have slightly higher MVC ion abundance than the control 
strands (1.5x on average), and the dyed strands appeared to have sli ghtly lower MVC ion abundance 
than the controls (0.6x on average). The MVC ion abundance remains unchanged between any 
treatment and the control strands, indicating that the manual manipulation of these strands with these 
three treatments had no significan t effect on the detection of MVC.  
 
 
Figure 2. Effect of cosmetic hair treatment on MVC signal, with bleached, dyed, relaxed, and control 
hair strands. (A) IR -MALDESI MS response to cholesterol (m/z  369.3516), (B) IR -MALDESI MS response 
to MVC (m/z 514.33 52), (C) Comparison of average MVC response in each hair strand for treated hairs 
and control.  
 
Ion images from a different location on the same strands in Error! Reference source not found.  of an u
nfragmented endogenous ion ( m/z 248.2457) and FTC ( m/z 248.1 → m/z 130.041) are shown in Error! 
Reference source not found. A and Error! Reference source not found. B, respectively. Error! Reference 
source not found. C shows the average intensity for FTC in each of the strands and treatments in Error! 

Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
 
210 Reference source not found. B. While FTC was detected in control strands, no FTC was measured in any 
of the three treated strands indicating that any of these three treatments remove FTC from the hair 
strands. The diffe rence in results between MVC and FTC may be due to the relative binding strength of 
MVC and FTC to melanin in hair strands. Evidence from previous research has shown that compounds 
with basic properties are incorporated more strongly into hair than those w ith non -basic properties 
because they bind more strongly to the melanin in hair. Because MVC is more basic than FTC (pK a of 7.3 
versus pK a of 2.65) and therefore may bind more strongly to melanin, hair treatment may have a lesser 
effect on the concentratio n of MVC in hair relative to FTC.  
 
Figure 3. Effect of cosmetic hair treatment on FTC signal, with bleached, dyed, relaxed, and control 
hair strands. (A) IR -MALDESI MS response to an endogenous marker (m/z  248.2457), (B) IR -MALDESI 
MS/MS response to FTC (m/z 248.1 ± 4 → m/z 130.041), (C) Co mparison of average FTC response in 
each hair strand for treated hairs and control.  
To investigate the effect of hair treatment on other antiretrovirals, we evaluated hair strands from 
another patient on ARV therapy with a different drug regimen (DTG with lamivudine (3TC) and abacavir 
(ABC)). Plots showing the average ion abundance for hair strands with three different drugs (3TC, m/z 
230.059; ABC, m/z 287.161; DTG, m/z 420.137) and three different manual treatments are shown in  
Error! Reference source not found. . Error! Re ference source not found. A, B, a nd C show the intensity fo
r each of the drugs in hair strands treated with and without relaxer. In each case, there was no 
difference between the treated strands and control strands. For the strands treated with bleach ( Error! R
eference source not found. D, E, and F ), observations in bleached strands were the same or more 
intense than those that were untreated for all three drugs. In the case of ABC ( Error! Reference source n
ot found. E), there was a statistically significant difference between the treated and untreated strands ( p 
< 0.05, paired two -tailed t -test). For the dyed strands, 3TC was undetectable in both the dyed and 
control indicating an experimental error. For the other two drugs, shown in Error! Reference source not f
ound. H and I , the dyed strands had slightly lower intensities, and there was a statistically significant 
difference for DTG. These results indicate that relaxer does not affect the amount of drug in hair strands 
for 3TC, ABC, or DTG. For bleach treated strands, the treatment had no effect or, in the case of ABC, 
actually improved the signal response. This improvement in signal could be due to breakdown in the 
fidelity of the hair strand, thus reducing the energy necessary for a blation during the IR -MALDESI 
process and/or increasing the penetration depth of the laser. However, given that this trend was only 

Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
 
211 observed for one drug, further investigation is required. The dye appeared to lower the response to ABC 
and DTG. This trend may be  
 
Figure 4. Comparison of relaxed (top row), bleached (middle row), and dyed (bottom row) with 
untreated hair strands from a patient on a regimen with 3TC (left column), ABC (middle column), and 
DTG (right column). Statistically significant differences are s hown with a bar and p -value.  
influenced by multiple factors. First, the dyeing process may extract some of the drug from the hair 
strand. Second, because the dye was mixed with a solution containing hydrogen peroxide, there may be 
reactions of the drugs w ith the dye solution, therefore reducing the concentration of the parent drug. 
Finally, the introduction of dye into the hair could increase the total number of molecules competing for 
ionization, resulting in ion suppression for the target of interest. On ly FTC was rendered completely 
undetectable through mechanical treatment of individual hair strands, which may result in harsher 
conditions than on a full head of hair.  To further assess the influence of hair treatments on FTC, we 
investigated clinical sa mples collected from donors reporting recent hair treatments.  

Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
 
212 FTC Detection in Clinical Samples with 
Reported Hair Treatment .  
Characteristics of hair samples collected 
from  8 donors in NCT0276877 9 with 
recent (<8 weeks prior) is shown in  Error! R
eference source not found. , which include  
hair treatment including hair color, type 
of treatment, and time since the 
treatment (reported by the patient). 
There were 4 different hair colors and 5 
different treatments sampled.  
Images from the proximal (closest to scalp) 7 mm of hair strands are shown in  Error! Reference source n
ot found. , where intensity from FTC (shown in cyan) is overlaid with an en dogenous ion to indicate the  
Table 1 - Clinical Samples with Reported Hair Treatment  
 
Figure 2. MS/MS images of FTC (m/z 248.1 ± 4 → m/z 130.041) from 8 patients with different 
cosmetic hair treatments and varying times after treatment. Patient IDs and corresponding 
treatments and timeline are detailed in Table 1.  
 

Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
 
213 location of the hair strands (shown in red/yellow). The proximal end of hair strands, reflecting more 
recent growth, are on the left side of the images.  
Treatments from the Previous Day . The patients P -1 and P -2 had different treatments the day 
immediately before sampling, but some FTC signal is observed in each hair strand. In the case of P -2, 
only the proximal end of the hair strands contain FTC, which suggests that the hair treatment (dye) may 
not have reached the base of th e scalp.  
Treatments 2 -4 Weeks Ago.  For P -3, FTC was observed along the length of the middle strand, was 
intermittent in the bottom strand, and was undetectable in the top strand. In the case of the 
undetectable strand, this is likely due to this particula r hair being in the dormant growth phase. For P -4, 
whose hair was similar in color, had similar treatment, and had hair treatment on a similar timeline, FTC 
was observed consistently throughout all three hair strands. P -5 was the only patient who reported 
using a relaxer, and FTC detection was intermittent throughout the hair strand but concentrated more 
toward the proximal end.  
Treatments more than 4 Weeks Ago. Hair from patients P -6, P-7, and P -8 showed consistent detection of 
FTC throughout each of the strands.  
Assuming a growth rate of ~1 cm/month, 7 mm of hair would correspond to about 3 weeks (21 days) of 
hair growth. Thus, we would expect to see FTC signal regardless of treatment for hair that was treated 
more than 3 weeks prior. However, because ou r method of acquiring the hair was cutting with scissors 
rather than plucking, approximately 3 to 5 mm of hair may remain below the scalp, and some hairs may 
not be cut at exactly the same point. This relative imprecision of this cutting method may account  for 
the inter -strand variability in FTC response seen in P -3 and P -5. Nevertheless, if hair was treated very 
close to sample collection and FTC signal was observed, then that indicated that the hair treatment did 
not remove all of the drug from the hair s trands, as with P -1 and P -2. 
We chose to perform IR -MALDESI MSI analysis further along the length of hair strands from one patient 
with consistent FTC response (P -4) to evaluate a longer time p eriod of hair growth and to observe the 
time point of treatment. Error! Reference source not found.  shows the MS image of FTC overlaid with a
n endogenou s ion, sampled on the proximal 15 mm of the hair strand. In the top strand, a clear 
transition is observable at approximately 8mm from hair containing FTC to hair without any FTC. This  
Figure 3. MS/MS image of FTC (m/z 248.1 ± 4 → m/z 130.041) and endogenous (m/z  248.2457) 
from P -4 sampled on the proximal 15 mm of hair.  

Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non -Adherence (ENLIGHTEN)  Version v1.0 
Protocol 122319                                                          25 September 2019  
 
214 position, approximately 7 mm from the proximal end of the hair strand, would correspond to about 3 
weeks of hair growth and is consistent with the self -reported time since treatment. The transition was 
less stark in the other two strands, but there was difference in FTC detection around 12 mm in the 
image, or about 11 mm from  the proximal end of the strands. With imprecision in cutting, this indicates 
that the treatment may not have reached the base of the scalp, or that some hairs may be layered 
beneath others and protected from treatment. In the case of layering, some hairs may be unaffected by 
treatment. For the strands sampled here, an 8 -fold decrease in FTC response was measured in the 
treated region of hair strands relative to the proximal untreated region.  
The effect of a range of hair treatments on the detectability of  several antiretrovirals was assessed by IR -
MALDESI MSI. Our results indicated that a commercial relaxer, dye, and bleach had little or no effect for 
all but one of the drugs sampled. FTC was completely removed from hair strands following mechanical 
treatm ent of individual strands by any of the three hair treatments. Evaluation of treated hair samples 
from donors on FTC -based regimens indicated that IR -MALDESI MSI was capable of measuring FTC in 
samples undergoing treatment as recently as the previous day. FTC response was diminished in regions 
of hair strands exposed to treatment. To ensure fidelity of hair accumulation of FTC for adherence 
monitoring over a period of one month, we find that any hair treatment should have been conducted 
more than 4 weeks in  the past.  
 
 
 